#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Impaired mixed emotion processing in the right ventrolateral prefrontal cortex in schizophrenia: an fMRI study
#Text=Background
#Text=Schizophrenia has a negative effect on the activity of the temporal and prefrontal cortices in the processing of emotional facial expressions.
1-1	0-8	Impaired	_
1-2	9-14	mixed	_
1-3	15-22	emotion	_
1-4	23-33	processing	_
1-5	34-36	in	_
1-6	37-40	the	_
1-7	41-46	right	_
1-8	47-60	ventrolateral	_
1-9	61-71	prefrontal	_
1-10	72-78	cortex	_
1-11	79-81	in	_
1-12	82-95	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	95-96	:	_
1-14	97-99	an	_
1-15	100-104	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	105-110	study	_
1-17	111-121	Background	_
1-18	122-135	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-19	136-139	has	_
1-20	140-141	a	_
1-21	142-150	negative	_
1-22	151-157	effect	_
1-23	158-160	on	_
1-24	161-164	the	_
1-25	165-173	activity	_
1-26	174-176	of	_
1-27	177-180	the	_
1-28	181-189	temporal	_
1-29	190-193	and	_
1-30	194-204	prefrontal	_
1-31	205-213	cortices	_
1-32	214-216	in	_
1-33	217-220	the	_
1-34	221-231	processing	_
1-35	232-234	of	_
1-36	235-244	emotional	_
1-37	245-251	facial	_
1-38	252-263	expressions	_
1-39	263-264	.	_

#Text=However no previous research focused on the evaluation of mixed emotions in schizophrenia, albeit they are frequently expressed in everyday situations and negative emotions are frequently expressed by mixed facial expressions.
2-1	265-272	However	_
2-2	273-275	no	_
2-3	276-284	previous	_
2-4	285-293	research	_
2-5	294-301	focused	_
2-6	302-304	on	_
2-7	305-308	the	_
2-8	309-319	evaluation	_
2-9	320-322	of	_
2-10	323-328	mixed	_
2-11	329-337	emotions	_
2-12	338-340	in	_
2-13	341-354	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-14	354-355	,	_
2-15	356-362	albeit	_
2-16	363-367	they	_
2-17	368-371	are	_
2-18	372-382	frequently	_
2-19	383-392	expressed	_
2-20	393-395	in	_
2-21	396-404	everyday	_
2-22	405-415	situations	_
2-23	416-419	and	_
2-24	420-428	negative	_
2-25	429-437	emotions	_
2-26	438-441	are	_
2-27	442-452	frequently	_
2-28	453-462	expressed	_
2-29	463-465	by	_
2-30	466-471	mixed	_
2-31	472-478	facial	_
2-32	479-490	expressions	_
2-33	490-491	.	_

#Text=Methods
#Text=Altogether 37 subjects, 19 patients with schizophrenia and 18 healthy control subjects were enrolled in the study.
3-1	492-499	Methods	_
3-2	500-510	Altogether	_
3-3	511-513	37	_
3-4	514-522	subjects	_
3-5	522-523	,	_
3-6	524-526	19	_
3-7	527-535	patients	_
3-8	536-540	with	_
3-9	541-554	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-10	555-558	and	_
3-11	559-561	18	_
3-12	562-569	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
3-13	570-577	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
3-14	578-586	subjects	_
3-15	587-591	were	_
3-16	592-600	enrolled	_
3-17	601-603	in	_
3-18	604-607	the	_
3-19	608-613	study	_
3-20	613-614	.	_

#Text=The two study groups did not differ in age and education.
4-1	615-618	The	_
4-2	619-622	two	_
4-3	623-628	study	_
4-4	629-635	groups	_
4-5	636-639	did	_
4-6	640-643	not	_
4-7	644-650	differ	_
4-8	651-653	in	_
4-9	654-657	age	_
4-10	658-661	and	_
4-11	662-671	education	_
4-12	671-672	.	_

#Text=The stimulus set consisted of 10 fearful (100%), 10 happy (100%), 10 mixed fear (70% fear and 30% happy) and 10 mixed happy facial expressions.
5-1	673-676	The	_
5-2	677-685	stimulus	_
5-3	686-689	set	_
5-4	690-699	consisted	_
5-5	700-702	of	_
5-6	703-705	10	_
5-7	706-713	fearful	_
5-8	714-715	(	_
5-9	715-719	100%	_
5-10	719-720	)	_
5-11	720-721	,	_
5-12	722-724	10	_
5-13	725-730	happy	_
5-14	731-732	(	_
5-15	732-736	100%	_
5-16	736-737	)	_
5-17	737-738	,	_
5-18	739-741	10	_
5-19	742-747	mixed	_
5-20	748-752	fear	_
5-21	753-754	(	_
5-22	754-757	70%	_
5-23	758-762	fear	_
5-24	763-766	and	_
5-25	767-770	30%	_
5-26	771-776	happy	_
5-27	776-777	)	_
5-28	778-781	and	_
5-29	782-784	10	_
5-30	785-790	mixed	_
5-31	791-796	happy	_
5-32	797-803	facial	_
5-33	804-815	expressions	_
5-34	815-816	.	_

#Text=During the fMRI acquisition pictures were presented in a randomized order and subjects had to categorize expressions by button press.
6-1	817-823	During	_
6-2	824-827	the	_
6-3	828-832	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-4	833-844	acquisition	_
6-5	845-853	pictures	_
6-6	854-858	were	_
6-7	859-868	presented	_
6-8	869-871	in	_
6-9	872-873	a	_
6-10	874-884	randomized	_
6-11	885-890	order	_
6-12	891-894	and	_
6-13	895-903	subjects	_
6-14	904-907	had	_
6-15	908-910	to	_
6-16	911-921	categorize	_
6-17	922-933	expressions	_
6-18	934-936	by	_
6-19	937-943	button	_
6-20	944-949	press	_
6-21	949-950	.	_

#Text=Results
#Text=A decreased activation was found in the patient group during fear, mixed fear and mixed happy processing in the right ventrolateral prefrontal cortex (VLPFC) and the right anterior insula (RAI) at voxel and cluster level after familywise error correction.
7-1	951-958	Results	_
7-2	959-960	A	_
7-3	961-970	decreased	_
7-4	971-981	activation	_
7-5	982-985	was	_
7-6	986-991	found	_
7-7	992-994	in	_
7-8	995-998	the	_
7-9	999-1006	patient	_
7-10	1007-1012	group	_
7-11	1013-1019	during	_
7-12	1020-1024	fear	_
7-13	1024-1025	,	_
7-14	1026-1031	mixed	_
7-15	1032-1036	fear	_
7-16	1037-1040	and	_
7-17	1041-1046	mixed	_
7-18	1047-1052	happy	_
7-19	1053-1063	processing	_
7-20	1064-1066	in	_
7-21	1067-1070	the	_
7-22	1071-1076	right	_
7-23	1077-1090	ventrolateral	_
7-24	1091-1101	prefrontal	_
7-25	1102-1108	cortex	_
7-26	1109-1110	(	_
7-27	1110-1115	VLPFC	_
7-28	1115-1116	)	_
7-29	1117-1120	and	_
7-30	1121-1124	the	_
7-31	1125-1130	right	_
7-32	1131-1139	anterior	_
7-33	1140-1146	insula	_
7-34	1147-1148	(	_
7-35	1148-1151	RAI	_
7-36	1151-1152	)	_
7-37	1153-1155	at	_
7-38	1156-1161	voxel	_
7-39	1162-1165	and	_
7-40	1166-1173	cluster	_
7-41	1174-1179	level	_
7-42	1180-1185	after	_
7-43	1186-1196	familywise	_
7-44	1197-1202	error	_
7-45	1203-1213	correction	_
7-46	1213-1214	.	_

#Text=No difference was found between study groups in activations to happy facial condition.
8-1	1215-1217	No	_
8-2	1218-1228	difference	_
8-3	1229-1232	was	_
8-4	1233-1238	found	_
8-5	1239-1246	between	_
8-6	1247-1252	study	_
8-7	1253-1259	groups	_
8-8	1260-1262	in	_
8-9	1263-1274	activations	_
8-10	1275-1277	to	_
8-11	1278-1283	happy	_
8-12	1284-1290	facial	_
8-13	1291-1300	condition	_
8-14	1300-1301	.	_

#Text=Patients with schizophrenia did not show a differential activation between mixed happy and happy facial expression similar to controls in the right dorsolateral prefrontal cortex (DLPFC).
9-1	1302-1310	Patients	_
9-2	1311-1315	with	_
9-3	1316-1329	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-4	1330-1333	did	_
9-5	1334-1337	not	_
9-6	1338-1342	show	_
9-7	1343-1344	a	_
9-8	1345-1357	differential	_
9-9	1358-1368	activation	_
9-10	1369-1376	between	_
9-11	1377-1382	mixed	_
9-12	1383-1388	happy	_
9-13	1389-1392	and	_
9-14	1393-1398	happy	_
9-15	1399-1405	facial	_
9-16	1406-1416	expression	_
9-17	1417-1424	similar	_
9-18	1425-1427	to	_
9-19	1428-1436	controls	_
9-20	1437-1439	in	_
9-21	1440-1443	the	_
9-22	1444-1449	right	_
9-23	1450-1462	dorsolateral	_
9-24	1463-1473	prefrontal	_
9-25	1474-1480	cortex	_
9-26	1481-1482	(	_
9-27	1482-1487	DLPFC	_
9-28	1487-1488	)	_
9-29	1488-1489	.	_

#Text=Conclusions
#Text=Patients with schizophrenia showed decreased functioning in right prefrontal regions responsible for salience signaling and valence evaluation during emotion recognition.
10-1	1490-1501	Conclusions	_
10-2	1502-1510	Patients	_
10-3	1511-1515	with	_
10-4	1516-1529	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-5	1530-1536	showed	_
10-6	1537-1546	decreased	_
10-7	1547-1558	functioning	_
10-8	1559-1561	in	_
10-9	1562-1567	right	_
10-10	1568-1578	prefrontal	_
10-11	1579-1586	regions	_
10-12	1587-1598	responsible	_
10-13	1599-1602	for	_
10-14	1603-1611	salience	_
10-15	1612-1621	signaling	_
10-16	1622-1625	and	_
10-17	1626-1633	valence	_
10-18	1634-1644	evaluation	_
10-19	1645-1651	during	_
10-20	1652-1659	emotion	_
10-21	1660-1671	recognition	_
10-22	1671-1672	.	_

#Text=Our results indicate that fear and mixed happy/fear processing are impaired in schizophrenia, while happy facial expression processing is relatively intact.
11-1	1673-1676	Our	_
11-2	1677-1684	results	_
11-3	1685-1693	indicate	_
11-4	1694-1698	that	_
11-5	1699-1703	fear	_
11-6	1704-1707	and	_
11-7	1708-1713	mixed	_
11-8	1714-1719	happy	_
11-9	1719-1720	/	_
11-10	1720-1724	fear	_
11-11	1725-1735	processing	_
11-12	1736-1739	are	_
11-13	1740-1748	impaired	_
11-14	1749-1751	in	_
11-15	1752-1765	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-16	1765-1766	,	_
11-17	1767-1772	while	_
11-18	1773-1778	happy	_
11-19	1779-1785	facial	_
11-20	1786-1796	expression	_
11-21	1797-1807	processing	_
11-22	1808-1810	is	_
11-23	1811-1821	relatively	_
11-24	1822-1828	intact	_
11-25	1828-1829	.	_

#Text=Background
#Text=Schizophrenia is characterized with neurocognitive and social cognitive impairments, both of which contribute to decreased psychosocial functioning.
12-1	1830-1840	Background	_
12-2	1841-1854	Schizophrenia	_
12-3	1855-1857	is	_
12-4	1858-1871	characterized	_
12-5	1872-1876	with	_
12-6	1877-1891	neurocognitive	_
12-7	1892-1895	and	_
12-8	1896-1902	social	_
12-9	1903-1912	cognitive	_
12-10	1913-1924	impairments	_
12-11	1924-1925	,	_
12-12	1926-1930	both	_
12-13	1931-1933	of	_
12-14	1934-1939	which	_
12-15	1940-1950	contribute	_
12-16	1951-1953	to	_
12-17	1954-1963	decreased	_
12-18	1964-1976	psychosocial	_
12-19	1977-1988	functioning	_
12-20	1988-1989	.	_

#Text=Social cognition consists of three major areas: attributional style, theory of mind and emotion recognition.
13-1	1990-1996	Social	_
13-2	1997-2006	cognition	_
13-3	2007-2015	consists	_
13-4	2016-2018	of	_
13-5	2019-2024	three	_
13-6	2025-2030	major	_
13-7	2031-2036	areas	_
13-8	2036-2037	:	_
13-9	2038-2051	attributional	_
13-10	2052-2057	style	_
13-11	2057-2058	,	_
13-12	2059-2065	theory	_
13-13	2066-2068	of	_
13-14	2069-2073	mind	_
13-15	2074-2077	and	_
13-16	2078-2085	emotion	_
13-17	2086-2097	recognition	_
13-18	2097-2098	.	_

#Text=In the present investigation the focus was on emotion processing and recognition from facial displays.
14-1	2099-2101	In	_
14-2	2102-2105	the	_
14-3	2106-2113	present	_
14-4	2114-2127	investigation	_
14-5	2128-2131	the	_
14-6	2132-2137	focus	_
14-7	2138-2141	was	_
14-8	2142-2144	on	_
14-9	2145-2152	emotion	_
14-10	2153-2163	processing	_
14-11	2164-2167	and	_
14-12	2168-2179	recognition	_
14-13	2180-2184	from	_
14-14	2185-2191	facial	_
14-15	2192-2200	displays	_
14-16	2200-2201	.	_

#Text=Brain regions involved in emotion processing are the amygdala, the basal ganglia, the lateral and medial parietal cortex, the medial temporal lobe, the lateral temporal cortex, the dorsal and rostral anterior cingulate cortex, the anterior insular cortex, and the prefrontal cortex.
15-1	2202-2207	Brain	_
15-2	2208-2215	regions	_
15-3	2216-2224	involved	_
15-4	2225-2227	in	_
15-5	2228-2235	emotion	_
15-6	2236-2246	processing	_
15-7	2247-2250	are	_
15-8	2251-2254	the	_
15-9	2255-2263	amygdala	_
15-10	2263-2264	,	_
15-11	2265-2268	the	_
15-12	2269-2274	basal	_
15-13	2275-2282	ganglia	_
15-14	2282-2283	,	_
15-15	2284-2287	the	_
15-16	2288-2295	lateral	_
15-17	2296-2299	and	_
15-18	2300-2306	medial	_
15-19	2307-2315	parietal	_
15-20	2316-2322	cortex	_
15-21	2322-2323	,	_
15-22	2324-2327	the	_
15-23	2328-2334	medial	_
15-24	2335-2343	temporal	_
15-25	2344-2348	lobe	_
15-26	2348-2349	,	_
15-27	2350-2353	the	_
15-28	2354-2361	lateral	_
15-29	2362-2370	temporal	_
15-30	2371-2377	cortex	_
15-31	2377-2378	,	_
15-32	2379-2382	the	_
15-33	2383-2389	dorsal	_
15-34	2390-2393	and	_
15-35	2394-2401	rostral	_
15-36	2402-2410	anterior	_
15-37	2411-2420	cingulate	_
15-38	2421-2427	cortex	_
15-39	2427-2428	,	_
15-40	2429-2432	the	_
15-41	2433-2441	anterior	_
15-42	2442-2449	insular	_
15-43	2450-2456	cortex	_
15-44	2456-2457	,	_
15-45	2458-2461	and	_
15-46	2462-2465	the	_
15-47	2466-2476	prefrontal	_
15-48	2477-2483	cortex	_
15-49	2483-2484	.	_

#Text=The amygdala is primarily responsible for the cognitive representation of fear.
16-1	2485-2488	The	_
16-2	2489-2497	amygdala	_
16-3	2498-2500	is	_
16-4	2501-2510	primarily	_
16-5	2511-2522	responsible	_
16-6	2523-2526	for	_
16-7	2527-2530	the	_
16-8	2531-2540	cognitive	_
16-9	2541-2555	representation	_
16-10	2556-2558	of	_
16-11	2559-2563	fear	_
16-12	2563-2564	.	_

#Text=The temporal-parietal structures are activated in the process of face and facial expression detection.
17-1	2565-2568	The	_
17-2	2569-2586	temporal-parietal	_
17-3	2587-2597	structures	_
17-4	2598-2601	are	_
17-5	2602-2611	activated	_
17-6	2612-2614	in	_
17-7	2615-2618	the	_
17-8	2619-2626	process	_
17-9	2627-2629	of	_
17-10	2630-2634	face	_
17-11	2635-2638	and	_
17-12	2639-2645	facial	_
17-13	2646-2656	expression	_
17-14	2657-2666	detection	_
17-15	2666-2667	.	_

#Text=The ventromedial prefrontal cortex (VMPFC) and the dorsolateral prefrontal cortex (DLPFC) are involved in the regulation of cognitive functions linked to emotions such as attention, while the ventrolateral prefrontal cortex (VLPFC) signals emotion salience and the need to regulate.The right VLPFC is also implicated in the integration of viscerosensory information with affective signals between the bilateral anterior VLPFCs and the bilateral amygdale and activated in situations with decision uncertainty.
18-1	2668-2671	The	_
18-2	2672-2684	ventromedial	_
18-3	2685-2695	prefrontal	_
18-4	2696-2702	cortex	_
18-5	2703-2704	(	_
18-6	2704-2709	VMPFC	_
18-7	2709-2710	)	_
18-8	2711-2714	and	_
18-9	2715-2718	the	_
18-10	2719-2731	dorsolateral	_
18-11	2732-2742	prefrontal	_
18-12	2743-2749	cortex	_
18-13	2750-2751	(	_
18-14	2751-2756	DLPFC	_
18-15	2756-2757	)	_
18-16	2758-2761	are	_
18-17	2762-2770	involved	_
18-18	2771-2773	in	_
18-19	2774-2777	the	_
18-20	2778-2788	regulation	_
18-21	2789-2791	of	_
18-22	2792-2801	cognitive	_
18-23	2802-2811	functions	_
18-24	2812-2818	linked	_
18-25	2819-2821	to	_
18-26	2822-2830	emotions	_
18-27	2831-2835	such	_
18-28	2836-2838	as	_
18-29	2839-2848	attention	_
18-30	2848-2849	,	_
18-31	2850-2855	while	_
18-32	2856-2859	the	_
18-33	2860-2873	ventrolateral	_
18-34	2874-2884	prefrontal	_
18-35	2885-2891	cortex	_
18-36	2892-2893	(	_
18-37	2893-2898	VLPFC	_
18-38	2898-2899	)	_
18-39	2900-2907	signals	_
18-40	2908-2915	emotion	_
18-41	2916-2924	salience	_
18-42	2925-2928	and	_
18-43	2929-2932	the	_
18-44	2933-2937	need	_
18-45	2938-2940	to	_
18-46	2941-2953	regulate.The	_
18-47	2954-2959	right	_
18-48	2960-2965	VLPFC	_
18-49	2966-2968	is	_
18-50	2969-2973	also	_
18-51	2974-2984	implicated	_
18-52	2985-2987	in	_
18-53	2988-2991	the	_
18-54	2992-3003	integration	_
18-55	3004-3006	of	_
18-56	3007-3021	viscerosensory	_
18-57	3022-3033	information	_
18-58	3034-3038	with	_
18-59	3039-3048	affective	_
18-60	3049-3056	signals	_
18-61	3057-3064	between	_
18-62	3065-3068	the	_
18-63	3069-3078	bilateral	_
18-64	3079-3087	anterior	_
18-65	3088-3094	VLPFCs	_
18-66	3095-3098	and	_
18-67	3099-3102	the	_
18-68	3103-3112	bilateral	_
18-69	3113-3121	amygdale	_
18-70	3122-3125	and	_
18-71	3126-3135	activated	_
18-72	3136-3138	in	_
18-73	3139-3149	situations	_
18-74	3150-3154	with	_
18-75	3155-3163	decision	_
18-76	3164-3175	uncertainty	_
18-77	3175-3176	.	_

#Text=The anterior insula and anterior cingulate cortex are involved in emotional tasks with cognitive demand.
19-1	3177-3180	The	_
19-2	3181-3189	anterior	_
19-3	3190-3196	insula	_
19-4	3197-3200	and	_
19-5	3201-3209	anterior	_
19-6	3210-3219	cingulate	_
19-7	3220-3226	cortex	_
19-8	3227-3230	are	_
19-9	3231-3239	involved	_
19-10	3240-3242	in	_
19-11	3243-3252	emotional	_
19-12	3253-3258	tasks	_
19-13	3259-3263	with	_
19-14	3264-3273	cognitive	_
19-15	3274-3280	demand	_
19-16	3280-3281	.	_

#Text=Multiple previous studies have shown that schizophrenia has an effect on the functioning of the temporal and prefrontal cortices, including the detection, evaluation and reappraisal of facial emotions.
20-1	3282-3290	Multiple	_
20-2	3291-3299	previous	_
20-3	3300-3307	studies	_
20-4	3308-3312	have	_
20-5	3313-3318	shown	_
20-6	3319-3323	that	_
20-7	3324-3337	schizophrenia	_
20-8	3338-3341	has	_
20-9	3342-3344	an	_
20-10	3345-3351	effect	_
20-11	3352-3354	on	_
20-12	3355-3358	the	_
20-13	3359-3370	functioning	_
20-14	3371-3373	of	_
20-15	3374-3377	the	_
20-16	3378-3386	temporal	_
20-17	3387-3390	and	_
20-18	3391-3401	prefrontal	_
20-19	3402-3410	cortices	_
20-20	3410-3411	,	_
20-21	3412-3421	including	_
20-22	3422-3425	the	_
20-23	3426-3435	detection	_
20-24	3435-3436	,	_
20-25	3437-3447	evaluation	_
20-26	3448-3451	and	_
20-27	3452-3463	reappraisal	_
20-28	3464-3466	of	_
20-29	3467-3473	facial	_
20-30	3474-3482	emotions	_
20-31	3482-3483	.	_

#Text=A recent study also revealed that the neural networks of frontolimbic regions are impaired in adolescents at high risk for schizophrenia.
21-1	3484-3485	A	_
21-2	3486-3492	recent	_
21-3	3493-3498	study	_
21-4	3499-3503	also	_
21-5	3504-3512	revealed	_
21-6	3513-3517	that	_
21-7	3518-3521	the	_
21-8	3522-3528	neural	_
21-9	3529-3537	networks	_
21-10	3538-3540	of	_
21-11	3541-3553	frontolimbic	_
21-12	3554-3561	regions	_
21-13	3562-3565	are	_
21-14	3566-3574	impaired	_
21-15	3575-3577	in	_
21-16	3578-3589	adolescents	_
21-17	3590-3592	at	_
21-18	3593-3597	high	_
21-19	3598-3602	risk	_
21-20	3603-3606	for	_
21-21	3607-3620	schizophrenia	_
21-22	3620-3621	.	_

#Text=While several previous investigations examined the recognition of basic emotions in schizophrenia, only a few studied the processing of different emotion intensities, while no previous research focused on the evaluation of mixed emotions, however they are requently expressed in everyday situations.
22-1	3622-3627	While	_
22-2	3628-3635	several	_
22-3	3636-3644	previous	_
22-4	3645-3659	investigations	_
22-5	3660-3668	examined	_
22-6	3669-3672	the	_
22-7	3673-3684	recognition	_
22-8	3685-3687	of	_
22-9	3688-3693	basic	_
22-10	3694-3702	emotions	_
22-11	3703-3705	in	_
22-12	3706-3719	schizophrenia	_
22-13	3719-3720	,	_
22-14	3721-3725	only	_
22-15	3726-3727	a	_
22-16	3728-3731	few	_
22-17	3732-3739	studied	_
22-18	3740-3743	the	_
22-19	3744-3754	processing	_
22-20	3755-3757	of	_
22-21	3758-3767	different	_
22-22	3768-3775	emotion	_
22-23	3776-3787	intensities	_
22-24	3787-3788	,	_
22-25	3789-3794	while	_
22-26	3795-3797	no	_
22-27	3798-3806	previous	_
22-28	3807-3815	research	_
22-29	3816-3823	focused	_
22-30	3824-3826	on	_
22-31	3827-3830	the	_
22-32	3831-3841	evaluation	_
22-33	3842-3844	of	_
22-34	3845-3850	mixed	_
22-35	3851-3859	emotions	_
22-36	3859-3860	,	_
22-37	3861-3868	however	_
22-38	3869-3873	they	_
22-39	3874-3877	are	_
22-40	3878-3887	requently	_
22-41	3888-3897	expressed	_
22-42	3898-3900	in	_
22-43	3901-3909	everyday	_
22-44	3910-3920	situations	_
22-45	3920-3921	.	_

#Text=Furthermore in many cases negative emotions such as fear are expressed by mixed facial expression (e.g. a mixture of a smile and a fearful facial display).
23-1	3922-3933	Furthermore	_
23-2	3934-3936	in	_
23-3	3937-3941	many	_
23-4	3942-3947	cases	_
23-5	3948-3956	negative	_
23-6	3957-3965	emotions	_
23-7	3966-3970	such	_
23-8	3971-3973	as	_
23-9	3974-3978	fear	_
23-10	3979-3982	are	_
23-11	3983-3992	expressed	_
23-12	3993-3995	by	_
23-13	3996-4001	mixed	_
23-14	4002-4008	facial	_
23-15	4009-4019	expression	_
23-16	4020-4021	(	_
23-17	4021-4024	e.g	_
23-18	4024-4025	.	_
23-19	4026-4027	a	_
23-20	4028-4035	mixture	_
23-21	4036-4038	of	_
23-22	4039-4040	a	_
23-23	4041-4046	smile	_
23-24	4047-4050	and	_
23-25	4051-4052	a	_
23-26	4053-4060	fearful	_
23-27	4061-4067	facial	_
23-28	4068-4075	display	_
23-29	4075-4076	)	_
23-30	4076-4077	.	_

#Text=Therefore using mixed emotions can be more ecological valid.
24-1	4078-4087	Therefore	_
24-2	4088-4093	using	_
24-3	4094-4099	mixed	_
24-4	4100-4108	emotions	_
24-5	4109-4112	can	_
24-6	4113-4115	be	_
24-7	4116-4120	more	_
24-8	4121-4131	ecological	_
24-9	4132-4137	valid	_
24-10	4137-4138	.	_

#Text=Hence in the present investigation facial displays of mixed positive and negative emotions were also presented to patients with schizophrenia and healthy subjects.
25-1	4139-4144	Hence	_
25-2	4145-4147	in	_
25-3	4148-4151	the	_
25-4	4152-4159	present	_
25-5	4160-4173	investigation	_
25-6	4174-4180	facial	_
25-7	4181-4189	displays	_
25-8	4190-4192	of	_
25-9	4193-4198	mixed	_
25-10	4199-4207	positive	_
25-11	4208-4211	and	_
25-12	4212-4220	negative	_
25-13	4221-4229	emotions	_
25-14	4230-4234	were	_
25-15	4235-4239	also	_
25-16	4240-4249	presented	_
25-17	4250-4252	to	_
25-18	4253-4261	patients	_
25-19	4262-4266	with	_
25-20	4267-4280	schizophrenia	_
25-21	4281-4284	and	_
25-22	4285-4292	healthy	_
25-23	4293-4301	subjects	_
25-24	4301-4302	.	_

#Text=We hypothesized that the processing of these more complex emotions are more severely impaired in schizophrenia, and therefore a better differentiation of patients from controls can be achieved based on activation patterns.
26-1	4303-4305	We	_
26-2	4306-4318	hypothesized	_
26-3	4319-4323	that	_
26-4	4324-4327	the	_
26-5	4328-4338	processing	_
26-6	4339-4341	of	_
26-7	4342-4347	these	_
26-8	4348-4352	more	_
26-9	4353-4360	complex	_
26-10	4361-4369	emotions	_
26-11	4370-4373	are	_
26-12	4374-4378	more	_
26-13	4379-4387	severely	_
26-14	4388-4396	impaired	_
26-15	4397-4399	in	_
26-16	4400-4413	schizophrenia	_
26-17	4413-4414	,	_
26-18	4415-4418	and	_
26-19	4419-4428	therefore	_
26-20	4429-4430	a	_
26-21	4431-4437	better	_
26-22	4438-4453	differentiation	_
26-23	4454-4456	of	_
26-24	4457-4465	patients	_
26-25	4466-4470	from	_
26-26	4471-4479	controls	_
26-27	4480-4483	can	_
26-28	4484-4486	be	_
26-29	4487-4495	achieved	_
26-30	4496-4501	based	_
26-31	4502-4504	on	_
26-32	4505-4515	activation	_
26-33	4516-4524	patterns	_
26-34	4524-4525	.	_

#Text=Specifically decreased activations were expected in regions involved in facial emotion processing in the patient group, especially in prefrontal regions, where previous investigation found activation in task with high cognitive demand linked to emotion processing such the anterior insula and also in regions linked to salience signaling such as the ventrolateral prefrontal cortex.
27-1	4526-4538	Specifically	_
27-2	4539-4548	decreased	_
27-3	4549-4560	activations	_
27-4	4561-4565	were	_
27-5	4566-4574	expected	_
27-6	4575-4577	in	_
27-7	4578-4585	regions	_
27-8	4586-4594	involved	_
27-9	4595-4597	in	_
27-10	4598-4604	facial	_
27-11	4605-4612	emotion	_
27-12	4613-4623	processing	_
27-13	4624-4626	in	_
27-14	4627-4630	the	_
27-15	4631-4638	patient	_
27-16	4639-4644	group	_
27-17	4644-4645	,	_
27-18	4646-4656	especially	_
27-19	4657-4659	in	_
27-20	4660-4670	prefrontal	_
27-21	4671-4678	regions	_
27-22	4678-4679	,	_
27-23	4680-4685	where	_
27-24	4686-4694	previous	_
27-25	4695-4708	investigation	_
27-26	4709-4714	found	_
27-27	4715-4725	activation	_
27-28	4726-4728	in	_
27-29	4729-4733	task	_
27-30	4734-4738	with	_
27-31	4739-4743	high	_
27-32	4744-4753	cognitive	_
27-33	4754-4760	demand	_
27-34	4761-4767	linked	_
27-35	4768-4770	to	_
27-36	4771-4778	emotion	_
27-37	4779-4789	processing	_
27-38	4790-4794	such	_
27-39	4795-4798	the	_
27-40	4799-4807	anterior	_
27-41	4808-4814	insula	_
27-42	4815-4818	and	_
27-43	4819-4823	also	_
27-44	4824-4826	in	_
27-45	4827-4834	regions	_
27-46	4835-4841	linked	_
27-47	4842-4844	to	_
27-48	4845-4853	salience	_
27-49	4854-4863	signaling	_
27-50	4864-4868	such	_
27-51	4869-4871	as	_
27-52	4872-4875	the	_
27-53	4876-4889	ventrolateral	_
27-54	4890-4900	prefrontal	_
27-55	4901-4907	cortex	_
27-56	4907-4908	.	_

#Text=Methods
#Text=Subjects
#Text=Altogether 19 patients with schizophrenia and 18 healthy control subjects were enrolled in the study.
28-1	4909-4916	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
28-2	4917-4925	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-3	4926-4936	Altogether	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-4	4937-4939	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-5	4940-4948	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-6	4949-4953	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-7	4954-4967	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
28-8	4968-4971	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-9	4972-4974	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-10	4975-4982	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
28-11	4983-4990	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
28-12	4991-4999	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-13	5000-5004	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-14	5005-5013	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-15	5014-5016	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-16	5017-5020	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-17	5021-5026	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
28-18	5026-5027	.	_

#Text=All participants underwent a series of psychological tests, EEG (electroencephalographic) examinations and finally a set of functional MRI (magnetic resonance imaging) tasks.
29-1	5028-5031	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-2	5032-5044	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-3	5045-5054	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-4	5055-5056	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-5	5057-5063	series	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-6	5064-5066	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-7	5067-5080	psychological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-8	5081-5086	tests	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-9	5086-5087	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-10	5088-5091	EEG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|*[6]
29-11	5092-5093	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|*[6]
29-12	5093-5116	electroencephalographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|*[6]
29-13	5116-5117	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|*[6]
29-14	5118-5130	examinations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-15	5131-5134	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-16	5135-5142	finally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-17	5143-5144	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-18	5145-5148	set	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-19	5149-5151	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
29-20	5152-5162	functional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]
29-21	5163-5166	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]
29-22	5167-5168	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]
29-23	5168-5176	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]
29-24	5177-5186	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]
29-25	5187-5194	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]
29-26	5194-5195	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]
29-27	5196-5201	tasks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
29-28	5201-5202	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]

#Text=The two study groups did not differ in age and education (Table 1).
30-1	5203-5206	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-2	5207-5210	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-3	5211-5216	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-4	5217-5223	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-5	5224-5227	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-6	5228-5231	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-7	5232-5238	differ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-8	5239-5241	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-9	5242-5245	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-10	5246-5249	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-11	5250-5259	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
30-12	5260-5261	(	_
30-13	5261-5266	Table	_
30-14	5266-5267	 	_
30-15	5267-5268	1	_
30-16	5268-5269	)	_
30-17	5269-5270	.	_

#Text=All participants were right-handed with the exception of one left-handed and one mixed handed patient and two left-handed healthy controls.
31-1	5271-5274	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-2	5275-5287	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-3	5288-5292	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-4	5293-5305	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-5	5306-5310	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-6	5311-5314	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-7	5315-5324	exception	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-8	5325-5327	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-9	5328-5331	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-10	5332-5343	left-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-11	5344-5347	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-12	5348-5351	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-13	5352-5357	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-14	5358-5364	handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-15	5365-5372	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-16	5373-5376	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-17	5377-5380	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-18	5381-5392	left-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
31-19	5393-5400	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]
31-20	5401-5409	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]
31-21	5409-5410	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]

#Text=All participants had normal or corrected-to-normal vision.
32-1	5411-5414	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
32-2	5415-5427	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
32-3	5428-5431	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
32-4	5432-5438	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
32-5	5439-5441	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
32-6	5442-5461	corrected-to-normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
32-7	5462-5468	vision	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
32-8	5468-5469	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]

#Text=Selection criteria for all participants were no history of any CNS (central nervous system) disease, mental retardation, epileptic seizure, substance dependence or substance abuse in the past 3 months, no history of head injury with loss of consciousness more than 10 minutes.
33-1	5470-5479	Selection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-2	5480-5488	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-3	5489-5492	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-4	5493-5496	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-5	5497-5509	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-6	5510-5514	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-7	5515-5517	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-8	5518-5525	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-9	5526-5528	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-10	5529-5532	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-11	5533-5536	CNS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-12	5537-5538	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-13	5538-5545	central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-14	5546-5553	nervous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-15	5554-5560	system	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-16	5560-5561	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-17	5562-5569	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-18	5569-5570	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-19	5571-5577	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-20	5578-5589	retardation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-21	5589-5590	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-22	5591-5600	epileptic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-23	5601-5608	seizure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-24	5608-5609	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-25	5610-5619	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-26	5620-5630	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-27	5631-5633	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-28	5634-5643	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-29	5644-5649	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-30	5650-5652	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-31	5653-5656	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-32	5657-5661	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-33	5662-5663	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-34	5663-5664	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-35	5664-5670	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-36	5670-5671	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-37	5672-5674	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-38	5675-5682	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-39	5683-5685	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-40	5686-5690	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-41	5691-5697	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-42	5698-5702	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-43	5703-5707	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-44	5708-5710	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-45	5711-5724	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-46	5725-5729	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-47	5730-5734	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-48	5735-5737	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-49	5738-5745	minutes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
33-50	5745-5746	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=For healthy controls further exclusion criteria were any psychiatric disorder and a global severity index of >114 on the Symptom Checklist–90–R, according to a Hungarian population sample, in order to exclude subjects with high risk for psychiatric disorders.
34-1	5747-5750	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-2	5751-5758	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
34-3	5759-5767	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
34-4	5768-5775	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-5	5776-5785	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-6	5786-5794	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-7	5795-5799	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-8	5800-5803	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-9	5804-5815	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-10	5816-5824	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-11	5825-5828	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-12	5829-5830	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-13	5831-5837	global	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-14	5838-5846	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-15	5847-5852	index	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-16	5853-5855	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-17	5856-5857	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-18	5857-5860	114	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-19	5861-5863	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-20	5864-5867	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-21	5868-5875	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-22	5876-5885	Checklist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-23	5885-5886	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-24	5886-5888	90	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-25	5888-5889	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-26	5889-5890	R	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-27	5890-5891	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-28	5892-5901	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-29	5902-5904	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-30	5905-5906	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-31	5907-5916	Hungarian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-32	5917-5927	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-33	5928-5934	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-34	5934-5935	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-35	5936-5938	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-36	5939-5944	order	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-37	5945-5947	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-38	5948-5955	exclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-39	5956-5964	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-40	5965-5969	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-41	5970-5974	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-42	5975-5979	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-43	5980-5983	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-44	5984-5995	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-45	5996-6005	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
34-46	6005-6006	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=Demographic information for both study groups and clinical characteristics of the schizophrenia group
#Text=\tSchizophrenia Group(n = 19)Mean (SD)\tControl Group(n = 18)Mean (SD)\tstatistics\tp value\t \tGender (male/female)\t12 / 6\t11/8\tChi2 = 0.3\tn.s.
35-1	6007-6018	Demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-2	6019-6030	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-3	6031-6034	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-4	6035-6039	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-5	6040-6045	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-6	6046-6052	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-7	6053-6056	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-8	6057-6065	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-9	6066-6081	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-10	6082-6084	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-11	6085-6088	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-12	6089-6102	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]
35-13	6103-6108	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]
35-14	6110-6123	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[20]
35-15	6124-6129	Group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-16	6129-6130	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-17	6130-6131	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-18	6131-6132	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-19	6132-6133	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-20	6134-6136	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-21	6136-6137	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-22	6137-6141	Mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-23	6142-6143	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-24	6143-6145	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-25	6145-6146	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-26	6147-6154	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
35-27	6155-6160	Group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
35-28	6160-6161	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-29	6161-6162	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-30	6162-6163	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-31	6163-6164	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-32	6165-6167	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-33	6167-6168	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-34	6168-6172	Mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-35	6173-6174	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-36	6174-6176	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-37	6176-6177	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-38	6178-6188	statistics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-39	6189-6190	p	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-40	6191-6196	value	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-41	6199-6205	Gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-42	6206-6207	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-43	6207-6211	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-44	6211-6212	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-45	6212-6218	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-46	6218-6219	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-47	6220-6222	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-48	6223-6224	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-49	6225-6226	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-50	6227-6229	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-51	6229-6230	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-52	6230-6231	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-53	6232-6236	Chi2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-54	6236-6237	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-55	6237-6238	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-56	6239-6242	0.3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-57	6243-6246	n.s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
35-58	6246-6247	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]

#Text=Age\t37.4 (8.4)\t37.6 (10.9)\tt = 0.1\tn.s.
36-1	6250-6253	Age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-2	6254-6258	37.4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-3	6259-6260	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-4	6260-6263	8.4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-5	6263-6264	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-6	6265-6269	37.6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-7	6270-6271	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-8	6271-6275	10.9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-9	6275-6276	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-10	6277-6278	t	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-11	6278-6279	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-12	6279-6280	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-13	6281-6284	0.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-14	6285-6288	n.s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
36-15	6288-6289	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]

#Text=Educationa\t2/5/6/6\t1/2/7/8\tFisher’s exact test\tn.s.
37-1	6292-6302	Educationa	_
37-2	6303-6304	2	_
37-3	6304-6305	/	_
37-4	6305-6306	5	_
37-5	6306-6307	/	_
37-6	6307-6308	6	_
37-7	6308-6309	/	_
37-8	6309-6310	6	_
37-9	6311-6312	1	_
37-10	6312-6313	/	_
37-11	6313-6314	2	_
37-12	6314-6315	/	_
37-13	6315-6316	7	_
37-14	6316-6317	/	_
37-15	6317-6318	8	_
37-16	6319-6325	Fisher	_
37-17	6325-6326	’	_
37-18	6326-6327	s	_
37-19	6328-6333	exact	_
37-20	6334-6338	test	_
37-21	6339-6342	n.s	_
37-22	6342-6343	.	_

#Text=Illness duration (years)\t12.2 (6.3)\t–\t\t\t \tIn−/Outpatients\t9 / 10\t–\t\t\t \tCPZ equivalent dose\t716 mg (337)\t–\t\t\t \tPANSS total score\t77.7 (18.5)\t–\t\t\t \t PANSS positive subscore\t17.6 (6.7)\t–\t\t\t \t PANSS negative subscore\t20.3 (6.8)\t–\t\t\t \t PANSS general subscore\t39.8 (9.1)\t–\t\t\t \tPSP\t59.5 (16.1)\t–\t\t\t \t
#Text=
#Text=a1 = elementary school; 2 = high school; 3 = vocational school; 4 = college/university
#Text=(CPZ = chlorpromazine equivalent dose; PANSS = Positive and Negative Symptoms Scale; PSP = Personal and Social Performance Scale)
#Text=Patients were recruited from the Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
38-1	6346-6353	Illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-2	6354-6362	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-3	6363-6364	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-4	6364-6369	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-5	6369-6370	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-6	6371-6375	12.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-7	6376-6377	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-8	6377-6380	6.3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-9	6380-6381	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-10	6382-6383	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-11	6388-6390	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-12	6390-6391	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-13	6391-6392	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-14	6392-6403	Outpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-15	6404-6405	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-16	6406-6407	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-17	6408-6410	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-18	6411-6412	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-19	6417-6420	CPZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-20	6421-6431	equivalent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-21	6432-6436	dose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-22	6437-6440	716	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-23	6440-6441	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-24	6441-6443	mg	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-25	6444-6445	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-26	6445-6448	337	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-27	6448-6449	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-28	6450-6451	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-29	6456-6461	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]
38-30	6462-6467	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-31	6468-6473	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-32	6474-6478	77.7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-33	6479-6480	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-34	6480-6484	18.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-35	6484-6485	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-36	6486-6487	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-37	6493-6498	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-38	6499-6507	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-39	6508-6516	subscore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-40	6517-6521	17.6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-41	6522-6523	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-42	6523-6526	6.7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-43	6526-6527	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-44	6528-6529	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-45	6535-6540	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-46	6541-6549	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-47	6550-6558	subscore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-48	6559-6563	20.3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-49	6564-6565	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-50	6565-6568	6.8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-51	6568-6569	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-52	6570-6571	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-53	6577-6582	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-54	6583-6590	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-55	6591-6599	subscore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-56	6600-6604	39.8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-57	6605-6606	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-58	6606-6609	9.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-59	6609-6610	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-60	6611-6612	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-61	6617-6620	PSP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-62	6621-6625	59.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-63	6626-6627	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-64	6627-6631	16.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-65	6631-6632	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-66	6633-6634	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-67	6641-6643	a1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-68	6644-6645	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-69	6646-6656	elementary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-70	6657-6663	school	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-71	6663-6664	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-72	6665-6666	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-73	6667-6668	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-74	6669-6673	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-75	6674-6680	school	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-76	6680-6681	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-77	6682-6683	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-78	6684-6685	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-79	6686-6696	vocational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-80	6697-6703	school	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-81	6703-6704	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-82	6705-6706	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-83	6707-6708	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-84	6709-6716	college	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-85	6716-6717	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-86	6717-6727	university	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-87	6728-6729	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-88	6729-6732	CPZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-89	6733-6734	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-90	6735-6749	chlorpromazine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-91	6750-6760	equivalent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-92	6761-6765	dose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-93	6765-6766	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-94	6767-6772	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-95	6773-6774	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-96	6775-6783	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-97	6784-6787	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-98	6788-6796	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-99	6797-6805	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-100	6806-6811	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-101	6811-6812	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-102	6813-6816	PSP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-103	6817-6818	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-104	6819-6827	Personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-105	6828-6831	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-106	6832-6838	Social	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-107	6839-6850	Performance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-108	6851-6856	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-109	6856-6857	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-110	6858-6866	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-111	6867-6871	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-112	6872-6881	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-113	6882-6886	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-114	6887-6890	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-115	6891-6901	Department	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-116	6902-6904	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-117	6905-6915	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-118	6916-6919	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-119	6920-6933	Psychotherapy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-120	6933-6934	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-121	6935-6945	Semmelweis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-122	6946-6956	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-123	6956-6957	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-124	6958-6966	Budapest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-125	6966-6967	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-126	6968-6975	Hungary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
38-127	6975-6976	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]

#Text=All patients met the criteria for schizophrenia based on the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4thEdition (DSM-IV)(American Psychiatry Association 1994).
39-1	6977-6980	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-2	6981-6989	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-3	6990-6993	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-4	6994-6997	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-5	6998-7006	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-6	7007-7010	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-7	7011-7024	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[26]
39-8	7025-7030	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-9	7031-7033	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-10	7034-7037	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-11	7038-7048	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-12	7049-7057	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-13	7058-7067	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-14	7068-7071	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-15	7072-7082	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-16	7083-7086	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-17	7087-7098	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-18	7099-7105	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-19	7106-7108	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-20	7109-7115	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-21	7116-7125	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-22	7125-7126	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-23	7127-7137	4thEdition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-24	7138-7139	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-25	7139-7145	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-26	7145-7146	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
39-27	7146-7147	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-28	7147-7155	American	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-29	7156-7166	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-30	7167-7178	Association	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-31	7179-7183	1994	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-32	7183-7184	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
39-33	7184-7185	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=The Positive and Negative Syndrome Scale (PANSS) were evaluated by a trained psychiatrist.
40-1	7186-7189	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
40-2	7190-7198	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-3	7199-7202	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-4	7203-7211	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-5	7212-7220	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-6	7221-7226	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-7	7227-7228	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-8	7228-7233	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-9	7233-7234	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[29]
40-10	7235-7239	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
40-11	7240-7249	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
40-12	7250-7252	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
40-13	7253-7254	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
40-14	7255-7262	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
40-15	7263-7275	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
40-16	7275-7276	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]

#Text=At the time of testing all patients took antipsychotic medication, the mean Chlorpromazine equivalent dose (Gardner et al. 2010) was 716 mg/day (SD = 337), while 10 patients took Benzodiazepines (BZD), and the mean Clonazepam equivalent dose (CPZ) was 1.6 mg/day (SD = 1.1 mg).
41-1	7277-7279	At	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-2	7280-7283	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-3	7284-7288	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-4	7289-7291	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-5	7292-7299	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-6	7300-7303	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-7	7304-7312	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-8	7313-7317	took	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-9	7318-7331	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-10	7332-7342	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-11	7342-7343	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-12	7344-7347	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-13	7348-7352	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-14	7353-7367	Chlorpromazine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-15	7368-7378	equivalent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-16	7379-7383	dose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-17	7384-7385	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-18	7385-7392	Gardner	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-19	7393-7395	et	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-20	7396-7398	al	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-21	7398-7399	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-22	7400-7404	2010	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-23	7404-7405	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-24	7406-7409	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-25	7410-7413	716	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-26	7413-7414	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-27	7414-7416	mg	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-28	7416-7417	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-29	7417-7420	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-30	7421-7422	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-31	7422-7424	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-32	7425-7426	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-33	7427-7430	337	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-34	7430-7431	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-35	7431-7432	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-36	7433-7438	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-37	7439-7441	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-38	7442-7450	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-39	7451-7455	took	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-40	7456-7471	Benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-41	7472-7473	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-42	7473-7476	BZD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-43	7476-7477	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-44	7477-7478	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-45	7479-7482	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-46	7483-7486	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-47	7487-7491	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-48	7492-7502	Clonazepam	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-49	7503-7513	equivalent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-50	7514-7518	dose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-51	7519-7520	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-52	7520-7523	CPZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-53	7523-7524	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-54	7525-7528	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-55	7529-7532	1.6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-56	7532-7533	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-57	7533-7535	mg	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-58	7535-7536	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-59	7536-7539	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-60	7540-7541	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-61	7541-7543	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-62	7544-7545	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-63	7546-7549	1.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-64	7549-7550	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-65	7550-7552	mg	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-66	7552-7553	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
41-67	7553-7554	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]

#Text=Psychosocial functioning was measured by the Personal and Social Performance Scale (PSP).
42-1	7555-7567	Psychosocial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
42-2	7568-7579	functioning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
42-3	7580-7583	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
42-4	7584-7592	measured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
42-5	7593-7595	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
42-6	7596-7599	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
42-7	7600-7608	Personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-8	7609-7612	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-9	7613-7619	Social	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-10	7620-7631	Performance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-11	7632-7637	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-12	7638-7639	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-13	7639-7642	PSP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-14	7642-7643	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[32]
42-15	7643-7644	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]

#Text=Demographic information for both study groups and the clinical characteristics of the patient group are presented in Table 1 .
43-1	7645-7656	Demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-2	7657-7668	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-3	7669-7672	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-4	7673-7677	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-5	7678-7683	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-6	7684-7690	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-7	7691-7694	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-8	7695-7698	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-9	7699-7707	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-10	7708-7723	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-11	7724-7726	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-12	7727-7730	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-13	7731-7738	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-14	7739-7744	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-15	7745-7748	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-16	7749-7758	presented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-17	7759-7761	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-18	7762-7767	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-19	7768-7769	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
43-20	7770-7771	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]

#Text=Procedures
#Text=Stimuli
#Text=In order to generate mixed emotional facial expressions morphed faces from the Ekman database were used.
44-1	7774-7784	Procedures	_
44-2	7785-7792	Stimuli	_
44-3	7793-7795	In	_
44-4	7796-7801	order	_
44-5	7802-7804	to	_
44-6	7805-7813	generate	_
44-7	7814-7819	mixed	_
44-8	7820-7829	emotional	_
44-9	7830-7836	facial	_
44-10	7837-7848	expressions	_
44-11	7849-7856	morphed	_
44-12	7857-7862	faces	_
44-13	7863-7867	from	_
44-14	7868-7871	the	_
44-15	7872-7877	Ekman	_
44-16	7878-7886	database	_
44-17	7887-7891	were	_
44-18	7892-7896	used	_
44-19	7896-7897	.	_

#Text=These morphed faces were tested in a different group of healthy subjects (n = 20), who had not participated in the MRI study.
45-1	7898-7903	These	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-2	7904-7911	morphed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-3	7912-7917	faces	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-4	7918-7922	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-5	7923-7929	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-6	7930-7932	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-7	7933-7934	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-8	7935-7944	different	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-9	7945-7950	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-10	7951-7953	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-11	7954-7961	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-12	7962-7970	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-13	7971-7972	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-14	7972-7973	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-15	7973-7974	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-16	7974-7975	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-17	7976-7978	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-18	7978-7979	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-19	7979-7980	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-20	7981-7984	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-21	7985-7988	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-22	7989-7992	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-23	7993-8005	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-24	8006-8008	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-25	8009-8012	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-26	8013-8016	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-27	8017-8022	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
45-28	8022-8023	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]

#Text=Subjects had to select the faces which expressed the mixture of the two emotions the best, but dominantly happy or fear respectively.
46-1	8024-8032	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-2	8033-8036	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-3	8037-8039	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-4	8040-8046	select	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-5	8047-8050	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-6	8051-8056	faces	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-7	8057-8062	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-8	8063-8072	expressed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-9	8073-8076	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-10	8077-8084	mixture	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-11	8085-8087	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-12	8088-8091	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-13	8092-8095	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-14	8096-8104	emotions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-15	8105-8108	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-16	8109-8113	best	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-17	8113-8114	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-18	8115-8118	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-19	8119-8129	dominantly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-20	8130-8135	happy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-21	8136-8138	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-22	8139-8143	fear	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-23	8144-8156	respectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
46-24	8156-8157	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=The ones with 30% and 70% mixture of the emotions were selected for the final task as mixed emotions.
47-1	8158-8161	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-2	8162-8166	ones	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-3	8167-8171	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-4	8172-8175	30%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-5	8176-8179	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-6	8180-8183	70%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-7	8184-8191	mixture	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-8	8192-8194	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-9	8195-8198	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-10	8199-8207	emotions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-11	8208-8212	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-12	8213-8221	selected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-13	8222-8225	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-14	8226-8229	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-15	8230-8235	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-16	8236-8240	task	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-17	8241-8243	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-18	8244-8249	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-19	8250-8258	emotions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
47-20	8258-8259	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]

#Text=We refer to these mixed emotions by the 70% component: mixed fear is 70% fear and 30% happy, while mixed happy is 70% happy and 30% fear.
48-1	8260-8262	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-2	8263-8268	refer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-3	8269-8271	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-4	8272-8277	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-5	8278-8283	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-6	8284-8292	emotions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-7	8293-8295	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-8	8296-8299	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-9	8300-8303	70%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-10	8304-8313	component	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-11	8313-8314	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-12	8315-8320	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-13	8321-8325	fear	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-14	8326-8328	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-15	8329-8332	70%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-16	8333-8337	fear	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-17	8338-8341	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-18	8342-8345	30%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-19	8346-8351	happy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-20	8351-8352	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-21	8353-8358	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-22	8359-8364	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-23	8365-8370	happy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-24	8371-8373	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-25	8374-8377	70%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-26	8378-8383	happy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-27	8384-8387	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-28	8388-8391	30%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-29	8392-8396	fear	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
48-30	8396-8397	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]

#Text=The stimulus set consisted of 10 fearful (100%) facial expression, 10 happy (100%) faces and 10 mixed fear and 10 mixed happy faces.
49-1	8398-8401	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-2	8402-8410	stimulus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-3	8411-8414	set	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-4	8415-8424	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-5	8425-8427	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-6	8428-8430	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-7	8431-8438	fearful	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-8	8439-8440	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-9	8440-8444	100%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-10	8444-8445	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-11	8446-8452	facial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-12	8453-8463	expression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-13	8463-8464	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-14	8465-8467	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-15	8468-8473	happy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-16	8474-8475	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-17	8475-8479	100%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-18	8479-8480	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-19	8481-8486	faces	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-20	8487-8490	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-21	8491-8493	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-22	8494-8499	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-23	8500-8504	fear	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-24	8505-8508	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-25	8509-8511	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-26	8512-8517	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-27	8518-8523	happy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-28	8524-8529	faces	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
49-29	8529-8530	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]

#Text=Schematic illustration of the experimental paradigm.
50-1	8531-8540	Schematic	_
50-2	8541-8553	illustration	_
50-3	8554-8556	of	_
50-4	8557-8560	the	_
50-5	8561-8573	experimental	_
50-6	8574-8582	paradigm	_
50-7	8582-8583	.	_

#Text=Pictures of happy (100%), fear (100%), mixed happy (70% happy and 30% fear) and mixed fear (70% fear and 30% happy) facial expression (http://www.paulekman.com) were presented for 2 s in a randomized order, the inter-stimulus baseline was a distorted (scrambled) picture, which was a Fourier transformation of all the original images.
51-1	8584-8592	Pictures	_
51-2	8593-8595	of	_
51-3	8596-8601	happy	_
51-4	8602-8603	(	_
51-5	8603-8607	100%	_
51-6	8607-8608	)	_
51-7	8608-8609	,	_
51-8	8610-8614	fear	_
51-9	8615-8616	(	_
51-10	8616-8620	100%	_
51-11	8620-8621	)	_
51-12	8621-8622	,	_
51-13	8623-8628	mixed	_
51-14	8629-8634	happy	_
51-15	8635-8636	(	_
51-16	8636-8639	70%	_
51-17	8640-8645	happy	_
51-18	8646-8649	and	_
51-19	8650-8653	30%	_
51-20	8654-8658	fear	_
51-21	8658-8659	)	_
51-22	8660-8663	and	_
51-23	8664-8669	mixed	_
51-24	8670-8674	fear	_
51-25	8675-8676	(	_
51-26	8676-8679	70%	_
51-27	8680-8684	fear	_
51-28	8685-8688	and	_
51-29	8689-8692	30%	_
51-30	8693-8698	happy	_
51-31	8698-8699	)	_
51-32	8700-8706	facial	_
51-33	8707-8717	expression	_
51-34	8718-8719	(	_
51-35	8719-8723	http	_
51-36	8723-8724	:	_
51-37	8724-8725	/	_
51-38	8725-8726	/	_
51-39	8726-8743	www.paulekman.com	_
51-40	8743-8744	)	_
51-41	8745-8749	were	_
51-42	8750-8759	presented	_
51-43	8760-8763	for	_
51-44	8764-8765	2	_
51-45	8765-8766	 	_
51-46	8766-8767	s	_
51-47	8768-8770	in	_
51-48	8771-8772	a	_
51-49	8773-8783	randomized	_
51-50	8784-8789	order	_
51-51	8789-8790	,	_
51-52	8791-8794	the	_
51-53	8795-8809	inter-stimulus	_
51-54	8810-8818	baseline	_
51-55	8819-8822	was	_
51-56	8823-8824	a	_
51-57	8825-8834	distorted	_
51-58	8835-8836	(	_
51-59	8836-8845	scrambled	_
51-60	8845-8846	)	_
51-61	8847-8854	picture	_
51-62	8854-8855	,	_
51-63	8856-8861	which	_
51-64	8862-8865	was	_
51-65	8866-8867	a	_
51-66	8868-8875	Fourier	_
51-67	8876-8890	transformation	_
51-68	8891-8893	of	_
51-69	8894-8897	all	_
51-70	8898-8901	the	_
51-71	8902-8910	original	_
51-72	8911-8917	images	_
51-73	8917-8918	.	_

#Text=The inter-stimulus interval was randomized between 2 and 10 s.
52-1	8919-8922	The	_
52-2	8923-8937	inter-stimulus	_
52-3	8938-8946	interval	_
52-4	8947-8950	was	_
52-5	8951-8961	randomized	_
52-6	8962-8969	between	_
52-7	8970-8971	2	_
52-8	8972-8975	and	_
52-9	8976-8978	10	_
52-10	8978-8979	 	_
52-11	8979-8980	s	_
52-12	8980-8981	.	_

#Text=The subjects had to respond by a button press whether they see a happy or a fearful facial expression
#Text=All pictures were presented for 2 s in a randomized order, the inter-stimulus baseline was a distorted (scrambled) picture, which was a Fourier transformation of all the original images (Fig. 1).
53-1	8982-8985	The	_
53-2	8986-8994	subjects	_
53-3	8995-8998	had	_
53-4	8999-9001	to	_
53-5	9002-9009	respond	_
53-6	9010-9012	by	_
53-7	9013-9014	a	_
53-8	9015-9021	button	_
53-9	9022-9027	press	_
53-10	9028-9035	whether	_
53-11	9036-9040	they	_
53-12	9041-9044	see	_
53-13	9045-9046	a	_
53-14	9047-9052	happy	_
53-15	9053-9055	or	_
53-16	9056-9057	a	_
53-17	9058-9065	fearful	_
53-18	9066-9072	facial	_
53-19	9073-9083	expression	_
53-20	9084-9087	All	_
53-21	9088-9096	pictures	_
53-22	9097-9101	were	_
53-23	9102-9111	presented	_
53-24	9112-9115	for	_
53-25	9116-9117	2	_
53-26	9117-9118	 	_
53-27	9118-9119	s	_
53-28	9120-9122	in	_
53-29	9123-9124	a	_
53-30	9125-9135	randomized	_
53-31	9136-9141	order	_
53-32	9141-9142	,	_
53-33	9143-9146	the	_
53-34	9147-9161	inter-stimulus	_
53-35	9162-9170	baseline	_
53-36	9171-9174	was	_
53-37	9175-9176	a	_
53-38	9177-9186	distorted	_
53-39	9187-9188	(	_
53-40	9188-9197	scrambled	_
53-41	9197-9198	)	_
53-42	9199-9206	picture	_
53-43	9206-9207	,	_
53-44	9208-9213	which	_
53-45	9214-9217	was	_
53-46	9218-9219	a	_
53-47	9220-9227	Fourier	_
53-48	9228-9242	transformation	_
53-49	9243-9245	of	_
53-50	9246-9249	all	_
53-51	9250-9253	the	_
53-52	9254-9262	original	_
53-53	9263-9269	images	_
53-54	9270-9271	(	_
53-55	9271-9274	Fig	_
53-56	9274-9275	.	_
53-57	9275-9276	 	_
53-58	9276-9277	1	_
53-59	9277-9278	)	_
53-60	9278-9279	.	_

#Text=The inter-stimulus interval was randomized between 2 and 10 s.
54-1	9280-9283	The	_
54-2	9284-9298	inter-stimulus	_
54-3	9299-9307	interval	_
54-4	9308-9311	was	_
54-5	9312-9322	randomized	_
54-6	9323-9330	between	_
54-7	9331-9332	2	_
54-8	9333-9336	and	_
54-9	9337-9339	10	_
54-10	9339-9340	 	_
54-11	9340-9341	s	_
54-12	9341-9342	.	_

#Text=The subjects had to respond by a button press whether they had seen a happy or a fearful facial expression.
55-1	9343-9346	The	_
55-2	9347-9355	subjects	_
55-3	9356-9359	had	_
55-4	9360-9362	to	_
55-5	9363-9370	respond	_
55-6	9371-9373	by	_
55-7	9374-9375	a	_
55-8	9376-9382	button	_
55-9	9383-9388	press	_
55-10	9389-9396	whether	_
55-11	9397-9401	they	_
55-12	9402-9405	had	_
55-13	9406-9410	seen	_
55-14	9411-9412	a	_
55-15	9413-9418	happy	_
55-16	9419-9421	or	_
55-17	9422-9423	a	_
55-18	9424-9431	fearful	_
55-19	9432-9438	facial	_
55-20	9439-9449	expression	_
55-21	9449-9450	.	_

#Text=The viewing distance was 60 cm.
56-1	9451-9454	The	_
56-2	9455-9462	viewing	_
56-3	9463-9471	distance	_
56-4	9472-9475	was	_
56-5	9476-9478	60	_
56-6	9478-9479	 	_
56-7	9479-9481	cm	_
56-8	9481-9482	.	_

#Text=Happy facial expression was selected as counterparts of fearful faces, since the recognition of happiness was found to be mildly affected compared to impaired fear processing in patient with schizophrenia according to previous studies, while the processing of neutral facial expressions were found to be severely impaired in schizophrenia.
57-1	9483-9488	Happy	_
57-2	9489-9495	facial	_
57-3	9496-9506	expression	_
57-4	9507-9510	was	_
57-5	9511-9519	selected	_
57-6	9520-9522	as	_
57-7	9523-9535	counterparts	_
57-8	9536-9538	of	_
57-9	9539-9546	fearful	_
57-10	9547-9552	faces	_
57-11	9552-9553	,	_
57-12	9554-9559	since	_
57-13	9560-9563	the	_
57-14	9564-9575	recognition	_
57-15	9576-9578	of	_
57-16	9579-9588	happiness	_
57-17	9589-9592	was	_
57-18	9593-9598	found	_
57-19	9599-9601	to	_
57-20	9602-9604	be	_
57-21	9605-9611	mildly	_
57-22	9612-9620	affected	_
57-23	9621-9629	compared	_
57-24	9630-9632	to	_
57-25	9633-9641	impaired	_
57-26	9642-9646	fear	_
57-27	9647-9657	processing	_
57-28	9658-9660	in	_
57-29	9661-9668	patient	_
57-30	9669-9673	with	_
57-31	9674-9687	schizophrenia	_
57-32	9688-9697	according	_
57-33	9698-9700	to	_
57-34	9701-9709	previous	_
57-35	9710-9717	studies	_
57-36	9717-9718	,	_
57-37	9719-9724	while	_
57-38	9725-9728	the	_
57-39	9729-9739	processing	_
57-40	9740-9742	of	_
57-41	9743-9750	neutral	_
57-42	9751-9757	facial	_
57-43	9758-9769	expressions	_
57-44	9770-9774	were	_
57-45	9775-9780	found	_
57-46	9781-9783	to	_
57-47	9784-9786	be	_
57-48	9787-9795	severely	_
57-49	9796-9804	impaired	_
57-50	9805-9807	in	_
57-51	9808-9821	schizophrenia	_
57-52	9821-9822	.	_

#Text=We decided to exclude neutral facial displays from the paradigm due to the following reasons: using three response buttons may overcomplicate the task and the increasing number of stimuli would have made the task too long, both of which might have raised attentional issues and might have biased the results, especially in the patient group.
58-1	9823-9825	We	_
58-2	9826-9833	decided	_
58-3	9834-9836	to	_
58-4	9837-9844	exclude	_
58-5	9845-9852	neutral	_
58-6	9853-9859	facial	_
58-7	9860-9868	displays	_
58-8	9869-9873	from	_
58-9	9874-9877	the	_
58-10	9878-9886	paradigm	_
58-11	9887-9890	due	_
58-12	9891-9893	to	_
58-13	9894-9897	the	_
58-14	9898-9907	following	_
58-15	9908-9915	reasons	_
58-16	9915-9916	:	_
58-17	9917-9922	using	_
58-18	9923-9928	three	_
58-19	9929-9937	response	_
58-20	9938-9945	buttons	_
58-21	9946-9949	may	_
58-22	9950-9964	overcomplicate	_
58-23	9965-9968	the	_
58-24	9969-9973	task	_
58-25	9974-9977	and	_
58-26	9978-9981	the	_
58-27	9982-9992	increasing	_
58-28	9993-9999	number	_
58-29	10000-10002	of	_
58-30	10003-10010	stimuli	_
58-31	10011-10016	would	_
58-32	10017-10021	have	_
58-33	10022-10026	made	_
58-34	10027-10030	the	_
58-35	10031-10035	task	_
58-36	10036-10039	too	_
58-37	10040-10044	long	_
58-38	10044-10045	,	_
58-39	10046-10050	both	_
58-40	10051-10053	of	_
58-41	10054-10059	which	_
58-42	10060-10065	might	_
58-43	10066-10070	have	_
58-44	10071-10077	raised	_
58-45	10078-10089	attentional	_
58-46	10090-10096	issues	_
58-47	10097-10100	and	_
58-48	10101-10106	might	_
58-49	10107-10111	have	_
58-50	10112-10118	biased	_
58-51	10119-10122	the	_
58-52	10123-10130	results	_
58-53	10130-10131	,	_
58-54	10132-10142	especially	_
58-55	10143-10145	in	_
58-56	10146-10149	the	_
58-57	10150-10157	patient	_
58-58	10158-10163	group	_
58-59	10163-10164	.	_

#Text=Image acquisition
#Text=The described MRI procedure took 30 min and were done at the MR Research Center, Semmelweis University on a 3 Tesla Philips Achieva whole body clinical MRI scanner (Philips Medical Systems, Best, The Netherlands) equipped with an 8-channel SENSE head-coil.
59-1	10166-10171	Image	_
59-2	10172-10183	acquisition	_
59-3	10184-10187	The	_
59-4	10188-10197	described	_
59-5	10198-10201	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument
59-6	10202-10211	procedure	_
59-7	10212-10216	took	_
59-8	10217-10219	30	_
59-9	10219-10220	 	_
59-10	10220-10223	min	_
59-11	10224-10227	and	_
59-12	10228-10232	were	_
59-13	10233-10237	done	_
59-14	10238-10240	at	_
59-15	10241-10244	the	_
59-16	10245-10247	MR	_
59-17	10248-10256	Research	_
59-18	10257-10263	Center	_
59-19	10263-10264	,	_
59-20	10265-10275	Semmelweis	_
59-21	10276-10286	University	_
59-22	10287-10289	on	_
59-23	10290-10291	a	_
59-24	10292-10293	3	_
59-25	10294-10299	Tesla	_
59-26	10300-10307	Philips	_
59-27	10308-10315	Achieva	_
59-28	10316-10321	whole	_
59-29	10322-10326	body	_
59-30	10327-10335	clinical	_
59-31	10336-10339	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[39]
59-32	10340-10347	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[39]
59-33	10348-10349	(	_
59-34	10349-10356	Philips	_
59-35	10357-10364	Medical	_
59-36	10365-10372	Systems	_
59-37	10372-10373	,	_
59-38	10374-10378	Best	_
59-39	10378-10379	,	_
59-40	10380-10383	The	_
59-41	10384-10395	Netherlands	_
59-42	10395-10396	)	_
59-43	10397-10405	equipped	_
59-44	10406-10410	with	_
59-45	10411-10413	an	_
59-46	10414-10415	8	_
59-47	10415-10416	-	_
59-48	10416-10423	channel	_
59-49	10424-10429	SENSE	_
59-50	10430-10439	head-coil	_
59-51	10439-10440	.	_

#Text=The high resolution, whole brain anatomical images were obtained using a T1 weighted 3 dimensional spoiled gradient echo (T1 W 3D TFE) sequence. 180 contiguous slices were acquired from each subject with the following imaging parameters: TR (time resolution) = 9.7 ms; TE (echo time) = 4.6 ms; flip angle = 8°; FOV (Field-of view) of 240 mm × 240 mm; voxel size of 1.0 × 1.0 × 1.0 mm.
60-1	10441-10444	The	_
60-2	10445-10449	high	_
60-3	10450-10460	resolution	_
60-4	10460-10461	,	_
60-5	10462-10467	whole	_
60-6	10468-10473	brain	_
60-7	10474-10484	anatomical	_
60-8	10485-10491	images	_
60-9	10492-10496	were	_
60-10	10497-10505	obtained	_
60-11	10506-10511	using	_
60-12	10512-10513	a	_
60-13	10514-10516	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[40]
60-14	10517-10525	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[40]
60-15	10526-10527	3	_
60-16	10528-10539	dimensional	_
60-17	10540-10547	spoiled	_
60-18	10548-10556	gradient	_
60-19	10557-10561	echo	_
60-20	10562-10563	(	_
60-21	10563-10565	T1	_
60-22	10565-10566	 	_
60-23	10566-10567	W	_
60-24	10568-10570	3D	_
60-25	10571-10574	TFE	_
60-26	10574-10575	)	_
60-27	10576-10584	sequence	_
60-28	10584-10585	.	_
60-29	10586-10589	180	_
60-30	10590-10600	contiguous	_
60-31	10601-10607	slices	_
60-32	10608-10612	were	_
60-33	10613-10621	acquired	_
60-34	10622-10626	from	_
60-35	10627-10631	each	_
60-36	10632-10639	subject	_
60-37	10640-10644	with	_
60-38	10645-10648	the	_
60-39	10649-10658	following	_
60-40	10659-10666	imaging	_
60-41	10667-10677	parameters	_
60-42	10677-10678	:	_
60-43	10679-10681	TR	_
60-44	10682-10683	(	_
60-45	10683-10687	time	_
60-46	10688-10698	resolution	_
60-47	10698-10699	)	_
60-48	10700-10701	=	_
60-49	10702-10705	9.7	_
60-50	10705-10706	 	_
60-51	10706-10708	ms	_
60-52	10708-10709	;	_
60-53	10710-10712	TE	_
60-54	10713-10714	(	_
60-55	10714-10718	echo	_
60-56	10719-10723	time	_
60-57	10723-10724	)	_
60-58	10725-10726	=	_
60-59	10727-10730	4.6	_
60-60	10730-10731	 	_
60-61	10731-10733	ms	_
60-62	10733-10734	;	_
60-63	10735-10739	flip	_
60-64	10740-10745	angle	_
60-65	10746-10747	=	_
60-66	10748-10749	8	_
60-67	10749-10750	°	_
60-68	10750-10751	;	_
60-69	10752-10755	FOV	_
60-70	10756-10757	(	_
60-71	10757-10765	Field-of	_
60-72	10766-10770	view	_
60-73	10770-10771	)	_
60-74	10772-10774	of	_
60-75	10775-10778	240	_
60-76	10778-10779	 	_
60-77	10779-10781	mm	_
60-78	10782-10783	×	_
60-79	10784-10787	240	_
60-80	10787-10788	 	_
60-81	10788-10790	mm	_
60-82	10790-10791	;	_
60-83	10792-10797	voxel	_
60-84	10798-10802	size	_
60-85	10803-10805	of	_
60-86	10806-10809	1.0	_
60-87	10810-10811	×	_
60-88	10812-10815	1.0	_
60-89	10816-10817	×	_
60-90	10818-10821	1.0	_
60-91	10821-10822	 	_
60-92	10822-10824	mm	_
60-93	10824-10825	.	_

#Text=Functional images were acquired using a T2* weighted gradient echo echo-planar imaging sequence with the following parameters: TR = 2.0 ms; TE = 30 ms; flip angle = 70°, FOV of 240 mm × 240 mm; voxel size of 3.0 × 3.0 × 4.0 mm; maximum number of slices = 36.
61-1	10826-10836	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[41]
61-2	10837-10843	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[41]
61-3	10844-10848	were	_
61-4	10849-10857	acquired	_
61-5	10858-10863	using	_
61-6	10864-10865	a	_
61-7	10866-10868	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[42]
61-8	10868-10869	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[42]
61-9	10870-10878	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[42]
61-10	10879-10887	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[42]
61-11	10888-10892	echo	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[42]
61-12	10893-10904	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[42]
61-13	10905-10912	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[42]
61-14	10913-10921	sequence	_
61-15	10922-10926	with	_
61-16	10927-10930	the	_
61-17	10931-10940	following	_
61-18	10941-10951	parameters	_
61-19	10951-10952	:	_
61-20	10953-10955	TR	_
61-21	10956-10957	=	_
61-22	10958-10961	2.0	_
61-23	10961-10962	 	_
61-24	10962-10964	ms	_
61-25	10964-10965	;	_
61-26	10966-10968	TE	_
61-27	10969-10970	=	_
61-28	10971-10973	30	_
61-29	10973-10974	 	_
61-30	10974-10976	ms	_
61-31	10976-10977	;	_
61-32	10978-10982	flip	_
61-33	10983-10988	angle	_
61-34	10989-10990	=	_
61-35	10991-10993	70	_
61-36	10993-10994	°	_
61-37	10994-10995	,	_
61-38	10996-10999	FOV	_
61-39	11000-11002	of	_
61-40	11003-11006	240	_
61-41	11006-11007	 	_
61-42	11007-11009	mm	_
61-43	11010-11011	×	_
61-44	11012-11015	240	_
61-45	11015-11016	 	_
61-46	11016-11018	mm	_
61-47	11018-11019	;	_
61-48	11020-11025	voxel	_
61-49	11026-11030	size	_
61-50	11031-11033	of	_
61-51	11034-11037	3.0	_
61-52	11038-11039	×	_
61-53	11040-11043	3.0	_
61-54	11044-11045	×	_
61-55	11046-11049	4.0	_
61-56	11049-11050	 	_
61-57	11050-11052	mm	_
61-58	11052-11053	;	_
61-59	11054-11061	maximum	_
61-60	11062-11068	number	_
61-61	11069-11071	of	_
61-62	11072-11078	slices	_
61-63	11079-11080	=	_
61-64	11081-11083	36	_
61-65	11083-11084	.	_

#Text=NordicNeuroLab SyncBox and ResponseGrip (NordicNeuroLab, Bergen, Norway) were used to record subject responses during tasks.
62-1	11085-11099	NordicNeuroLab	_
62-2	11100-11107	SyncBox	_
62-3	11108-11111	and	_
62-4	11112-11124	ResponseGrip	_
62-5	11125-11126	(	_
62-6	11126-11140	NordicNeuroLab	_
62-7	11140-11141	,	_
62-8	11142-11148	Bergen	_
62-9	11148-11149	,	_
62-10	11150-11156	Norway	_
62-11	11156-11157	)	_
62-12	11158-11162	were	_
62-13	11163-11167	used	_
62-14	11168-11170	to	_
62-15	11171-11177	record	_
62-16	11178-11185	subject	_
62-17	11186-11195	responses	_
62-18	11196-11202	during	_
62-19	11203-11208	tasks	_
62-20	11208-11209	.	_

#Text=Stimuli were presented in Psychtoolbox (http://psychtoolbox.org/), a Matlab R2012A (Mathworks, Natick, MA, USA) toolbox used for visual stimulus presentation.
63-1	11210-11217	Stimuli	_
63-2	11218-11222	were	_
63-3	11223-11232	presented	_
63-4	11233-11235	in	_
63-5	11236-11248	Psychtoolbox	_
63-6	11249-11250	(	_
63-7	11250-11254	http	_
63-8	11254-11255	:	_
63-9	11255-11256	/	_
63-10	11256-11257	/	_
63-11	11257-11273	psychtoolbox.org	_
63-12	11273-11274	/	_
63-13	11274-11275	)	_
63-14	11275-11276	,	_
63-15	11277-11278	a	_
63-16	11279-11285	Matlab	_
63-17	11286-11292	R2012A	_
63-18	11293-11294	(	_
63-19	11294-11303	Mathworks	_
63-20	11303-11304	,	_
63-21	11305-11311	Natick	_
63-22	11311-11312	,	_
63-23	11313-11315	MA	_
63-24	11315-11316	,	_
63-25	11317-11320	USA	_
63-26	11320-11321	)	_
63-27	11322-11329	toolbox	_
63-28	11330-11334	used	_
63-29	11335-11338	for	_
63-30	11339-11345	visual	_
63-31	11346-11354	stimulus	_
63-32	11355-11367	presentation	_
63-33	11367-11368	.	_

#Text=In During the fMRI experiment visual stimuli were projected onto a translucent screen located at the back of the scanner bore using an Panasonic Panasonic PT-D3500E DLP projector (Matsushita Electric Industrial Co., Osaka, Japan) at a refresh rate of 75 Hz.
64-1	11369-11371	In	_
64-2	11372-11378	During	_
64-3	11379-11382	the	_
64-4	11383-11387	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-5	11388-11398	experiment	_
64-6	11399-11405	visual	_
64-7	11406-11413	stimuli	_
64-8	11414-11418	were	_
64-9	11419-11428	projected	_
64-10	11429-11433	onto	_
64-11	11434-11435	a	_
64-12	11436-11447	translucent	_
64-13	11448-11454	screen	_
64-14	11455-11462	located	_
64-15	11463-11465	at	_
64-16	11466-11469	the	_
64-17	11470-11474	back	_
64-18	11475-11477	of	_
64-19	11478-11481	the	_
64-20	11482-11489	scanner	_
64-21	11490-11494	bore	_
64-22	11495-11500	using	_
64-23	11501-11503	an	_
64-24	11504-11513	Panasonic	_
64-25	11514-11523	Panasonic	_
64-26	11524-11533	PT-D3500E	_
64-27	11534-11537	DLP	_
64-28	11538-11547	projector	_
64-29	11548-11549	(	_
64-30	11549-11559	Matsushita	_
64-31	11560-11568	Electric	_
64-32	11569-11579	Industrial	_
64-33	11580-11582	Co	_
64-34	11582-11583	.	_
64-35	11583-11584	,	_
64-36	11585-11590	Osaka	_
64-37	11590-11591	,	_
64-38	11592-11597	Japan	_
64-39	11597-11598	)	_
64-40	11599-11601	at	_
64-41	11602-11603	a	_
64-42	11604-11611	refresh	_
64-43	11612-11616	rate	_
64-44	11617-11619	of	_
64-45	11620-11622	75	_
64-46	11622-11623	 	_
64-47	11623-11625	Hz	_
64-48	11625-11626	.	_

#Text=Stimuli were viewed from inside the magnet bore by through a mirror system attached to the head coil, the viewing distance was 58 cm.
65-1	11627-11634	Stimuli	_
65-2	11635-11639	were	_
65-3	11640-11646	viewed	_
65-4	11647-11651	from	_
65-5	11652-11658	inside	_
65-6	11659-11662	the	_
65-7	11663-11669	magnet	_
65-8	11670-11674	bore	_
65-9	11675-11677	by	_
65-10	11678-11685	through	_
65-11	11686-11687	a	_
65-12	11688-11694	mirror	_
65-13	11695-11701	system	_
65-14	11702-11710	attached	_
65-15	11711-11713	to	_
65-16	11714-11717	the	_
65-17	11718-11722	head	_
65-18	11723-11727	coil	_
65-19	11727-11728	,	_
65-20	11729-11732	the	_
65-21	11733-11740	viewing	_
65-22	11741-11749	distance	_
65-23	11750-11753	was	_
65-24	11754-11756	58	_
65-25	11756-11757	 	_
65-26	11757-11759	cm	_
65-27	11759-11760	.	_

#Text=Head motion was minimized using foam padding.
66-1	11761-11765	Head	_
66-2	11766-11772	motion	_
66-3	11773-11776	was	_
66-4	11777-11786	minimized	_
66-5	11787-11792	using	_
66-6	11793-11797	foam	_
66-7	11798-11805	padding	_
66-8	11805-11806	.	_

#Text=MRI preprocessing and statistical analysis
#Text=Between group differences in brain activations
#Text=Condition/Anatomical region\tBrodmann areas (BA)\tPeak MNI coordinates\tVoxel level\tCluster level\t \tX\tY\tZ\tp value (FWE-corr.)\tcluster size (voxels/cm3)\tp value(FWE-corr.)
67-1	11807-11810	MRI	_
67-2	11811-11824	preprocessing	_
67-3	11825-11828	and	_
67-4	11829-11840	statistical	_
67-5	11841-11849	analysis	_
67-6	11850-11857	Between	_
67-7	11858-11863	group	_
67-8	11864-11875	differences	_
67-9	11876-11878	in	_
67-10	11879-11884	brain	_
67-11	11885-11896	activations	_
67-12	11897-11906	Condition	_
67-13	11906-11907	/	_
67-14	11907-11917	Anatomical	_
67-15	11918-11924	region	_
67-16	11925-11933	Brodmann	_
67-17	11934-11939	areas	_
67-18	11940-11941	(	_
67-19	11941-11943	BA	_
67-20	11943-11944	)	_
67-21	11945-11949	Peak	_
67-22	11950-11953	MNI	_
67-23	11954-11965	coordinates	_
67-24	11966-11971	Voxel	_
67-25	11972-11977	level	_
67-26	11978-11985	Cluster	_
67-27	11986-11991	level	_
67-28	11994-11995	X	_
67-29	11996-11997	Y	_
67-30	11998-11999	Z	_
67-31	12000-12001	p	_
67-32	12002-12007	value	_
67-33	12008-12009	(	_
67-34	12009-12017	FWE-corr	_
67-35	12017-12018	.	_
67-36	12018-12019	)	_
67-37	12020-12027	cluster	_
67-38	12028-12032	size	_
67-39	12033-12034	(	_
67-40	12034-12040	voxels	_
67-41	12040-12041	/	_
67-42	12041-12044	cm3	_
67-43	12044-12045	)	_
67-44	12046-12047	p	_
67-45	12048-12053	value	_
67-46	12053-12054	(	_
67-47	12054-12062	FWE-corr	_
67-48	12062-12063	.	_
67-49	12063-12064	)	_

#Text=Fear (100% Fear)\t \t Right Middle Frontal Gyrus (RMFG)\t10\t42\t50\t2\t0.01\t181/6.5\t0.006\t \t Right Anterior Insula (RAI), Right Ventrolateral Prefrontal Cortex (VLPFC)\t13, 47\t45\t20\t−6\t0.01\t166/6.0\t0.006\t \t Right and Left Medial Frontal Gyrus, Dorsomedial Prefrontal Cortex (DMPFC)\t8, 9\t3\t35\t42\t0.03\t142/5.1\t0.008\t \tMixed fear (70% Fear / 30% Happy)\t \t Right Anterior Insula (RAI), Right Ventrolateral Prefrontal Cortex (VLPFC)\t13, 47\t45\t20\t−6\t0.003\t218/7.8\t0.002\t \tMixed happy (70% Happy/30% Fear)\t \t Right Anterior Insula (RAI), Right Ventrolateral Prefrontal Cortex (VLPFC)\t13, 47\t33\t35\t−10\t0.03\t171/6.2\t0.004\t \t Right Middle Occipital Gyrus (RMOG)\t18\t39\t−85\t−6\tns.\t54/1.9\t0.04\t \t
#Text=Image preprocessing was performed using Statistical Parametric Mapping (SPM12, Wellcome Department of Cognitive Neurology, London, UK) under Matlab 2012 (Mathworks, Natick, MA, USA).
68-1	12067-12071	Fear	_
68-2	12072-12073	(	_
68-3	12073-12077	100%	_
68-4	12078-12082	Fear	_
68-5	12082-12083	)	_
68-6	12087-12092	Right	_
68-7	12093-12099	Middle	_
68-8	12100-12107	Frontal	_
68-9	12108-12113	Gyrus	_
68-10	12114-12115	(	_
68-11	12115-12119	RMFG	_
68-12	12119-12120	)	_
68-13	12121-12123	10	_
68-14	12124-12126	42	_
68-15	12127-12129	50	_
68-16	12130-12131	2	_
68-17	12132-12136	0.01	_
68-18	12137-12140	181	_
68-19	12140-12141	/	_
68-20	12141-12144	6.5	_
68-21	12145-12150	0.006	_
68-22	12154-12159	Right	_
68-23	12160-12168	Anterior	_
68-24	12169-12175	Insula	_
68-25	12176-12177	(	_
68-26	12177-12180	RAI	_
68-27	12180-12181	)	_
68-28	12181-12182	,	_
68-29	12183-12188	Right	_
68-30	12189-12202	Ventrolateral	_
68-31	12203-12213	Prefrontal	_
68-32	12214-12220	Cortex	_
68-33	12221-12222	(	_
68-34	12222-12227	VLPFC	_
68-35	12227-12228	)	_
68-36	12229-12231	13	_
68-37	12231-12232	,	_
68-38	12233-12235	47	_
68-39	12236-12238	45	_
68-40	12239-12241	20	_
68-41	12242-12243	−	_
68-42	12243-12244	6	_
68-43	12245-12249	0.01	_
68-44	12250-12253	166	_
68-45	12253-12254	/	_
68-46	12254-12257	6.0	_
68-47	12258-12263	0.006	_
68-48	12267-12272	Right	_
68-49	12273-12276	and	_
68-50	12277-12281	Left	_
68-51	12282-12288	Medial	_
68-52	12289-12296	Frontal	_
68-53	12297-12302	Gyrus	_
68-54	12302-12303	,	_
68-55	12304-12315	Dorsomedial	_
68-56	12316-12326	Prefrontal	_
68-57	12327-12333	Cortex	_
68-58	12334-12335	(	_
68-59	12335-12340	DMPFC	_
68-60	12340-12341	)	_
68-61	12342-12343	8	_
68-62	12343-12344	,	_
68-63	12345-12346	9	_
68-64	12347-12348	3	_
68-65	12349-12351	35	_
68-66	12352-12354	42	_
68-67	12355-12359	0.03	_
68-68	12360-12363	142	_
68-69	12363-12364	/	_
68-70	12364-12367	5.1	_
68-71	12368-12373	0.008	_
68-72	12376-12381	Mixed	_
68-73	12382-12386	fear	_
68-74	12387-12388	(	_
68-75	12388-12391	70%	_
68-76	12392-12396	Fear	_
68-77	12397-12398	/	_
68-78	12399-12402	30%	_
68-79	12403-12408	Happy	_
68-80	12408-12409	)	_
68-81	12413-12418	Right	_
68-82	12419-12427	Anterior	_
68-83	12428-12434	Insula	_
68-84	12435-12436	(	_
68-85	12436-12439	RAI	_
68-86	12439-12440	)	_
68-87	12440-12441	,	_
68-88	12442-12447	Right	_
68-89	12448-12461	Ventrolateral	_
68-90	12462-12472	Prefrontal	_
68-91	12473-12479	Cortex	_
68-92	12480-12481	(	_
68-93	12481-12486	VLPFC	_
68-94	12486-12487	)	_
68-95	12488-12490	13	_
68-96	12490-12491	,	_
68-97	12492-12494	47	_
68-98	12495-12497	45	_
68-99	12498-12500	20	_
68-100	12501-12502	−	_
68-101	12502-12503	6	_
68-102	12504-12509	0.003	_
68-103	12510-12513	218	_
68-104	12513-12514	/	_
68-105	12514-12517	7.8	_
68-106	12518-12523	0.002	_
68-107	12526-12531	Mixed	_
68-108	12532-12537	happy	_
68-109	12538-12539	(	_
68-110	12539-12542	70%	_
68-111	12543-12548	Happy	_
68-112	12548-12549	/	_
68-113	12549-12552	30%	_
68-114	12553-12557	Fear	_
68-115	12557-12558	)	_
68-116	12562-12567	Right	_
68-117	12568-12576	Anterior	_
68-118	12577-12583	Insula	_
68-119	12584-12585	(	_
68-120	12585-12588	RAI	_
68-121	12588-12589	)	_
68-122	12589-12590	,	_
68-123	12591-12596	Right	_
68-124	12597-12610	Ventrolateral	_
68-125	12611-12621	Prefrontal	_
68-126	12622-12628	Cortex	_
68-127	12629-12630	(	_
68-128	12630-12635	VLPFC	_
68-129	12635-12636	)	_
68-130	12637-12639	13	_
68-131	12639-12640	,	_
68-132	12641-12643	47	_
68-133	12644-12646	33	_
68-134	12647-12649	35	_
68-135	12650-12651	−	_
68-136	12651-12653	10	_
68-137	12654-12658	0.03	_
68-138	12659-12662	171	_
68-139	12662-12663	/	_
68-140	12663-12666	6.2	_
68-141	12667-12672	0.004	_
68-142	12676-12681	Right	_
68-143	12682-12688	Middle	_
68-144	12689-12698	Occipital	_
68-145	12699-12704	Gyrus	_
68-146	12705-12706	(	_
68-147	12706-12710	RMOG	_
68-148	12710-12711	)	_
68-149	12712-12714	18	_
68-150	12715-12717	39	_
68-151	12718-12719	−	_
68-152	12719-12721	85	_
68-153	12722-12723	−	_
68-154	12723-12724	6	_
68-155	12725-12727	ns	_
68-156	12727-12728	.	_
68-157	12729-12731	54	_
68-158	12731-12732	/	_
68-159	12732-12735	1.9	_
68-160	12736-12740	0.04	_
68-161	12744-12749	Image	_
68-162	12750-12763	preprocessing	_
68-163	12764-12767	was	_
68-164	12768-12777	performed	_
68-165	12778-12783	using	_
68-166	12784-12795	Statistical	_
68-167	12796-12806	Parametric	_
68-168	12807-12814	Mapping	_
68-169	12815-12816	(	_
68-170	12816-12821	SPM12	_
68-171	12821-12822	,	_
68-172	12823-12831	Wellcome	_
68-173	12832-12842	Department	_
68-174	12843-12845	of	_
68-175	12846-12855	Cognitive	_
68-176	12856-12865	Neurology	_
68-177	12865-12866	,	_
68-178	12867-12873	London	_
68-179	12873-12874	,	_
68-180	12875-12877	UK	_
68-181	12877-12878	)	_
68-182	12879-12884	under	_
68-183	12885-12891	Matlab	_
68-184	12892-12896	2012	_
68-185	12897-12898	(	_
68-186	12898-12907	Mathworks	_
68-187	12907-12908	,	_
68-188	12909-12915	Natick	_
68-189	12915-12916	,	_
68-190	12917-12919	MA	_
68-191	12919-12920	,	_
68-192	12921-12924	USA	_
68-193	12924-12925	)	_
68-194	12925-12926	.	_

#Text=Echo-planar imaging (EPI) data of each subject were preprocessed, which included slice timing, realignment and normalization into a standard template (Montreal Neurological Institute, MNI).
69-1	12927-12938	Echo-planar	_
69-2	12939-12946	imaging	_
69-3	12947-12948	(	_
69-4	12948-12951	EPI	_
69-5	12951-12952	)	_
69-6	12953-12957	data	_
69-7	12958-12960	of	_
69-8	12961-12965	each	_
69-9	12966-12973	subject	_
69-10	12974-12978	were	_
69-11	12979-12991	preprocessed	_
69-12	12991-12992	,	_
69-13	12993-12998	which	_
69-14	12999-13007	included	_
69-15	13008-13013	slice	_
69-16	13014-13020	timing	_
69-17	13020-13021	,	_
69-18	13022-13033	realignment	_
69-19	13034-13037	and	_
69-20	13038-13051	normalization	_
69-21	13052-13056	into	_
69-22	13057-13058	a	_
69-23	13059-13067	standard	_
69-24	13068-13076	template	_
69-25	13077-13078	(	_
69-26	13078-13086	Montreal	_
69-27	13087-13099	Neurological	_
69-28	13100-13109	Institute	_
69-29	13109-13110	,	_
69-30	13111-13114	MNI	_
69-31	13114-13115	)	_
69-32	13115-13116	.	_

#Text=A motions threshold of 3mms were used (equals to voxel size), any subjects moved beyond this threshold were excluded.
70-1	13117-13118	A	_
70-2	13119-13126	motions	_
70-3	13127-13136	threshold	_
70-4	13137-13139	of	_
70-5	13140-13144	3mms	_
70-6	13145-13149	were	_
70-7	13150-13154	used	_
70-8	13155-13156	(	_
70-9	13156-13162	equals	_
70-10	13163-13165	to	_
70-11	13166-13171	voxel	_
70-12	13172-13176	size	_
70-13	13176-13177	)	_
70-14	13177-13178	,	_
70-15	13179-13182	any	_
70-16	13183-13191	subjects	_
70-17	13192-13197	moved	_
70-18	13198-13204	beyond	_
70-19	13205-13209	this	_
70-20	13210-13219	threshold	_
70-21	13220-13224	were	_
70-22	13225-13233	excluded	_
70-23	13233-13234	.	_

#Text=Based on these criteria altogether four subjects were excluded from the study.
71-1	13235-13240	Based	_
71-2	13241-13243	on	_
71-3	13244-13249	these	_
71-4	13250-13258	criteria	_
71-5	13259-13269	altogether	_
71-6	13270-13274	four	_
71-7	13275-13283	subjects	_
71-8	13284-13288	were	_
71-9	13289-13297	excluded	_
71-10	13298-13302	from	_
71-11	13303-13306	the	_
71-12	13307-13312	study	_
71-13	13312-13313	.	_

#Text=Normalized images were finally smoothed in space with an 8 mm full-width at half-maximum (FWHM) 3D isotropic Gaussian kernel.
72-1	13314-13324	Normalized	_
72-2	13325-13331	images	_
72-3	13332-13336	were	_
72-4	13337-13344	finally	_
72-5	13345-13353	smoothed	_
72-6	13354-13356	in	_
72-7	13357-13362	space	_
72-8	13363-13367	with	_
72-9	13368-13370	an	_
72-10	13371-13372	8	_
72-11	13372-13373	 	_
72-12	13373-13375	mm	_
72-13	13376-13386	full-width	_
72-14	13387-13389	at	_
72-15	13390-13402	half-maximum	_
72-16	13403-13404	(	_
72-17	13404-13408	FWHM	_
72-18	13408-13409	)	_
72-19	13410-13412	3D	_
72-20	13413-13422	isotropic	_
72-21	13423-13431	Gaussian	_
72-22	13432-13438	kernel	_
72-23	13438-13439	.	_

#Text=Images were finally filtered with a high-pass filter of 128 s to remove low frequency drifts.
73-1	13440-13446	Images	_
73-2	13447-13451	were	_
73-3	13452-13459	finally	_
73-4	13460-13468	filtered	_
73-5	13469-13473	with	_
73-6	13474-13475	a	_
73-7	13476-13485	high-pass	_
73-8	13486-13492	filter	_
73-9	13493-13495	of	_
73-10	13496-13499	128	_
73-11	13499-13500	 	_
73-12	13500-13501	s	_
73-13	13502-13504	to	_
73-14	13505-13511	remove	_
73-15	13512-13515	low	_
73-16	13516-13525	frequency	_
73-17	13526-13532	drifts	_
73-18	13532-13533	.	_

#Text=After preprocessing, statistical analyses for each individual subject was performed based on fixed-effects general linear models (GLM).
74-1	13534-13539	After	_
74-2	13540-13553	preprocessing	_
74-3	13553-13554	,	_
74-4	13555-13566	statistical	_
74-5	13567-13575	analyses	_
74-6	13576-13579	for	_
74-7	13580-13584	each	_
74-8	13585-13595	individual	_
74-9	13596-13603	subject	_
74-10	13604-13607	was	_
74-11	13608-13617	performed	_
74-12	13618-13623	based	_
74-13	13624-13626	on	_
74-14	13627-13640	fixed-effects	_
74-15	13641-13648	general	_
74-16	13649-13655	linear	_
74-17	13656-13662	models	_
74-18	13663-13664	(	_
74-19	13664-13667	GLM	_
74-20	13667-13668	)	_
74-21	13668-13669	.	_

#Text=Individual events were modeled as single delta (aka stick) functions at each stimulus onset and convolved with the canonical hemodynamical response function (HRF).
75-1	13670-13680	Individual	_
75-2	13681-13687	events	_
75-3	13688-13692	were	_
75-4	13693-13700	modeled	_
75-5	13701-13703	as	_
75-6	13704-13710	single	_
75-7	13711-13716	delta	_
75-8	13717-13718	(	_
75-9	13718-13721	aka	_
75-10	13722-13727	stick	_
75-11	13727-13728	)	_
75-12	13729-13738	functions	_
75-13	13739-13741	at	_
75-14	13742-13746	each	_
75-15	13747-13755	stimulus	_
75-16	13756-13761	onset	_
75-17	13762-13765	and	_
75-18	13766-13775	convolved	_
75-19	13776-13780	with	_
75-20	13781-13784	the	_
75-21	13785-13794	canonical	_
75-22	13795-13808	hemodynamical	_
75-23	13809-13817	response	_
75-24	13818-13826	function	_
75-25	13827-13828	(	_
75-26	13828-13831	HRF	_
75-27	13831-13832	)	_
75-28	13832-13833	.	_

#Text=In the 1st level analysis the four conditions (happy, fear, mixed happy, mixed fear) were modelled, while the 24-motion parameters were included as nuisance regressors (the motion parameters, their first derivatives, the squared motion parameters, and the squared derivatives).
76-1	13834-13836	In	_
76-2	13837-13840	the	_
76-3	13841-13844	1st	_
76-4	13845-13850	level	_
76-5	13851-13859	analysis	_
76-6	13860-13863	the	_
76-7	13864-13868	four	_
76-8	13869-13879	conditions	_
76-9	13880-13881	(	_
76-10	13881-13886	happy	_
76-11	13886-13887	,	_
76-12	13888-13892	fear	_
76-13	13892-13893	,	_
76-14	13894-13899	mixed	_
76-15	13900-13905	happy	_
76-16	13905-13906	,	_
76-17	13907-13912	mixed	_
76-18	13913-13917	fear	_
76-19	13917-13918	)	_
76-20	13919-13923	were	_
76-21	13924-13932	modelled	_
76-22	13932-13933	,	_
76-23	13934-13939	while	_
76-24	13940-13943	the	_
76-25	13944-13946	24	_
76-26	13946-13947	-	_
76-27	13947-13953	motion	_
76-28	13954-13964	parameters	_
76-29	13965-13969	were	_
76-30	13970-13978	included	_
76-31	13979-13981	as	_
76-32	13982-13990	nuisance	_
76-33	13991-14001	regressors	_
76-34	14002-14003	(	_
76-35	14003-14006	the	_
76-36	14007-14013	motion	_
76-37	14014-14024	parameters	_
76-38	14024-14025	,	_
76-39	14026-14031	their	_
76-40	14032-14037	first	_
76-41	14038-14049	derivatives	_
76-42	14049-14050	,	_
76-43	14051-14054	the	_
76-44	14055-14062	squared	_
76-45	14063-14069	motion	_
76-46	14070-14080	parameters	_
76-47	14080-14081	,	_
76-48	14082-14085	and	_
76-49	14086-14089	the	_
76-50	14090-14097	squared	_
76-51	14098-14109	derivatives	_
76-52	14109-14110	)	_
76-53	14110-14111	.	_

#Text=Group level analyses was performed by Statistical Non-Parametric Mapping (SNPM version 13) (http://warwick.ac.uk/snpm), a permutation based approach.
77-1	14112-14117	Group	_
77-2	14118-14123	level	_
77-3	14124-14132	analyses	_
77-4	14133-14136	was	_
77-5	14137-14146	performed	_
77-6	14147-14149	by	_
77-7	14150-14161	Statistical	_
77-8	14162-14176	Non-Parametric	_
77-9	14177-14184	Mapping	_
77-10	14185-14186	(	_
77-11	14186-14190	SNPM	_
77-12	14191-14198	version	_
77-13	14199-14201	13	_
77-14	14201-14202	)	_
77-15	14203-14204	(	_
77-16	14204-14208	http	_
77-17	14208-14209	:	_
77-18	14209-14210	/	_
77-19	14210-14211	/	_
77-20	14211-14224	warwick.ac.uk	_
77-21	14224-14225	/	_
77-22	14225-14229	snpm	_
77-23	14229-14230	)	_
77-24	14230-14231	,	_
77-25	14232-14233	a	_
77-26	14234-14245	permutation	_
77-27	14246-14251	based	_
77-28	14252-14260	approach	_
77-29	14260-14261	.	_

#Text=In the second level analysis both voxel-wise and cluster-wise results were calculated with 10.000 permutations (pseudo-T values were calculated), in the latter case a cluster defining threshold (CDT) of p < 0.001 was used in SNPM to determine significant activations.
78-1	14262-14264	In	_
78-2	14265-14268	the	_
78-3	14269-14275	second	_
78-4	14276-14281	level	_
78-5	14282-14290	analysis	_
78-6	14291-14295	both	_
78-7	14296-14306	voxel-wise	_
78-8	14307-14310	and	_
78-9	14311-14323	cluster-wise	_
78-10	14324-14331	results	_
78-11	14332-14336	were	_
78-12	14337-14347	calculated	_
78-13	14348-14352	with	_
78-14	14353-14359	10.000	_
78-15	14360-14372	permutations	_
78-16	14373-14374	(	_
78-17	14374-14382	pseudo-T	_
78-18	14383-14389	values	_
78-19	14390-14394	were	_
78-20	14395-14405	calculated	_
78-21	14405-14406	)	_
78-22	14406-14407	,	_
78-23	14408-14410	in	_
78-24	14411-14414	the	_
78-25	14415-14421	latter	_
78-26	14422-14426	case	_
78-27	14427-14428	a	_
78-28	14429-14436	cluster	_
78-29	14437-14445	defining	_
78-30	14446-14455	threshold	_
78-31	14456-14457	(	_
78-32	14457-14460	CDT	_
78-33	14460-14461	)	_
78-34	14462-14464	of	_
78-35	14465-14466	p	_
78-36	14466-14467	 	_
78-37	14467-14468	<	_
78-38	14469-14474	0.001	_
78-39	14475-14478	was	_
78-40	14479-14483	used	_
78-41	14484-14486	in	_
78-42	14487-14491	SNPM	_
78-43	14492-14494	to	_
78-44	14495-14504	determine	_
78-45	14505-14516	significant	_
78-46	14517-14528	activations	_
78-47	14528-14529	.	_

#Text=Age and gender were included as covariates in the analysis.
79-1	14530-14533	Age	_
79-2	14534-14537	and	_
79-3	14538-14544	gender	_
79-4	14545-14549	were	_
79-5	14550-14558	included	_
79-6	14559-14561	as	_
79-7	14562-14572	covariates	_
79-8	14573-14575	in	_
79-9	14576-14579	the	_
79-10	14580-14588	analysis	_
79-11	14588-14589	.	_

#Text=The results of the 2nd level analysis are presented in Table 2 including corresponding anatomical regions and Brodmann areas detected using xjView toolbox (http://www.alivelearn.net/xjview).
80-1	14590-14593	The	_
80-2	14594-14601	results	_
80-3	14602-14604	of	_
80-4	14605-14608	the	_
80-5	14609-14612	2nd	_
80-6	14613-14618	level	_
80-7	14619-14627	analysis	_
80-8	14628-14631	are	_
80-9	14632-14641	presented	_
80-10	14642-14644	in	_
80-11	14645-14650	Table	_
80-12	14650-14651	 	_
80-13	14651-14652	2	_
80-14	14653-14662	including	_
80-15	14663-14676	corresponding	_
80-16	14677-14687	anatomical	_
80-17	14688-14695	regions	_
80-18	14696-14699	and	_
80-19	14700-14708	Brodmann	_
80-20	14709-14714	areas	_
80-21	14715-14723	detected	_
80-22	14724-14729	using	_
80-23	14730-14736	xjView	_
80-24	14737-14744	toolbox	_
80-25	14745-14746	(	_
80-26	14746-14750	http	_
80-27	14750-14751	:	_
80-28	14751-14752	/	_
80-29	14752-14753	/	_
80-30	14753-14771	www.alivelearn.net	_
80-31	14771-14772	/	_
80-32	14772-14778	xjview	_
80-33	14778-14779	)	_
80-34	14779-14780	.	_

#Text=Additionally correlational analyses were performed between clinical variables (PANSS, PSP, AP and BZD dose) and the activations in the clusters/regions where group differences were found.
81-1	14782-14794	Additionally	_
81-2	14795-14808	correlational	_
81-3	14809-14817	analyses	_
81-4	14818-14822	were	_
81-5	14823-14832	performed	_
81-6	14833-14840	between	_
81-7	14841-14849	clinical	_
81-8	14850-14859	variables	_
81-9	14860-14861	(	_
81-10	14861-14866	PANSS	_
81-11	14866-14867	,	_
81-12	14868-14871	PSP	_
81-13	14871-14872	,	_
81-14	14873-14875	AP	_
81-15	14876-14879	and	_
81-16	14880-14883	BZD	_
81-17	14884-14888	dose	_
81-18	14888-14889	)	_
81-19	14890-14893	and	_
81-20	14894-14897	the	_
81-21	14898-14909	activations	_
81-22	14910-14912	in	_
81-23	14913-14916	the	_
81-24	14917-14925	clusters	_
81-25	14925-14926	/	_
81-26	14926-14933	regions	_
81-27	14934-14939	where	_
81-28	14940-14945	group	_
81-29	14946-14957	differences	_
81-30	14958-14962	were	_
81-31	14963-14968	found	_
81-32	14968-14969	.	_

#Text=Correlational analyses were performed in SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
82-1	14970-14983	Correlational	_
82-2	14984-14992	analyses	_
82-3	14993-14997	were	_
82-4	14998-15007	performed	_
82-5	15008-15010	in	_
82-6	15011-15014	SAS	_
82-7	15015-15018	9.3	_
82-8	15019-15020	(	_
82-9	15020-15023	SAS	_
82-10	15024-15033	Institute	_
82-11	15034-15037	Inc	_
82-12	15037-15038	.	_
82-13	15038-15039	,	_
82-14	15040-15044	Cary	_
82-15	15044-15045	,	_
82-16	15046-15048	NC	_
82-17	15048-15049	,	_
82-18	15050-15053	USA	_
82-19	15053-15054	)	_
82-20	15054-15055	.	_

#Text=Further ROIs selected from the AAL (Automated Anatomical Labeling) brain atlas corresponding to emotion processing were created and extracted by Marsbar.
83-1	15056-15063	Further	_
83-2	15064-15068	ROIs	_
83-3	15069-15077	selected	_
83-4	15078-15082	from	_
83-5	15083-15086	the	_
83-6	15087-15090	AAL	_
83-7	15091-15092	(	_
83-8	15092-15101	Automated	_
83-9	15102-15112	Anatomical	_
83-10	15113-15121	Labeling	_
83-11	15121-15122	)	_
83-12	15123-15128	brain	_
83-13	15129-15134	atlas	_
83-14	15135-15148	corresponding	_
83-15	15149-15151	to	_
83-16	15152-15159	emotion	_
83-17	15160-15170	processing	_
83-18	15171-15175	were	_
83-19	15176-15183	created	_
83-20	15184-15187	and	_
83-21	15188-15197	extracted	_
83-22	15198-15200	by	_
83-23	15201-15208	Marsbar	_
83-24	15208-15209	.	_

#Text=Correlational analyses were performed for these 14 ROIs (Left and Right Amygdala, Fusiform gyrus, Superior/Middle/Inferior Temporal gyrus and Superior/Middle Temporal Pole) with the same clinical variables as listed above.
84-1	15210-15223	Correlational	_
84-2	15224-15232	analyses	_
84-3	15233-15237	were	_
84-4	15238-15247	performed	_
84-5	15248-15251	for	_
84-6	15252-15257	these	_
84-7	15258-15260	14	_
84-8	15261-15265	ROIs	_
84-9	15266-15267	(	_
84-10	15267-15271	Left	_
84-11	15272-15275	and	_
84-12	15276-15281	Right	_
84-13	15282-15290	Amygdala	_
84-14	15290-15291	,	_
84-15	15292-15300	Fusiform	_
84-16	15301-15306	gyrus	_
84-17	15306-15307	,	_
84-18	15308-15316	Superior	_
84-19	15316-15317	/	_
84-20	15317-15323	Middle	_
84-21	15323-15324	/	_
84-22	15324-15332	Inferior	_
84-23	15333-15341	Temporal	_
84-24	15342-15347	gyrus	_
84-25	15348-15351	and	_
84-26	15352-15360	Superior	_
84-27	15360-15361	/	_
84-28	15361-15367	Middle	_
84-29	15368-15376	Temporal	_
84-30	15377-15381	Pole	_
84-31	15381-15382	)	_
84-32	15383-15387	with	_
84-33	15388-15391	the	_
84-34	15392-15396	same	_
84-35	15397-15405	clinical	_
84-36	15406-15415	variables	_
84-37	15416-15418	as	_
84-38	15419-15425	listed	_
84-39	15426-15431	above	_
84-40	15431-15432	.	_

#Text=Cortical reconstruction and volumetric segmentation were performed with the Freesurfer 5.3 image analysis suite, which is documented and freely available for download online (http://surfer.nmr.mgh.harvard.edu/), and the results contain information about each vertex of the created mesh.
85-1	15433-15441	Cortical	_
85-2	15442-15456	reconstruction	_
85-3	15457-15460	and	_
85-4	15461-15471	volumetric	_
85-5	15472-15484	segmentation	_
85-6	15485-15489	were	_
85-7	15490-15499	performed	_
85-8	15500-15504	with	_
85-9	15505-15508	the	_
85-10	15509-15519	Freesurfer	_
85-11	15520-15523	5.3	_
85-12	15524-15529	image	_
85-13	15530-15538	analysis	_
85-14	15539-15544	suite	_
85-15	15544-15545	,	_
85-16	15546-15551	which	_
85-17	15552-15554	is	_
85-18	15555-15565	documented	_
85-19	15566-15569	and	_
85-20	15570-15576	freely	_
85-21	15577-15586	available	_
85-22	15587-15590	for	_
85-23	15591-15599	download	_
85-24	15600-15606	online	_
85-25	15607-15608	(	_
85-26	15608-15612	http	_
85-27	15612-15613	:	_
85-28	15613-15614	/	_
85-29	15614-15615	/	_
85-30	15615-15641	surfer.nmr.mgh.harvard.edu	_
85-31	15641-15642	/	_
85-32	15642-15643	)	_
85-33	15643-15644	,	_
85-34	15645-15648	and	_
85-35	15649-15652	the	_
85-36	15653-15660	results	_
85-37	15661-15668	contain	_
85-38	15669-15680	information	_
85-39	15681-15686	about	_
85-40	15687-15691	each	_
85-41	15692-15698	vertex	_
85-42	15699-15701	of	_
85-43	15702-15705	the	_
85-44	15706-15713	created	_
85-45	15714-15718	mesh	_
85-46	15718-15719	.	_

#Text=The technical details of these procedures are described in prior publications; we made no changes to this pipeline.
86-1	15720-15723	The	_
86-2	15724-15733	technical	_
86-3	15734-15741	details	_
86-4	15742-15744	of	_
86-5	15745-15750	these	_
86-6	15751-15761	procedures	_
86-7	15762-15765	are	_
86-8	15766-15775	described	_
86-9	15776-15778	in	_
86-10	15779-15784	prior	_
86-11	15785-15797	publications	_
86-12	15797-15798	;	_
86-13	15799-15801	we	_
86-14	15802-15806	made	_
86-15	15807-15809	no	_
86-16	15810-15817	changes	_
86-17	15818-15820	to	_
86-18	15821-15825	this	_
86-19	15826-15834	pipeline	_
86-20	15834-15835	.	_

#Text=Segmentations and cortical models were checked and corrected manually on each subject.
87-1	15836-15849	Segmentations	_
87-2	15850-15853	and	_
87-3	15854-15862	cortical	_
87-4	15863-15869	models	_
87-5	15870-15874	were	_
87-6	15875-15882	checked	_
87-7	15883-15886	and	_
87-8	15887-15896	corrected	_
87-9	15897-15905	manually	_
87-10	15906-15908	on	_
87-11	15909-15913	each	_
87-12	15914-15921	subject	_
87-13	15921-15922	.	_

#Text=We used FreeSurfer’s QDEC (Query, Design, Estimate, Contrast) interface to perform group averaging and generate the statistical maps from the cortical morphometric data produced by FreeSurfer stream.
88-1	15923-15925	We	_
88-2	15926-15930	used	_
88-3	15931-15941	FreeSurfer	_
88-4	15941-15942	’	_
88-5	15942-15943	s	_
88-6	15944-15948	QDEC	_
88-7	15949-15950	(	_
88-8	15950-15955	Query	_
88-9	15955-15956	,	_
88-10	15957-15963	Design	_
88-11	15963-15964	,	_
88-12	15965-15973	Estimate	_
88-13	15973-15974	,	_
88-14	15975-15983	Contrast	_
88-15	15983-15984	)	_
88-16	15985-15994	interface	_
88-17	15995-15997	to	_
88-18	15998-16005	perform	_
88-19	16006-16011	group	_
88-20	16012-16021	averaging	_
88-21	16022-16025	and	_
88-22	16026-16034	generate	_
88-23	16035-16038	the	_
88-24	16039-16050	statistical	_
88-25	16051-16055	maps	_
88-26	16056-16060	from	_
88-27	16061-16064	the	_
88-28	16065-16073	cortical	_
88-29	16074-16086	morphometric	_
88-30	16087-16091	data	_
88-31	16092-16100	produced	_
88-32	16101-16103	by	_
88-33	16104-16114	FreeSurfer	_
88-34	16115-16121	stream	_
88-35	16121-16122	.	_

#Text=General Linear Model (GLM) was computed vertex-by-vertex for analysis of surface area and cortical thickness.
89-1	16123-16130	General	_
89-2	16131-16137	Linear	_
89-3	16138-16143	Model	_
89-4	16144-16145	(	_
89-5	16145-16148	GLM	_
89-6	16148-16149	)	_
89-7	16150-16153	was	_
89-8	16154-16162	computed	_
89-9	16163-16179	vertex-by-vertex	_
89-10	16180-16183	for	_
89-11	16184-16192	analysis	_
89-12	16193-16195	of	_
89-13	16196-16203	surface	_
89-14	16204-16208	area	_
89-15	16209-16212	and	_
89-16	16213-16221	cortical	_
89-17	16222-16231	thickness	_
89-18	16231-16232	.	_

#Text=The cortical volumes of the schizophrenic patient group was compared with healthy controls, accounting for the effects of age and gender.
90-1	16233-16236	The	_
90-2	16237-16245	cortical	_
90-3	16246-16253	volumes	_
90-4	16254-16256	of	_
90-5	16257-16260	the	_
90-6	16261-16274	schizophrenic	_
90-7	16275-16282	patient	_
90-8	16283-16288	group	_
90-9	16289-16292	was	_
90-10	16293-16301	compared	_
90-11	16302-16306	with	_
90-12	16307-16314	healthy	_
90-13	16315-16323	controls	_
90-14	16323-16324	,	_
90-15	16325-16335	accounting	_
90-16	16336-16339	for	_
90-17	16340-16343	the	_
90-18	16344-16351	effects	_
90-19	16352-16354	of	_
90-20	16355-16358	age	_
90-21	16359-16362	and	_
90-22	16363-16369	gender	_
90-23	16369-16370	.	_

#Text=From the different methods that QDEC provides for automatic design matrix creation, DODS (different offset, different slope) was used.
91-1	16371-16375	From	_
91-2	16376-16379	the	_
91-3	16380-16389	different	_
91-4	16390-16397	methods	_
91-5	16398-16402	that	_
91-6	16403-16407	QDEC	_
91-7	16408-16416	provides	_
91-8	16417-16420	for	_
91-9	16421-16430	automatic	_
91-10	16431-16437	design	_
91-11	16438-16444	matrix	_
91-12	16445-16453	creation	_
91-13	16453-16454	,	_
91-14	16455-16459	DODS	_
91-15	16460-16461	(	_
91-16	16461-16470	different	_
91-17	16471-16477	offset	_
91-18	16477-16478	,	_
91-19	16479-16488	different	_
91-20	16489-16494	slope	_
91-21	16494-16495	)	_
91-22	16496-16499	was	_
91-23	16500-16504	used	_
91-24	16504-16505	.	_

#Text=The results were visualised by overlaying the significant areas onto the cortical surfaces, maps were smoothed using a 10 mm full width at half maximum Gaussian kernel.
92-1	16506-16509	The	_
92-2	16510-16517	results	_
92-3	16518-16522	were	_
92-4	16523-16533	visualised	_
92-5	16534-16536	by	_
92-6	16537-16547	overlaying	_
92-7	16548-16551	the	_
92-8	16552-16563	significant	_
92-9	16564-16569	areas	_
92-10	16570-16574	onto	_
92-11	16575-16578	the	_
92-12	16579-16587	cortical	_
92-13	16588-16596	surfaces	_
92-14	16596-16597	,	_
92-15	16598-16602	maps	_
92-16	16603-16607	were	_
92-17	16608-16616	smoothed	_
92-18	16617-16622	using	_
92-19	16623-16624	a	_
92-20	16625-16627	10	_
92-21	16627-16628	 	_
92-22	16628-16630	mm	_
92-23	16631-16635	full	_
92-24	16636-16641	width	_
92-25	16642-16644	at	_
92-26	16645-16649	half	_
92-27	16650-16657	maximum	_
92-28	16658-16666	Gaussian	_
92-29	16667-16673	kernel	_
92-30	16673-16674	.	_

#Text=Multiple comparisons were corrected with a Monte Carlo Simulation using a p-value set at <0.05.
93-1	16675-16683	Multiple	_
93-2	16684-16695	comparisons	_
93-3	16696-16700	were	_
93-4	16701-16710	corrected	_
93-5	16711-16715	with	_
93-6	16716-16717	a	_
93-7	16718-16723	Monte	_
93-8	16724-16729	Carlo	_
93-9	16730-16740	Simulation	_
93-10	16741-16746	using	_
93-11	16747-16748	a	_
93-12	16749-16756	p-value	_
93-13	16757-16760	set	_
93-14	16761-16763	at	_
93-15	16764-16765	<	_
93-16	16765-16769	0.05	_
93-17	16769-16770	.	_

#Text=Results
#Text=Differentiation between study groups based on BOLD activations
#Text=Between group differences in brain activation to fear, mixed fear, and mixed happy stimuli respectively.1 Fear: Right Middle Frontal Gyrus (RMFG), Right Anterior Insula (RAI), Right Ventrolateral Prefrontal Cortex (VLPFC), Right and Left Medial Frontal Gyrus, Dorsomedial Prefrontal Cortex (DMPFC). 2 Mixed Fear: Right Anterior Insula (RAI), Right Ventrolateral Prefrontal Cortex (VLPFC). 3 (Happy: no between group difference). 4 Mixed Happy: Right Anterior Insula (RAI), Right Ventrolateral Prefrontal Cortex (VLPFC), Right Middle Occipital Gyrus (RMOG)
#Text=The clusters corresponding to the interactions between stimulus condition and study group are also presented. 1 Fear vs.
94-1	16771-16778	Results	_
94-2	16779-16794	Differentiation	_
94-3	16795-16802	between	_
94-4	16803-16808	study	_
94-5	16809-16815	groups	_
94-6	16816-16821	based	_
94-7	16822-16824	on	_
94-8	16825-16829	BOLD	_
94-9	16830-16841	activations	_
94-10	16842-16849	Between	_
94-11	16850-16855	group	_
94-12	16856-16867	differences	_
94-13	16868-16870	in	_
94-14	16871-16876	brain	_
94-15	16877-16887	activation	_
94-16	16888-16890	to	_
94-17	16891-16895	fear	_
94-18	16895-16896	,	_
94-19	16897-16902	mixed	_
94-20	16903-16907	fear	_
94-21	16907-16908	,	_
94-22	16909-16912	and	_
94-23	16913-16918	mixed	_
94-24	16919-16924	happy	_
94-25	16925-16932	stimuli	_
94-26	16933-16945	respectively	_
94-27	16945-16947	.1	_
94-28	16948-16952	Fear	_
94-29	16952-16953	:	_
94-30	16954-16959	Right	_
94-31	16960-16966	Middle	_
94-32	16967-16974	Frontal	_
94-33	16975-16980	Gyrus	_
94-34	16981-16982	(	_
94-35	16982-16986	RMFG	_
94-36	16986-16987	)	_
94-37	16987-16988	,	_
94-38	16989-16994	Right	_
94-39	16995-17003	Anterior	_
94-40	17004-17010	Insula	_
94-41	17011-17012	(	_
94-42	17012-17015	RAI	_
94-43	17015-17016	)	_
94-44	17016-17017	,	_
94-45	17018-17023	Right	_
94-46	17024-17037	Ventrolateral	_
94-47	17038-17048	Prefrontal	_
94-48	17049-17055	Cortex	_
94-49	17056-17057	(	_
94-50	17057-17062	VLPFC	_
94-51	17062-17063	)	_
94-52	17063-17064	,	_
94-53	17065-17070	Right	_
94-54	17071-17074	and	_
94-55	17075-17079	Left	_
94-56	17080-17086	Medial	_
94-57	17087-17094	Frontal	_
94-58	17095-17100	Gyrus	_
94-59	17100-17101	,	_
94-60	17102-17113	Dorsomedial	_
94-61	17114-17124	Prefrontal	_
94-62	17125-17131	Cortex	_
94-63	17132-17133	(	_
94-64	17133-17138	DMPFC	_
94-65	17138-17139	)	_
94-66	17139-17140	.	_
94-67	17141-17142	2	_
94-68	17143-17148	Mixed	_
94-69	17149-17153	Fear	_
94-70	17153-17154	:	_
94-71	17155-17160	Right	_
94-72	17161-17169	Anterior	_
94-73	17170-17176	Insula	_
94-74	17177-17178	(	_
94-75	17178-17181	RAI	_
94-76	17181-17182	)	_
94-77	17182-17183	,	_
94-78	17184-17189	Right	_
94-79	17190-17203	Ventrolateral	_
94-80	17204-17214	Prefrontal	_
94-81	17215-17221	Cortex	_
94-82	17222-17223	(	_
94-83	17223-17228	VLPFC	_
94-84	17228-17229	)	_
94-85	17229-17230	.	_
94-86	17231-17232	3	_
94-87	17233-17234	(	_
94-88	17234-17239	Happy	_
94-89	17239-17240	:	_
94-90	17241-17243	no	_
94-91	17244-17251	between	_
94-92	17252-17257	group	_
94-93	17258-17268	difference	_
94-94	17268-17269	)	_
94-95	17269-17270	.	_
94-96	17271-17272	4	_
94-97	17273-17278	Mixed	_
94-98	17279-17284	Happy	_
94-99	17284-17285	:	_
94-100	17286-17291	Right	_
94-101	17292-17300	Anterior	_
94-102	17301-17307	Insula	_
94-103	17308-17309	(	_
94-104	17309-17312	RAI	_
94-105	17312-17313	)	_
94-106	17313-17314	,	_
94-107	17315-17320	Right	_
94-108	17321-17334	Ventrolateral	_
94-109	17335-17345	Prefrontal	_
94-110	17346-17352	Cortex	_
94-111	17353-17354	(	_
94-112	17354-17359	VLPFC	_
94-113	17359-17360	)	_
94-114	17360-17361	,	_
94-115	17362-17367	Right	_
94-116	17368-17374	Middle	_
94-117	17375-17384	Occipital	_
94-118	17385-17390	Gyrus	_
94-119	17391-17392	(	_
94-120	17392-17396	RMOG	_
94-121	17396-17397	)	_
94-122	17398-17401	The	_
94-123	17402-17410	clusters	_
94-124	17411-17424	corresponding	_
94-125	17425-17427	to	_
94-126	17428-17431	the	_
94-127	17432-17444	interactions	_
94-128	17445-17452	between	_
94-129	17453-17461	stimulus	_
94-130	17462-17471	condition	_
94-131	17472-17475	and	_
94-132	17476-17481	study	_
94-133	17482-17487	group	_
94-134	17488-17491	are	_
94-135	17492-17496	also	_
94-136	17497-17506	presented	_
94-137	17506-17507	.	_
94-138	17508-17509	1	_
94-139	17510-17514	Fear	_
94-140	17515-17517	vs	_
94-141	17517-17518	.	_

#Text=Happy: Right Superior Temporal Gyrus (RSTG), Right Rolandic Operculum (RRO), Right Middle Frontal Gyrus (RMFG). 2 Mixed Happy vs.
95-1	17519-17524	Happy	_
95-2	17524-17525	:	_
95-3	17526-17531	Right	_
95-4	17532-17540	Superior	_
95-5	17541-17549	Temporal	_
95-6	17550-17555	Gyrus	_
95-7	17556-17557	(	_
95-8	17557-17561	RSTG	_
95-9	17561-17562	)	_
95-10	17562-17563	,	_
95-11	17564-17569	Right	_
95-12	17570-17578	Rolandic	_
95-13	17579-17588	Operculum	_
95-14	17589-17590	(	_
95-15	17590-17593	RRO	_
95-16	17593-17594	)	_
95-17	17594-17595	,	_
95-18	17596-17601	Right	_
95-19	17602-17608	Middle	_
95-20	17609-17616	Frontal	_
95-21	17617-17622	Gyrus	_
95-22	17623-17624	(	_
95-23	17624-17628	RMFG	_
95-24	17628-17629	)	_
95-25	17629-17630	.	_
95-26	17631-17632	2	_
95-27	17633-17638	Mixed	_
95-28	17639-17644	Happy	_
95-29	17645-17647	vs	_
95-30	17647-17648	.	_

#Text=Happy:, Vermis of the Cerebellum Right Middle and Inferior Frontal Gyrus, Right Dorsolateral Prefrontal Cortex (DLPFC).
96-1	17649-17654	Happy	_
96-2	17654-17655	:	_
96-3	17655-17656	,	_
96-4	17657-17663	Vermis	_
96-5	17664-17666	of	_
96-6	17667-17670	the	_
96-7	17671-17681	Cerebellum	_
96-8	17682-17687	Right	_
96-9	17688-17694	Middle	_
96-10	17695-17698	and	_
96-11	17699-17707	Inferior	_
96-12	17708-17715	Frontal	_
96-13	17716-17721	Gyrus	_
96-14	17721-17722	,	_
96-15	17723-17728	Right	_
96-16	17729-17741	Dorsolateral	_
96-17	17742-17752	Prefrontal	_
96-18	17753-17759	Cortex	_
96-19	17760-17761	(	_
96-20	17761-17766	DLPFC	_
96-21	17766-17767	)	_
96-22	17767-17768	.	_

#Text=Results are based on permutation based statistics (n = 10,000) from Statistical non-Parametric Mapping (SnPM).
97-1	17769-17776	Results	_
97-2	17777-17780	are	_
97-3	17781-17786	based	_
97-4	17787-17789	on	_
97-5	17790-17801	permutation	_
97-6	17802-17807	based	_
97-7	17808-17818	statistics	_
97-8	17819-17820	(	_
97-9	17820-17821	n	_
97-10	17821-17822	 	_
97-11	17822-17823	=	_
97-12	17824-17830	10,000	_
97-13	17830-17831	)	_
97-14	17832-17836	from	_
97-15	17837-17848	Statistical	_
97-16	17849-17863	non-Parametric	_
97-17	17864-17871	Mapping	_
97-18	17872-17873	(	_
97-19	17873-17877	SnPM	_
97-20	17877-17878	)	_
97-21	17878-17879	.	_

#Text=Decreased activation was found in the patient group during fear (Fig. 2/A) and mixed fear (Fig. 2/B) processing in clusters corresponding to the right VLPFC (Brodmann Area 47 = BA47), the right anterior insula (RAI/BA13), and the right dorsomedial prefrontal cortex (DMPFC/BA9) at voxel and cluster level.
98-1	17880-17889	Decreased	_
98-2	17890-17900	activation	_
98-3	17901-17904	was	_
98-4	17905-17910	found	_
98-5	17911-17913	in	_
98-6	17914-17917	the	_
98-7	17918-17925	patient	_
98-8	17926-17931	group	_
98-9	17932-17938	during	_
98-10	17939-17943	fear	_
98-11	17944-17945	(	_
98-12	17945-17948	Fig	_
98-13	17948-17949	.	_
98-14	17949-17950	 	_
98-15	17950-17951	2	_
98-16	17951-17952	/	_
98-17	17952-17953	A	_
98-18	17953-17954	)	_
98-19	17955-17958	and	_
98-20	17959-17964	mixed	_
98-21	17965-17969	fear	_
98-22	17970-17971	(	_
98-23	17971-17974	Fig	_
98-24	17974-17975	.	_
98-25	17976-17977	2	_
98-26	17977-17978	/	_
98-27	17978-17979	B	_
98-28	17979-17980	)	_
98-29	17981-17991	processing	_
98-30	17992-17994	in	_
98-31	17995-18003	clusters	_
98-32	18004-18017	corresponding	_
98-33	18018-18020	to	_
98-34	18021-18024	the	_
98-35	18025-18030	right	_
98-36	18031-18036	VLPFC	_
98-37	18037-18038	(	_
98-38	18038-18046	Brodmann	_
98-39	18047-18051	Area	_
98-40	18052-18054	47	_
98-41	18055-18056	=	_
98-42	18057-18061	BA47	_
98-43	18061-18062	)	_
98-44	18062-18063	,	_
98-45	18064-18067	the	_
98-46	18068-18073	right	_
98-47	18074-18082	anterior	_
98-48	18083-18089	insula	_
98-49	18090-18091	(	_
98-50	18091-18094	RAI	_
98-51	18094-18095	/	_
98-52	18095-18099	BA13	_
98-53	18099-18100	)	_
98-54	18100-18101	,	_
98-55	18102-18105	and	_
98-56	18106-18109	the	_
98-57	18110-18115	right	_
98-58	18116-18127	dorsomedial	_
98-59	18128-18138	prefrontal	_
98-60	18139-18145	cortex	_
98-61	18146-18147	(	_
98-62	18147-18152	DMPFC	_
98-63	18152-18153	/	_
98-64	18153-18156	BA9	_
98-65	18156-18157	)	_
98-66	18158-18160	at	_
98-67	18161-18166	voxel	_
98-68	18167-18170	and	_
98-69	18171-18178	cluster	_
98-70	18179-18184	level	_
98-71	18184-18185	.	_

#Text=The results of the analyses are summarized in Table 2.
99-1	18186-18189	The	_
99-2	18190-18197	results	_
99-3	18198-18200	of	_
99-4	18201-18204	the	_
99-5	18205-18213	analyses	_
99-6	18214-18217	are	_
99-7	18218-18228	summarized	_
99-8	18229-18231	in	_
99-9	18232-18237	Table	_
99-10	18238-18239	2	_
99-11	18239-18240	.	_

#Text=A significant decrease at voxel and cluster level activation was also found in the right VLPFC and right anterior insula (RAI), and at cluster level in the right middle occipital gyrus (BA18/associative visual cortex) in patients when viewing mixed happy faces (Table 2 ; Fig. 2/B).
100-1	18242-18243	A	_
100-2	18244-18255	significant	_
100-3	18256-18264	decrease	_
100-4	18265-18267	at	_
100-5	18268-18273	voxel	_
100-6	18274-18277	and	_
100-7	18278-18285	cluster	_
100-8	18286-18291	level	_
100-9	18292-18302	activation	_
100-10	18303-18306	was	_
100-11	18307-18311	also	_
100-12	18312-18317	found	_
100-13	18318-18320	in	_
100-14	18321-18324	the	_
100-15	18325-18330	right	_
100-16	18331-18336	VLPFC	_
100-17	18337-18340	and	_
100-18	18341-18346	right	_
100-19	18347-18355	anterior	_
100-20	18356-18362	insula	_
100-21	18363-18364	(	_
100-22	18364-18367	RAI	_
100-23	18367-18368	)	_
100-24	18368-18369	,	_
100-25	18370-18373	and	_
100-26	18374-18376	at	_
100-27	18377-18384	cluster	_
100-28	18385-18390	level	_
100-29	18391-18393	in	_
100-30	18394-18397	the	_
100-31	18398-18403	right	_
100-32	18404-18410	middle	_
100-33	18411-18420	occipital	_
100-34	18421-18426	gyrus	_
100-35	18427-18428	(	_
100-36	18428-18432	BA18	_
100-37	18432-18433	/	_
100-38	18433-18444	associative	_
100-39	18445-18451	visual	_
100-40	18452-18458	cortex	_
100-41	18458-18459	)	_
100-42	18460-18462	in	_
100-43	18463-18471	patients	_
100-44	18472-18476	when	_
100-45	18477-18484	viewing	_
100-46	18485-18490	mixed	_
100-47	18491-18496	happy	_
100-48	18497-18502	faces	_
100-49	18503-18504	(	_
100-50	18504-18509	Table	_
100-51	18510-18511	2	_
100-52	18512-18513	;	_
100-53	18514-18517	Fig	_
100-54	18517-18518	.	_
100-55	18519-18520	2	_
100-56	18520-18521	/	_
100-57	18521-18522	B	_
100-58	18522-18523	)	_
100-59	18523-18524	.	_

#Text=No difference was found between study groups to happy faces in any regions.
101-1	18525-18527	No	_
101-2	18528-18538	difference	_
101-3	18539-18542	was	_
101-4	18543-18548	found	_
101-5	18549-18556	between	_
101-6	18557-18562	study	_
101-7	18563-18569	groups	_
101-8	18570-18572	to	_
101-9	18573-18578	happy	_
101-10	18579-18584	faces	_
101-11	18585-18587	in	_
101-12	18588-18591	any	_
101-13	18592-18599	regions	_
101-14	18599-18600	.	_

#Text=The correlation of the contrast estimate in the Right Amygdala to Mixed Happy condition and Antipsychotic Dose in CPZ Equivalents in patients with schizophrenia
#Text=Activations to all four emotion conditions in the right amygdala correlated negatively with antipsychotic dose, which was the strongest for mixed happy condition (mixed happy: r = −0.66, n = 19, p = 0.002; happy: r = −0.55, n = 19, p = 0.02; mixed fear: r = −0.47, n = 19, p = 0.04; fear: r = −0.48, n = 19, p = 0.04) (Fig. 3).
102-1	18601-18604	The	_
102-2	18605-18616	correlation	_
102-3	18617-18619	of	_
102-4	18620-18623	the	_
102-5	18624-18632	contrast	_
102-6	18633-18641	estimate	_
102-7	18642-18644	in	_
102-8	18645-18648	the	_
102-9	18649-18654	Right	_
102-10	18655-18663	Amygdala	_
102-11	18664-18666	to	_
102-12	18667-18672	Mixed	_
102-13	18673-18678	Happy	_
102-14	18679-18688	condition	_
102-15	18689-18692	and	_
102-16	18693-18706	Antipsychotic	_
102-17	18707-18711	Dose	_
102-18	18712-18714	in	_
102-19	18715-18718	CPZ	_
102-20	18719-18730	Equivalents	_
102-21	18731-18733	in	_
102-22	18734-18742	patients	_
102-23	18743-18747	with	_
102-24	18748-18761	schizophrenia	_
102-25	18762-18773	Activations	_
102-26	18774-18776	to	_
102-27	18777-18780	all	_
102-28	18781-18785	four	_
102-29	18786-18793	emotion	_
102-30	18794-18804	conditions	_
102-31	18805-18807	in	_
102-32	18808-18811	the	_
102-33	18812-18817	right	_
102-34	18818-18826	amygdala	_
102-35	18827-18837	correlated	_
102-36	18838-18848	negatively	_
102-37	18849-18853	with	_
102-38	18854-18867	antipsychotic	_
102-39	18868-18872	dose	_
102-40	18872-18873	,	_
102-41	18874-18879	which	_
102-42	18880-18883	was	_
102-43	18884-18887	the	_
102-44	18888-18897	strongest	_
102-45	18898-18901	for	_
102-46	18902-18907	mixed	_
102-47	18908-18913	happy	_
102-48	18914-18923	condition	_
102-49	18924-18925	(	_
102-50	18925-18930	mixed	_
102-51	18931-18936	happy	_
102-52	18936-18937	:	_
102-53	18938-18939	r	_
102-54	18939-18940	 	_
102-55	18940-18941	=	_
102-56	18942-18943	−	_
102-57	18943-18947	0.66	_
102-58	18947-18948	,	_
102-59	18949-18950	n	_
102-60	18950-18951	 	_
102-61	18951-18952	=	_
102-62	18953-18955	19	_
102-63	18955-18956	,	_
102-64	18957-18958	p	_
102-65	18958-18959	 	_
102-66	18959-18960	=	_
102-67	18961-18966	0.002	_
102-68	18966-18967	;	_
102-69	18968-18973	happy	_
102-70	18973-18974	:	_
102-71	18975-18976	r	_
102-72	18976-18977	 	_
102-73	18977-18978	=	_
102-74	18979-18980	−	_
102-75	18980-18984	0.55	_
102-76	18984-18985	,	_
102-77	18986-18987	n	_
102-78	18988-18989	=	_
102-79	18990-18992	19	_
102-80	18992-18993	,	_
102-81	18994-18995	p	_
102-82	18995-18996	 	_
102-83	18996-18997	=	_
102-84	18998-19002	0.02	_
102-85	19002-19003	;	_
102-86	19004-19009	mixed	_
102-87	19010-19014	fear	_
102-88	19014-19015	:	_
102-89	19016-19017	r	_
102-90	19017-19018	 	_
102-91	19018-19019	=	_
102-92	19020-19021	−	_
102-93	19021-19025	0.47	_
102-94	19025-19026	,	_
102-95	19027-19028	n	_
102-96	19029-19030	=	_
102-97	19031-19033	19	_
102-98	19033-19034	,	_
102-99	19035-19036	p	_
102-100	19036-19037	 	_
102-101	19037-19038	=	_
102-102	19039-19043	0.04	_
102-103	19043-19044	;	_
102-104	19045-19049	fear	_
102-105	19049-19050	:	_
102-106	19051-19052	r	_
102-107	19052-19053	 	_
102-108	19053-19054	=	_
102-109	19055-19056	−	_
102-110	19056-19060	0.48	_
102-111	19060-19061	,	_
102-112	19062-19063	n	_
102-113	19064-19065	=	_
102-114	19066-19068	19	_
102-115	19068-19069	,	_
102-116	19070-19071	p	_
102-117	19072-19073	=	_
102-118	19074-19078	0.04	_
102-119	19078-19079	)	_
102-120	19080-19081	(	_
102-121	19081-19084	Fig	_
102-122	19084-19085	.	_
102-123	19085-19086	 	_
102-124	19086-19087	3	_
102-125	19087-19088	)	_
102-126	19088-19089	.	_

#Text=Correlations of brain activations with psychotic symptom severity, psychosocial functioning and BZD doses did not reach significance in any regions.
103-1	19090-19102	Correlations	_
103-2	19103-19105	of	_
103-3	19106-19111	brain	_
103-4	19112-19123	activations	_
103-5	19124-19128	with	_
103-6	19129-19138	psychotic	_
103-7	19139-19146	symptom	_
103-8	19147-19155	severity	_
103-9	19155-19156	,	_
103-10	19157-19169	psychosocial	_
103-11	19170-19181	functioning	_
103-12	19182-19185	and	_
103-13	19186-19189	BZD	_
103-14	19190-19195	doses	_
103-15	19196-19199	did	_
103-16	19200-19203	not	_
103-17	19204-19209	reach	_
103-18	19210-19222	significance	_
103-19	19223-19225	in	_
103-20	19226-19229	any	_
103-21	19230-19237	regions	_
103-22	19237-19238	.	_

#Text=Interactions between study group and condition
#Text=Interaction between study group and stimulus condition in bran activations
#Text=Condition/Anatomical region\tBrodmann areas (BA)\tPeak MNI coordinates\tVoxel level\tCluster level\t \tX\tY\tZ\tp value (FWE-corr.)\tcluster size (voxels/cm3)\tp value(FWE-corr.)
104-1	19240-19252	Interactions	_
104-2	19253-19260	between	_
104-3	19261-19266	study	_
104-4	19267-19272	group	_
104-5	19273-19276	and	_
104-6	19277-19286	condition	_
104-7	19287-19298	Interaction	_
104-8	19299-19306	between	_
104-9	19307-19312	study	_
104-10	19313-19318	group	_
104-11	19319-19322	and	_
104-12	19323-19331	stimulus	_
104-13	19332-19341	condition	_
104-14	19342-19344	in	_
104-15	19345-19349	bran	_
104-16	19350-19361	activations	_
104-17	19362-19371	Condition	_
104-18	19371-19372	/	_
104-19	19372-19382	Anatomical	_
104-20	19383-19389	region	_
104-21	19390-19398	Brodmann	_
104-22	19399-19404	areas	_
104-23	19405-19406	(	_
104-24	19406-19408	BA	_
104-25	19408-19409	)	_
104-26	19410-19414	Peak	_
104-27	19415-19418	MNI	_
104-28	19419-19430	coordinates	_
104-29	19431-19436	Voxel	_
104-30	19437-19442	level	_
104-31	19443-19450	Cluster	_
104-32	19451-19456	level	_
104-33	19459-19460	X	_
104-34	19461-19462	Y	_
104-35	19463-19464	Z	_
104-36	19465-19466	p	_
104-37	19467-19472	value	_
104-38	19473-19474	(	_
104-39	19474-19482	FWE-corr	_
104-40	19482-19483	.	_
104-41	19483-19484	)	_
104-42	19485-19492	cluster	_
104-43	19493-19497	size	_
104-44	19498-19499	(	_
104-45	19499-19505	voxels	_
104-46	19505-19506	/	_
104-47	19506-19509	cm3	_
104-48	19509-19510	)	_
104-49	19511-19512	p	_
104-50	19513-19518	value	_
104-51	19518-19519	(	_
104-52	19519-19527	FWE-corr	_
104-53	19527-19528	.	_
104-54	19528-19529	)	_

#Text=(Fear vs Happy) X (Control vs Patient)\t \t Right Superior Temporal Gyrus (RSTG), Right Rolandic Operculum (RRO)\t22\t60\t−4\t6\tns.\t62/2.2\t0.03\t \t Right Middle Frontal Gyrus (RMFG)\t10\t30\t47\t6\tns.\t50/1.8\t0.04\t \t(Mixed Happy vs Happy) X (Control vs Patient)\t \t Right and Left Cerebellum, Vermis\tNA\t3\t−76\t−38\t< 0.05\t94/3.4\t0.01\t \t Right Middle and Inferior Frontal Gyrus, Right Dorsolateral Prefrontal Cortex (DLPFC)\t9, 46\t51\t23\t22\t0.06\t80/2.9\t0.02\t \t
#Text=On the top pane the study group x (Fear vs Happy) interaction is presented, while on the bottom pane the study group x (Mixed Happy vs Happy) interaction is presented.
105-1	19532-19533	(	_
105-2	19533-19537	Fear	_
105-3	19538-19540	vs	_
105-4	19541-19546	Happy	_
105-5	19546-19547	)	_
105-6	19548-19549	X	_
105-7	19550-19551	(	_
105-8	19551-19558	Control	_
105-9	19559-19561	vs	_
105-10	19562-19569	Patient	_
105-11	19569-19570	)	_
105-12	19574-19579	Right	_
105-13	19580-19588	Superior	_
105-14	19589-19597	Temporal	_
105-15	19598-19603	Gyrus	_
105-16	19604-19605	(	_
105-17	19605-19609	RSTG	_
105-18	19609-19610	)	_
105-19	19610-19611	,	_
105-20	19612-19617	Right	_
105-21	19618-19626	Rolandic	_
105-22	19627-19636	Operculum	_
105-23	19637-19638	(	_
105-24	19638-19641	RRO	_
105-25	19641-19642	)	_
105-26	19643-19645	22	_
105-27	19646-19648	60	_
105-28	19649-19650	−	_
105-29	19650-19651	4	_
105-30	19652-19653	6	_
105-31	19654-19656	ns	_
105-32	19656-19657	.	_
105-33	19658-19660	62	_
105-34	19660-19661	/	_
105-35	19661-19664	2.2	_
105-36	19665-19669	0.03	_
105-37	19673-19678	Right	_
105-38	19679-19685	Middle	_
105-39	19686-19693	Frontal	_
105-40	19694-19699	Gyrus	_
105-41	19700-19701	(	_
105-42	19701-19705	RMFG	_
105-43	19705-19706	)	_
105-44	19707-19709	10	_
105-45	19710-19712	30	_
105-46	19713-19715	47	_
105-47	19716-19717	6	_
105-48	19718-19720	ns	_
105-49	19720-19721	.	_
105-50	19722-19724	50	_
105-51	19724-19725	/	_
105-52	19725-19728	1.8	_
105-53	19729-19733	0.04	_
105-54	19736-19737	(	_
105-55	19737-19742	Mixed	_
105-56	19743-19748	Happy	_
105-57	19749-19751	vs	_
105-58	19752-19757	Happy	_
105-59	19757-19758	)	_
105-60	19759-19760	X	_
105-61	19761-19762	(	_
105-62	19762-19769	Control	_
105-63	19770-19772	vs	_
105-64	19773-19780	Patient	_
105-65	19780-19781	)	_
105-66	19785-19790	Right	_
105-67	19791-19794	and	_
105-68	19795-19799	Left	_
105-69	19800-19810	Cerebellum	_
105-70	19810-19811	,	_
105-71	19812-19818	Vermis	_
105-72	19819-19821	NA	_
105-73	19822-19823	3	_
105-74	19824-19825	−	_
105-75	19825-19827	76	_
105-76	19828-19829	−	_
105-77	19829-19831	38	_
105-78	19832-19833	<	_
105-79	19834-19838	0.05	_
105-80	19839-19841	94	_
105-81	19841-19842	/	_
105-82	19842-19845	3.4	_
105-83	19846-19850	0.01	_
105-84	19854-19859	Right	_
105-85	19860-19866	Middle	_
105-86	19867-19870	and	_
105-87	19871-19879	Inferior	_
105-88	19880-19887	Frontal	_
105-89	19888-19893	Gyrus	_
105-90	19893-19894	,	_
105-91	19895-19900	Right	_
105-92	19901-19913	Dorsolateral	_
105-93	19914-19924	Prefrontal	_
105-94	19925-19931	Cortex	_
105-95	19932-19933	(	_
105-96	19933-19938	DLPFC	_
105-97	19938-19939	)	_
105-98	19940-19941	9	_
105-99	19941-19942	,	_
105-100	19943-19945	46	_
105-101	19946-19948	51	_
105-102	19949-19951	23	_
105-103	19952-19954	22	_
105-104	19955-19959	0.06	_
105-105	19960-19962	80	_
105-106	19962-19963	/	_
105-107	19963-19966	2.9	_
105-108	19967-19971	0.02	_
105-109	19975-19977	On	_
105-110	19978-19981	the	_
105-111	19982-19985	top	_
105-112	19986-19990	pane	_
105-113	19991-19994	the	_
105-114	19995-20000	study	_
105-115	20001-20006	group	_
105-116	20007-20008	x	_
105-117	20009-20010	(	_
105-118	20010-20014	Fear	_
105-119	20015-20017	vs	_
105-120	20018-20023	Happy	_
105-121	20023-20024	)	_
105-122	20025-20036	interaction	_
105-123	20037-20039	is	_
105-124	20040-20049	presented	_
105-125	20049-20050	,	_
105-126	20051-20056	while	_
105-127	20057-20059	on	_
105-128	20060-20063	the	_
105-129	20064-20070	bottom	_
105-130	20071-20075	pane	_
105-131	20076-20079	the	_
105-132	20080-20085	study	_
105-133	20086-20091	group	_
105-134	20092-20093	x	_
105-135	20094-20095	(	_
105-136	20095-20100	Mixed	_
105-137	20101-20106	Happy	_
105-138	20107-20109	vs	_
105-139	20110-20115	Happy	_
105-140	20115-20116	)	_
105-141	20117-20128	interaction	_
105-142	20129-20131	is	_
105-143	20132-20141	presented	_
105-144	20141-20142	.	_

#Text=Blue bars represent contrast estimates to happy conditions, red bars represent contrast estimates to fear (top pane) and to mixed happy (bottom pane) conditions, while green bars represent the difference in contrast estimates between the former two stimuli
#Text=A study group X condition (Fear vs Happy) interaction was found significant (FWE corrected p = 0.03) in a 62 voxel cluster in the right parietal operculum (RPO) and right superior temporal gyrus (RSTG/BA22) and also in the right middle frontal gyrus (RMFG/BA10) (FWE corrected p = 0.04) in a 50 voxel cluster (Table 3 ; Fig. 2/C).
106-1	20143-20147	Blue	_
106-2	20148-20152	bars	_
106-3	20153-20162	represent	_
106-4	20163-20171	contrast	_
106-5	20172-20181	estimates	_
106-6	20182-20184	to	_
106-7	20185-20190	happy	_
106-8	20191-20201	conditions	_
106-9	20201-20202	,	_
106-10	20203-20206	red	_
106-11	20207-20211	bars	_
106-12	20212-20221	represent	_
106-13	20222-20230	contrast	_
106-14	20231-20240	estimates	_
106-15	20241-20243	to	_
106-16	20244-20248	fear	_
106-17	20249-20250	(	_
106-18	20250-20253	top	_
106-19	20254-20258	pane	_
106-20	20258-20259	)	_
106-21	20260-20263	and	_
106-22	20264-20266	to	_
106-23	20267-20272	mixed	_
106-24	20273-20278	happy	_
106-25	20279-20280	(	_
106-26	20280-20286	bottom	_
106-27	20287-20291	pane	_
106-28	20291-20292	)	_
106-29	20293-20303	conditions	_
106-30	20303-20304	,	_
106-31	20305-20310	while	_
106-32	20311-20316	green	_
106-33	20317-20321	bars	_
106-34	20322-20331	represent	_
106-35	20332-20335	the	_
106-36	20336-20346	difference	_
106-37	20347-20349	in	_
106-38	20350-20358	contrast	_
106-39	20359-20368	estimates	_
106-40	20369-20376	between	_
106-41	20377-20380	the	_
106-42	20381-20387	former	_
106-43	20388-20391	two	_
106-44	20392-20399	stimuli	_
106-45	20400-20401	A	_
106-46	20402-20407	study	_
106-47	20408-20413	group	_
106-48	20414-20415	X	_
106-49	20416-20425	condition	_
106-50	20426-20427	(	_
106-51	20427-20431	Fear	_
106-52	20432-20434	vs	_
106-53	20435-20440	Happy	_
106-54	20440-20441	)	_
106-55	20442-20453	interaction	_
106-56	20454-20457	was	_
106-57	20458-20463	found	_
106-58	20464-20475	significant	_
106-59	20476-20477	(	_
106-60	20477-20480	FWE	_
106-61	20481-20490	corrected	_
106-62	20491-20492	p	_
106-63	20492-20493	 	_
106-64	20493-20494	=	_
106-65	20495-20499	0.03	_
106-66	20499-20500	)	_
106-67	20501-20503	in	_
106-68	20504-20505	a	_
106-69	20506-20508	62	_
106-70	20509-20514	voxel	_
106-71	20515-20522	cluster	_
106-72	20523-20525	in	_
106-73	20526-20529	the	_
106-74	20530-20535	right	_
106-75	20536-20544	parietal	_
106-76	20545-20554	operculum	_
106-77	20555-20556	(	_
106-78	20556-20559	RPO	_
106-79	20559-20560	)	_
106-80	20561-20564	and	_
106-81	20565-20570	right	_
106-82	20571-20579	superior	_
106-83	20580-20588	temporal	_
106-84	20589-20594	gyrus	_
106-85	20595-20596	(	_
106-86	20596-20600	RSTG	_
106-87	20600-20601	/	_
106-88	20601-20605	BA22	_
106-89	20605-20606	)	_
106-90	20607-20610	and	_
106-91	20611-20615	also	_
106-92	20616-20618	in	_
106-93	20619-20622	the	_
106-94	20623-20628	right	_
106-95	20629-20635	middle	_
106-96	20636-20643	frontal	_
106-97	20644-20649	gyrus	_
106-98	20650-20651	(	_
106-99	20651-20655	RMFG	_
106-100	20655-20656	/	_
106-101	20656-20660	BA10	_
106-102	20660-20661	)	_
106-103	20662-20663	(	_
106-104	20663-20666	FWE	_
106-105	20667-20676	corrected	_
106-106	20677-20678	p	_
106-107	20678-20679	 	_
106-108	20679-20680	=	_
106-109	20681-20685	0.04	_
106-110	20685-20686	)	_
106-111	20687-20689	in	_
106-112	20690-20691	a	_
106-113	20692-20694	50	_
106-114	20695-20700	voxel	_
106-115	20701-20708	cluster	_
106-116	20709-20710	(	_
106-117	20710-20715	Table	_
106-118	20716-20717	3	_
106-119	20718-20719	;	_
106-120	20720-20723	Fig	_
106-121	20723-20724	.	_
106-122	20725-20726	2	_
106-123	20726-20727	/	_
106-124	20727-20728	C	_
106-125	20728-20729	)	_
106-126	20729-20730	.	_

#Text=Further analyzing average activations in these clusters (Fig. 4), increased activations to fear compared to happy facial expressions were found in controls in RPO and RSTG (p = 0.004), and in RMFG (p = 0.04), while there were increased activations to happy compared to fearful faces in patients in RPO and RSTG (p = 0.006), and in RMFG (p < 0.0001).
107-1	20731-20738	Further	_
107-2	20739-20748	analyzing	_
107-3	20749-20756	average	_
107-4	20757-20768	activations	_
107-5	20769-20771	in	_
107-6	20772-20777	these	_
107-7	20778-20786	clusters	_
107-8	20787-20788	(	_
107-9	20788-20791	Fig	_
107-10	20791-20792	.	_
107-11	20792-20793	 	_
107-12	20793-20794	4	_
107-13	20794-20795	)	_
107-14	20795-20796	,	_
107-15	20797-20806	increased	_
107-16	20807-20818	activations	_
107-17	20819-20821	to	_
107-18	20822-20826	fear	_
107-19	20827-20835	compared	_
107-20	20836-20838	to	_
107-21	20839-20844	happy	_
107-22	20845-20851	facial	_
107-23	20852-20863	expressions	_
107-24	20864-20868	were	_
107-25	20869-20874	found	_
107-26	20875-20877	in	_
107-27	20878-20886	controls	_
107-28	20887-20889	in	_
107-29	20890-20893	RPO	_
107-30	20894-20897	and	_
107-31	20898-20902	RSTG	_
107-32	20903-20904	(	_
107-33	20904-20905	p	_
107-34	20905-20906	 	_
107-35	20906-20907	=	_
107-36	20908-20913	0.004	_
107-37	20913-20914	)	_
107-38	20914-20915	,	_
107-39	20916-20919	and	_
107-40	20920-20922	in	_
107-41	20923-20927	RMFG	_
107-42	20928-20929	(	_
107-43	20929-20930	p	_
107-44	20931-20932	=	_
107-45	20933-20937	0.04	_
107-46	20937-20938	)	_
107-47	20938-20939	,	_
107-48	20940-20945	while	_
107-49	20946-20951	there	_
107-50	20952-20956	were	_
107-51	20957-20966	increased	_
107-52	20967-20978	activations	_
107-53	20979-20981	to	_
107-54	20982-20987	happy	_
107-55	20988-20996	compared	_
107-56	20997-20999	to	_
107-57	21000-21007	fearful	_
107-58	21008-21013	faces	_
107-59	21014-21016	in	_
107-60	21017-21025	patients	_
107-61	21026-21028	in	_
107-62	21029-21032	RPO	_
107-63	21033-21036	and	_
107-64	21037-21041	RSTG	_
107-65	21042-21043	(	_
107-66	21043-21044	p	_
107-67	21044-21045	 	_
107-68	21045-21046	=	_
107-69	21047-21052	0.006	_
107-70	21052-21053	)	_
107-71	21053-21054	,	_
107-72	21055-21058	and	_
107-73	21059-21061	in	_
107-74	21062-21066	RMFG	_
107-75	21067-21068	(	_
107-76	21068-21069	p	_
107-77	21069-21070	 	_
107-78	21070-21071	<	_
107-79	21072-21078	0.0001	_
107-80	21078-21079	)	_
107-81	21079-21080	.	_

#Text=Also the study group X condition (Mixed Happy vs Happy) interaction was found significant (FWE corrected p = 0.01 (cluster level) p < 0.05 (peak voxel)) in a 94 voxel cluster in the vermis of the Cerebellum (VC) and in the right dorsolateral prefrontal cortex (DLPFC/BA46) (FWE corrected p = 0.02) in a 80 voxel cluster (Table 3 ; Fig. 2/C).
108-1	21083-21087	Also	_
108-2	21088-21091	the	_
108-3	21092-21097	study	_
108-4	21098-21103	group	_
108-5	21104-21105	X	_
108-6	21106-21115	condition	_
108-7	21116-21117	(	_
108-8	21117-21122	Mixed	_
108-9	21123-21128	Happy	_
108-10	21129-21131	vs	_
108-11	21132-21137	Happy	_
108-12	21137-21138	)	_
108-13	21139-21150	interaction	_
108-14	21151-21154	was	_
108-15	21155-21160	found	_
108-16	21161-21172	significant	_
108-17	21173-21174	(	_
108-18	21174-21177	FWE	_
108-19	21178-21187	corrected	_
108-20	21188-21189	p	_
108-21	21189-21190	 	_
108-22	21190-21191	=	_
108-23	21192-21196	0.01	_
108-24	21197-21198	(	_
108-25	21198-21205	cluster	_
108-26	21206-21211	level	_
108-27	21211-21212	)	_
108-28	21213-21214	p	_
108-29	21214-21215	 	_
108-30	21215-21216	<	_
108-31	21217-21221	0.05	_
108-32	21222-21223	(	_
108-33	21223-21227	peak	_
108-34	21228-21233	voxel	_
108-35	21233-21234	)	_
108-36	21234-21235	)	_
108-37	21236-21238	in	_
108-38	21239-21240	a	_
108-39	21241-21243	94	_
108-40	21244-21249	voxel	_
108-41	21250-21257	cluster	_
108-42	21258-21260	in	_
108-43	21261-21264	the	_
108-44	21265-21271	vermis	_
108-45	21272-21274	of	_
108-46	21275-21278	the	_
108-47	21279-21289	Cerebellum	_
108-48	21290-21291	(	_
108-49	21291-21293	VC	_
108-50	21293-21294	)	_
108-51	21295-21298	and	_
108-52	21299-21301	in	_
108-53	21302-21305	the	_
108-54	21306-21311	right	_
108-55	21312-21324	dorsolateral	_
108-56	21325-21335	prefrontal	_
108-57	21336-21342	cortex	_
108-58	21343-21344	(	_
108-59	21344-21349	DLPFC	_
108-60	21349-21350	/	_
108-61	21350-21354	BA46	_
108-62	21354-21355	)	_
108-63	21356-21357	(	_
108-64	21357-21360	FWE	_
108-65	21361-21370	corrected	_
108-66	21371-21372	p	_
108-67	21372-21373	 	_
108-68	21373-21374	=	_
108-69	21375-21379	0.02	_
108-70	21379-21380	)	_
108-71	21381-21383	in	_
108-72	21384-21385	a	_
108-73	21386-21388	80	_
108-74	21389-21394	voxel	_
108-75	21395-21402	cluster	_
108-76	21403-21404	(	_
108-77	21404-21409	Table	_
108-78	21409-21410	 	_
108-79	21410-21411	3	_
108-80	21412-21413	;	_
108-81	21414-21417	Fig	_
108-82	21417-21418	.	_
108-83	21419-21420	2	_
108-84	21420-21421	/	_
108-85	21421-21422	C	_
108-86	21422-21423	)	_
108-87	21423-21424	.	_

#Text=Further analyzing average activations in these clusters (Fig. 4), increased activations to mixed happy compared to happy facial expressions were found in controls both in VC and (p < 0.0001), and in DLPFC (p < 0.0001), while there were no significant between condition differences in the patient groups in any of these regions.
109-1	21425-21432	Further	_
109-2	21433-21442	analyzing	_
109-3	21443-21450	average	_
109-4	21451-21462	activations	_
109-5	21463-21465	in	_
109-6	21466-21471	these	_
109-7	21472-21480	clusters	_
109-8	21481-21482	(	_
109-9	21482-21485	Fig	_
109-10	21485-21486	.	_
109-11	21487-21488	4	_
109-12	21488-21489	)	_
109-13	21489-21490	,	_
109-14	21491-21500	increased	_
109-15	21501-21512	activations	_
109-16	21513-21515	to	_
109-17	21516-21521	mixed	_
109-18	21522-21527	happy	_
109-19	21528-21536	compared	_
109-20	21537-21539	to	_
109-21	21540-21545	happy	_
109-22	21546-21552	facial	_
109-23	21553-21564	expressions	_
109-24	21565-21569	were	_
109-25	21570-21575	found	_
109-26	21576-21578	in	_
109-27	21579-21587	controls	_
109-28	21588-21592	both	_
109-29	21593-21595	in	_
109-30	21596-21598	VC	_
109-31	21599-21602	and	_
109-32	21603-21604	(	_
109-33	21604-21605	p	_
109-34	21606-21607	<	_
109-35	21608-21614	0.0001	_
109-36	21614-21615	)	_
109-37	21615-21616	,	_
109-38	21617-21620	and	_
109-39	21621-21623	in	_
109-40	21624-21629	DLPFC	_
109-41	21630-21631	(	_
109-42	21631-21632	p	_
109-43	21633-21634	<	_
109-44	21635-21641	0.0001	_
109-45	21641-21642	)	_
109-46	21642-21643	,	_
109-47	21644-21649	while	_
109-48	21650-21655	there	_
109-49	21656-21660	were	_
109-50	21661-21663	no	_
109-51	21664-21675	significant	_
109-52	21676-21683	between	_
109-53	21684-21693	condition	_
109-54	21694-21705	differences	_
109-55	21706-21708	in	_
109-56	21709-21712	the	_
109-57	21713-21720	patient	_
109-58	21721-21727	groups	_
109-59	21728-21730	in	_
109-60	21731-21734	any	_
109-61	21735-21737	of	_
109-62	21738-21743	these	_
109-63	21744-21751	regions	_
109-64	21751-21752	.	_

#Text=Behavioral results
#Text=Recognition performance
#Text=The study groups did not differ significantly in the recognition of happy, mixed happy, and fearful facial expressions (happy: Control subjects (Cntrl) = 92% (SD = 17%), Patients with Schizophrenia (Sch) = 98% (SD = 4%), t = 1.2, p = 0.2; mixed happy: Cntrl = 86% (SD = 17%), Sch = 90% (SD = 15%), t = 0.9, p = 0.4; fear: Cntrl = 99% (SD = 3%), Sch = 99% (SD = 3%), t = 0.2, p = 0.9), while patients recognized mixed fear emotions as fear at a significantly lower rate compared to controls (mixed fear: Cntrl = 90% (SD = 9%), Sch = 84% (SD = 11%), t = 2.4, p = 0.02, Effect Size = 0.6 in terms of Cohen’s d).
110-1	21753-21763	Behavioral	_
110-2	21764-21771	results	_
110-3	21772-21783	Recognition	_
110-4	21784-21795	performance	_
110-5	21796-21799	The	_
110-6	21800-21805	study	_
110-7	21806-21812	groups	_
110-8	21813-21816	did	_
110-9	21817-21820	not	_
110-10	21821-21827	differ	_
110-11	21828-21841	significantly	_
110-12	21842-21844	in	_
110-13	21845-21848	the	_
110-14	21849-21860	recognition	_
110-15	21861-21863	of	_
110-16	21864-21869	happy	_
110-17	21869-21870	,	_
110-18	21871-21876	mixed	_
110-19	21877-21882	happy	_
110-20	21882-21883	,	_
110-21	21884-21887	and	_
110-22	21888-21895	fearful	_
110-23	21896-21902	facial	_
110-24	21903-21914	expressions	_
110-25	21915-21916	(	_
110-26	21916-21921	happy	_
110-27	21921-21922	:	_
110-28	21923-21930	Control	_
110-29	21931-21939	subjects	_
110-30	21940-21941	(	_
110-31	21941-21946	Cntrl	_
110-32	21946-21947	)	_
110-33	21948-21949	=	_
110-34	21950-21953	92%	_
110-35	21954-21955	(	_
110-36	21955-21957	SD	_
110-37	21958-21959	=	_
110-38	21960-21963	17%	_
110-39	21963-21964	)	_
110-40	21964-21965	,	_
110-41	21966-21974	Patients	_
110-42	21975-21979	with	_
110-43	21980-21993	Schizophrenia	_
110-44	21994-21995	(	_
110-45	21995-21998	Sch	_
110-46	21998-21999	)	_
110-47	22000-22001	=	_
110-48	22002-22005	98%	_
110-49	22006-22007	(	_
110-50	22007-22009	SD	_
110-51	22010-22011	=	_
110-52	22012-22014	4%	_
110-53	22014-22015	)	_
110-54	22015-22016	,	_
110-55	22017-22018	t	_
110-56	22018-22019	 	_
110-57	22019-22020	=	_
110-58	22021-22024	1.2	_
110-59	22024-22025	,	_
110-60	22026-22027	p	_
110-61	22027-22028	 	_
110-62	22028-22029	=	_
110-63	22030-22033	0.2	_
110-64	22033-22034	;	_
110-65	22035-22040	mixed	_
110-66	22041-22046	happy	_
110-67	22046-22047	:	_
110-68	22048-22053	Cntrl	_
110-69	22054-22055	=	_
110-70	22056-22059	86%	_
110-71	22060-22061	(	_
110-72	22061-22063	SD	_
110-73	22064-22065	=	_
110-74	22066-22069	17%	_
110-75	22069-22070	)	_
110-76	22070-22071	,	_
110-77	22072-22075	Sch	_
110-78	22076-22077	=	_
110-79	22078-22081	90%	_
110-80	22082-22083	(	_
110-81	22083-22085	SD	_
110-82	22086-22087	=	_
110-83	22088-22091	15%	_
110-84	22091-22092	)	_
110-85	22092-22093	,	_
110-86	22094-22095	t	_
110-87	22095-22096	 	_
110-88	22096-22097	=	_
110-89	22098-22101	0.9	_
110-90	22101-22102	,	_
110-91	22103-22104	p	_
110-92	22104-22105	 	_
110-93	22105-22106	=	_
110-94	22107-22110	0.4	_
110-95	22110-22111	;	_
110-96	22112-22116	fear	_
110-97	22116-22117	:	_
110-98	22118-22123	Cntrl	_
110-99	22124-22125	=	_
110-100	22126-22129	99%	_
110-101	22130-22131	(	_
110-102	22131-22133	SD	_
110-103	22134-22135	=	_
110-104	22136-22138	3%	_
110-105	22138-22139	)	_
110-106	22139-22140	,	_
110-107	22141-22144	Sch	_
110-108	22145-22146	=	_
110-109	22147-22150	99%	_
110-110	22151-22152	(	_
110-111	22152-22154	SD	_
110-112	22155-22156	=	_
110-113	22157-22159	3%	_
110-114	22159-22160	)	_
110-115	22160-22161	,	_
110-116	22162-22163	t	_
110-117	22163-22164	 	_
110-118	22164-22165	=	_
110-119	22166-22169	0.2	_
110-120	22169-22170	,	_
110-121	22171-22172	p	_
110-122	22172-22173	 	_
110-123	22173-22174	=	_
110-124	22175-22178	0.9	_
110-125	22178-22179	)	_
110-126	22179-22180	,	_
110-127	22181-22186	while	_
110-128	22187-22195	patients	_
110-129	22196-22206	recognized	_
110-130	22207-22212	mixed	_
110-131	22213-22217	fear	_
110-132	22218-22226	emotions	_
110-133	22227-22229	as	_
110-134	22230-22234	fear	_
110-135	22235-22237	at	_
110-136	22238-22239	a	_
110-137	22240-22253	significantly	_
110-138	22254-22259	lower	_
110-139	22260-22264	rate	_
110-140	22265-22273	compared	_
110-141	22274-22276	to	_
110-142	22277-22285	controls	_
110-143	22286-22287	(	_
110-144	22287-22292	mixed	_
110-145	22293-22297	fear	_
110-146	22297-22298	:	_
110-147	22299-22304	Cntrl	_
110-148	22305-22306	=	_
110-149	22307-22310	90%	_
110-150	22311-22312	(	_
110-151	22312-22314	SD	_
110-152	22315-22316	=	_
110-153	22317-22319	9%	_
110-154	22319-22320	)	_
110-155	22320-22321	,	_
110-156	22322-22325	Sch	_
110-157	22326-22327	=	_
110-158	22328-22331	84%	_
110-159	22332-22333	(	_
110-160	22333-22335	SD	_
110-161	22336-22337	=	_
110-162	22338-22341	11%	_
110-163	22341-22342	)	_
110-164	22342-22343	,	_
110-165	22344-22345	t	_
110-166	22345-22346	 	_
110-167	22346-22347	=	_
110-168	22348-22351	2.4	_
110-169	22351-22352	,	_
110-170	22353-22354	p	_
110-171	22354-22355	 	_
110-172	22355-22356	=	_
110-173	22357-22361	0.02	_
110-174	22361-22362	,	_
110-175	22363-22369	Effect	_
110-176	22370-22374	Size	_
110-177	22375-22376	=	_
110-178	22377-22380	0.6	_
110-179	22381-22383	in	_
110-180	22384-22389	terms	_
110-181	22390-22392	of	_
110-182	22393-22398	Cohen	_
110-183	22398-22399	’	_
110-184	22399-22400	s	_
110-185	22401-22402	d	_
110-186	22402-22403	)	_
110-187	22403-22404	.	_

#Text=Reaction times
#Text=The two groups did not differ in reaction times (overall: Cntrl = 1.13 s (SD = 0.17 s), Sch = 1.21 s (SD = 0.23 s), t = −1.2, p = 0.24; happy: Cntrl = 1.07 s (SD = 0.19 s), Sch = 1.24 s (SD = 0.32 s), t = −1.9, p = 0.06; mixed happy: Cntrl = 1.26 s (SD = 0.23 s), Sch = 1.39 s (SD = 0.33 s), t = −1.4, p = 0.18; fear: Cntrl = 1.18 s (SD = 0.24 s), Sch = 1.47 s (SD = 0.36 s), t = −2.1, p = 0.054; mixed fear: Cntrl = 1.60s (SD = 0.33 s), Sch = 1.54 s (SD = 0.30s), t = 0.5, p = 0.61).
111-1	22405-22413	Reaction	_
111-2	22414-22419	times	_
111-3	22420-22423	The	_
111-4	22424-22427	two	_
111-5	22428-22434	groups	_
111-6	22435-22438	did	_
111-7	22439-22442	not	_
111-8	22443-22449	differ	_
111-9	22450-22452	in	_
111-10	22453-22461	reaction	_
111-11	22462-22467	times	_
111-12	22468-22469	(	_
111-13	22469-22476	overall	_
111-14	22476-22477	:	_
111-15	22478-22483	Cntrl	_
111-16	22484-22485	=	_
111-17	22486-22490	1.13	_
111-18	22490-22491	 	_
111-19	22491-22492	s	_
111-20	22493-22494	(	_
111-21	22494-22496	SD	_
111-22	22497-22498	=	_
111-23	22499-22503	0.17	_
111-24	22503-22504	 	_
111-25	22504-22505	s	_
111-26	22505-22506	)	_
111-27	22506-22507	,	_
111-28	22508-22511	Sch	_
111-29	22512-22513	=	_
111-30	22514-22518	1.21	_
111-31	22518-22519	 	_
111-32	22519-22520	s	_
111-33	22521-22522	(	_
111-34	22522-22524	SD	_
111-35	22525-22526	=	_
111-36	22527-22531	0.23	_
111-37	22531-22532	 	_
111-38	22532-22533	s	_
111-39	22533-22534	)	_
111-40	22534-22535	,	_
111-41	22536-22537	t	_
111-42	22537-22538	 	_
111-43	22538-22539	=	_
111-44	22540-22541	−	_
111-45	22541-22544	1.2	_
111-46	22544-22545	,	_
111-47	22546-22547	p	_
111-48	22547-22548	 	_
111-49	22548-22549	=	_
111-50	22550-22554	0.24	_
111-51	22554-22555	;	_
111-52	22556-22561	happy	_
111-53	22561-22562	:	_
111-54	22563-22568	Cntrl	_
111-55	22569-22570	=	_
111-56	22571-22575	1.07	_
111-57	22575-22576	 	_
111-58	22576-22577	s	_
111-59	22578-22579	(	_
111-60	22579-22581	SD	_
111-61	22582-22583	=	_
111-62	22584-22588	0.19	_
111-63	22588-22589	 	_
111-64	22589-22590	s	_
111-65	22590-22591	)	_
111-66	22591-22592	,	_
111-67	22593-22596	Sch	_
111-68	22597-22598	=	_
111-69	22599-22603	1.24	_
111-70	22603-22604	 	_
111-71	22604-22605	s	_
111-72	22606-22607	(	_
111-73	22607-22609	SD	_
111-74	22610-22611	=	_
111-75	22612-22616	0.32	_
111-76	22616-22617	 	_
111-77	22617-22618	s	_
111-78	22618-22619	)	_
111-79	22619-22620	,	_
111-80	22621-22622	t	_
111-81	22622-22623	 	_
111-82	22623-22624	=	_
111-83	22625-22626	−	_
111-84	22626-22629	1.9	_
111-85	22629-22630	,	_
111-86	22631-22632	p	_
111-87	22632-22633	 	_
111-88	22633-22634	=	_
111-89	22635-22639	0.06	_
111-90	22639-22640	;	_
111-91	22641-22646	mixed	_
111-92	22647-22652	happy	_
111-93	22652-22653	:	_
111-94	22654-22659	Cntrl	_
111-95	22660-22661	=	_
111-96	22662-22666	1.26	_
111-97	22666-22667	 	_
111-98	22667-22668	s	_
111-99	22669-22670	(	_
111-100	22670-22672	SD	_
111-101	22673-22674	=	_
111-102	22675-22679	0.23	_
111-103	22679-22680	 	_
111-104	22680-22681	s	_
111-105	22681-22682	)	_
111-106	22682-22683	,	_
111-107	22684-22687	Sch	_
111-108	22688-22689	=	_
111-109	22690-22694	1.39	_
111-110	22694-22695	 	_
111-111	22695-22696	s	_
111-112	22697-22698	(	_
111-113	22698-22700	SD	_
111-114	22701-22702	=	_
111-115	22703-22707	0.33	_
111-116	22707-22708	 	_
111-117	22708-22709	s	_
111-118	22709-22710	)	_
111-119	22710-22711	,	_
111-120	22712-22713	t	_
111-121	22713-22714	 	_
111-122	22714-22715	=	_
111-123	22716-22717	−	_
111-124	22717-22720	1.4	_
111-125	22720-22721	,	_
111-126	22722-22723	p	_
111-127	22723-22724	 	_
111-128	22724-22725	=	_
111-129	22726-22730	0.18	_
111-130	22730-22731	;	_
111-131	22732-22736	fear	_
111-132	22736-22737	:	_
111-133	22738-22743	Cntrl	_
111-134	22744-22745	=	_
111-135	22746-22750	1.18	_
111-136	22750-22751	 	_
111-137	22751-22752	s	_
111-138	22753-22754	(	_
111-139	22754-22756	SD	_
111-140	22757-22758	=	_
111-141	22759-22763	0.24	_
111-142	22763-22764	 	_
111-143	22764-22765	s	_
111-144	22765-22766	)	_
111-145	22766-22767	,	_
111-146	22768-22771	Sch	_
111-147	22772-22773	=	_
111-148	22774-22778	1.47	_
111-149	22778-22779	 	_
111-150	22779-22780	s	_
111-151	22781-22782	(	_
111-152	22782-22784	SD	_
111-153	22785-22786	=	_
111-154	22787-22791	0.36	_
111-155	22791-22792	 	_
111-156	22792-22793	s	_
111-157	22793-22794	)	_
111-158	22794-22795	,	_
111-159	22796-22797	t	_
111-160	22797-22798	 	_
111-161	22798-22799	=	_
111-162	22800-22801	−	_
111-163	22801-22804	2.1	_
111-164	22804-22805	,	_
111-165	22806-22807	p	_
111-166	22807-22808	 	_
111-167	22808-22809	=	_
111-168	22810-22815	0.054	_
111-169	22815-22816	;	_
111-170	22817-22822	mixed	_
111-171	22823-22827	fear	_
111-172	22827-22828	:	_
111-173	22829-22834	Cntrl	_
111-174	22835-22836	=	_
111-175	22837-22842	1.60s	_
111-176	22843-22844	(	_
111-177	22844-22846	SD	_
111-178	22847-22848	=	_
111-179	22849-22853	0.33	_
111-180	22853-22854	 	_
111-181	22854-22855	s	_
111-182	22855-22856	)	_
111-183	22856-22857	,	_
111-184	22858-22861	Sch	_
111-185	22862-22863	=	_
111-186	22864-22868	1.54	_
111-187	22868-22869	 	_
111-188	22869-22870	s	_
111-189	22871-22872	(	_
111-190	22872-22874	SD	_
111-191	22875-22876	=	_
111-192	22877-22882	0.30s	_
111-193	22882-22883	)	_
111-194	22883-22884	,	_
111-195	22885-22886	t	_
111-196	22886-22887	 	_
111-197	22887-22888	=	_
111-198	22889-22892	0.5	_
111-199	22892-22893	,	_
111-200	22894-22895	p	_
111-201	22895-22896	 	_
111-202	22896-22897	=	_
111-203	22898-22902	0.61	_
111-204	22902-22903	)	_
111-205	22903-22904	.	_

#Text=Volumetric comparison of patients and controls
#Text=The primary purpose of this analysis was to check if functional activation differences between the groups can be explained by volumetric differences.
112-1	22905-22915	Volumetric	_
112-2	22916-22926	comparison	_
112-3	22927-22929	of	_
112-4	22930-22938	patients	_
112-5	22939-22942	and	_
112-6	22943-22951	controls	_
112-7	22952-22955	The	_
112-8	22956-22963	primary	_
112-9	22964-22971	purpose	_
112-10	22972-22974	of	_
112-11	22975-22979	this	_
112-12	22980-22988	analysis	_
112-13	22989-22992	was	_
112-14	22993-22995	to	_
112-15	22996-23001	check	_
112-16	23002-23004	if	_
112-17	23005-23015	functional	_
112-18	23016-23026	activation	_
112-19	23027-23038	differences	_
112-20	23039-23046	between	_
112-21	23047-23050	the	_
112-22	23051-23057	groups	_
112-23	23058-23061	can	_
112-24	23062-23064	be	_
112-25	23065-23074	explained	_
112-26	23075-23077	by	_
112-27	23078-23088	volumetric	_
112-28	23089-23100	differences	_
112-29	23100-23101	.	_

#Text=After Familywise Error Correction (FEW) no significant structural differences were found between the study groups.
113-1	23102-23107	After	_
113-2	23108-23118	Familywise	_
113-3	23119-23124	Error	_
113-4	23125-23135	Correction	_
113-5	23136-23137	(	_
113-6	23137-23140	FEW	_
113-7	23140-23141	)	_
113-8	23142-23144	no	_
113-9	23145-23156	significant	_
113-10	23157-23167	structural	_
113-11	23168-23179	differences	_
113-12	23180-23184	were	_
113-13	23185-23190	found	_
113-14	23191-23198	between	_
113-15	23199-23202	the	_
113-16	23203-23208	study	_
113-17	23209-23215	groups	_
113-18	23215-23216	.	_

#Text=Discussion
#Text=In this study we examined emotion processing in a group of patients with schizophrenia and in healthy controls.
114-1	23217-23227	Discussion	_
114-2	23228-23230	In	_
114-3	23231-23235	this	_
114-4	23236-23241	study	_
114-5	23242-23244	we	_
114-6	23245-23253	examined	_
114-7	23254-23261	emotion	_
114-8	23262-23272	processing	_
114-9	23273-23275	in	_
114-10	23276-23277	a	_
114-11	23278-23283	group	_
114-12	23284-23286	of	_
114-13	23287-23295	patients	_
114-14	23296-23300	with	_
114-15	23301-23314	schizophrenia	_
114-16	23315-23318	and	_
114-17	23319-23321	in	_
114-18	23322-23329	healthy	_
114-19	23330-23338	controls	_
114-20	23338-23339	.	_

#Text=The study groups were matched by age, gender, and education.
115-1	23340-23343	The	_
115-2	23344-23349	study	_
115-3	23350-23356	groups	_
115-4	23357-23361	were	_
115-5	23362-23369	matched	_
115-6	23370-23372	by	_
115-7	23373-23376	age	_
115-8	23376-23377	,	_
115-9	23378-23384	gender	_
115-10	23384-23385	,	_
115-11	23386-23389	and	_
115-12	23390-23399	education	_
115-13	23399-23400	.	_

#Text=Patients showed a decreased activation in the right anterior insula (RAI), in the right VLPFC, in the right DMPFC during fear, mixed fear, and mixed happy facial processing and showed poorer emotion recognition performance in fear detection relative to controls.
116-1	23401-23409	Patients	_
116-2	23410-23416	showed	_
116-3	23417-23418	a	_
116-4	23419-23428	decreased	_
116-5	23429-23439	activation	_
116-6	23440-23442	in	_
116-7	23443-23446	the	_
116-8	23447-23452	right	_
116-9	23453-23461	anterior	_
116-10	23462-23468	insula	_
116-11	23469-23470	(	_
116-12	23470-23473	RAI	_
116-13	23473-23474	)	_
116-14	23474-23475	,	_
116-15	23476-23478	in	_
116-16	23479-23482	the	_
116-17	23483-23488	right	_
116-18	23489-23494	VLPFC	_
116-19	23494-23495	,	_
116-20	23496-23498	in	_
116-21	23499-23502	the	_
116-22	23503-23508	right	_
116-23	23509-23514	DMPFC	_
116-24	23515-23521	during	_
116-25	23522-23526	fear	_
116-26	23526-23527	,	_
116-27	23528-23533	mixed	_
116-28	23534-23538	fear	_
116-29	23538-23539	,	_
116-30	23540-23543	and	_
116-31	23544-23549	mixed	_
116-32	23550-23555	happy	_
116-33	23556-23562	facial	_
116-34	23563-23573	processing	_
116-35	23574-23577	and	_
116-36	23578-23584	showed	_
116-37	23585-23591	poorer	_
116-38	23592-23599	emotion	_
116-39	23600-23611	recognition	_
116-40	23612-23623	performance	_
116-41	23624-23626	in	_
116-42	23627-23631	fear	_
116-43	23632-23641	detection	_
116-44	23642-23650	relative	_
116-45	23651-23653	to	_
116-46	23654-23662	controls	_
116-47	23662-23663	.	_

#Text=In patients on higher doses of APs decreased activations to all emotional displays were detected in the right anterior amygdala, which correlation was the strongest for mixed happy faces.
117-1	23664-23666	In	_
117-2	23667-23675	patients	_
117-3	23676-23678	on	_
117-4	23679-23685	higher	_
117-5	23686-23691	doses	_
117-6	23692-23694	of	_
117-7	23695-23698	APs	_
117-8	23699-23708	decreased	_
117-9	23709-23720	activations	_
117-10	23721-23723	to	_
117-11	23724-23727	all	_
117-12	23728-23737	emotional	_
117-13	23738-23746	displays	_
117-14	23747-23751	were	_
117-15	23752-23760	detected	_
117-16	23761-23763	in	_
117-17	23764-23767	the	_
117-18	23768-23773	right	_
117-19	23774-23782	anterior	_
117-20	23783-23791	amygdala	_
117-21	23791-23792	,	_
117-22	23793-23798	which	_
117-23	23799-23810	correlation	_
117-24	23811-23814	was	_
117-25	23815-23818	the	_
117-26	23819-23828	strongest	_
117-27	23829-23832	for	_
117-28	23833-23838	mixed	_
117-29	23839-23844	happy	_
117-30	23845-23850	faces	_
117-31	23850-23851	.	_

#Text=Subjects were presented with facial displays of happiness, fear, and the mixture of these emotions as described in the methods section.
118-1	23852-23860	Subjects	_
118-2	23861-23865	were	_
118-3	23866-23875	presented	_
118-4	23876-23880	with	_
118-5	23881-23887	facial	_
118-6	23888-23896	displays	_
118-7	23897-23899	of	_
118-8	23900-23909	happiness	_
118-9	23909-23910	,	_
118-10	23911-23915	fear	_
118-11	23915-23916	,	_
118-12	23917-23920	and	_
118-13	23921-23924	the	_
118-14	23925-23932	mixture	_
118-15	23933-23935	of	_
118-16	23936-23941	these	_
118-17	23942-23950	emotions	_
118-18	23951-23953	as	_
118-19	23954-23963	described	_
118-20	23964-23966	in	_
118-21	23967-23970	the	_
118-22	23971-23978	methods	_
118-23	23979-23986	section	_
118-24	23986-23987	.	_

#Text=From previous research we know that VLPFC activation is related to emotion intensity and reappraisal, and signals the salience of the stimulus.
119-1	23988-23992	From	_
119-2	23993-24001	previous	_
119-3	24002-24010	research	_
119-4	24011-24013	we	_
119-5	24014-24018	know	_
119-6	24019-24023	that	_
119-7	24024-24029	VLPFC	_
119-8	24030-24040	activation	_
119-9	24041-24043	is	_
119-10	24044-24051	related	_
119-11	24052-24054	to	_
119-12	24055-24062	emotion	_
119-13	24063-24072	intensity	_
119-14	24073-24076	and	_
119-15	24077-24088	reappraisal	_
119-16	24088-24089	,	_
119-17	24090-24093	and	_
119-18	24094-24101	signals	_
119-19	24102-24105	the	_
119-20	24106-24114	salience	_
119-21	24115-24117	of	_
119-22	24118-24121	the	_
119-23	24122-24130	stimulus	_
119-24	24130-24131	.	_

#Text=Moreover, emotional tasks with cognitive demand involves primarily the anterior cingulate and insula.
120-1	24132-24140	Moreover	_
120-2	24140-24141	,	_
120-3	24142-24151	emotional	_
120-4	24152-24157	tasks	_
120-5	24158-24162	with	_
120-6	24163-24172	cognitive	_
120-7	24173-24179	demand	_
120-8	24180-24188	involves	_
120-9	24189-24198	primarily	_
120-10	24199-24202	the	_
120-11	24203-24211	anterior	_
120-12	24212-24221	cingulate	_
120-13	24222-24225	and	_
120-14	24226-24232	insula	_
120-15	24232-24233	.	_

#Text=Decreased activation was detected in the right anterior insula (RAI), and in the VLPFC region to fear, mixed fear, and mixed happy conditions in patients relative to controls.
121-1	24234-24243	Decreased	_
121-2	24244-24254	activation	_
121-3	24255-24258	was	_
121-4	24259-24267	detected	_
121-5	24268-24270	in	_
121-6	24271-24274	the	_
121-7	24275-24280	right	_
121-8	24281-24289	anterior	_
121-9	24290-24296	insula	_
121-10	24297-24298	(	_
121-11	24298-24301	RAI	_
121-12	24301-24302	)	_
121-13	24302-24303	,	_
121-14	24304-24307	and	_
121-15	24308-24310	in	_
121-16	24311-24314	the	_
121-17	24315-24320	VLPFC	_
121-18	24321-24327	region	_
121-19	24328-24330	to	_
121-20	24331-24335	fear	_
121-21	24335-24336	,	_
121-22	24337-24342	mixed	_
121-23	24343-24347	fear	_
121-24	24347-24348	,	_
121-25	24349-24352	and	_
121-26	24353-24358	mixed	_
121-27	24359-24364	happy	_
121-28	24365-24375	conditions	_
121-29	24376-24378	in	_
121-30	24379-24387	patients	_
121-31	24388-24396	relative	_
121-32	24397-24399	to	_
121-33	24400-24408	controls	_
121-34	24408-24409	.	_

#Text=Previous investigations showed that VLPFC plays a key role in emotion regulation and reappraisal through cortical-subcortical pathways especially to aversive stimuli.
122-1	24410-24418	Previous	_
122-2	24419-24433	investigations	_
122-3	24434-24440	showed	_
122-4	24441-24445	that	_
122-5	24446-24451	VLPFC	_
122-6	24452-24457	plays	_
122-7	24458-24459	a	_
122-8	24460-24463	key	_
122-9	24464-24468	role	_
122-10	24469-24471	in	_
122-11	24472-24479	emotion	_
122-12	24480-24490	regulation	_
122-13	24491-24494	and	_
122-14	24495-24506	reappraisal	_
122-15	24507-24514	through	_
122-16	24515-24535	cortical-subcortical	_
122-17	24536-24544	pathways	_
122-18	24545-24555	especially	_
122-19	24556-24558	to	_
122-20	24559-24567	aversive	_
122-21	24568-24575	stimuli	_
122-22	24575-24576	.	_

#Text=It is also found that VLPFC activity correlated with reduced negative emotional experience during cognitive reappraisal of aversive images.
123-1	24577-24579	It	_
123-2	24580-24582	is	_
123-3	24583-24587	also	_
123-4	24588-24593	found	_
123-5	24594-24598	that	_
123-6	24599-24604	VLPFC	_
123-7	24605-24613	activity	_
123-8	24614-24624	correlated	_
123-9	24625-24629	with	_
123-10	24630-24637	reduced	_
123-11	24638-24646	negative	_
123-12	24647-24656	emotional	_
123-13	24657-24667	experience	_
123-14	24668-24674	during	_
123-15	24675-24684	cognitive	_
123-16	24685-24696	reappraisal	_
123-17	24697-24699	of	_
123-18	24700-24708	aversive	_
123-19	24709-24715	images	_
123-20	24715-24716	.	_

#Text=Taken these results together with our findings raised the possibility that salience signaling and perhaps also emotion regulation linked to negative emotion processing are impaired in schizophrenia, which is in line with previous studies examining emotion processing in schizophrenia that found decreased activation in the VLPFC relative to controls.
124-1	24717-24722	Taken	_
124-2	24723-24728	these	_
124-3	24729-24736	results	_
124-4	24737-24745	together	_
124-5	24746-24750	with	_
124-6	24751-24754	our	_
124-7	24755-24763	findings	_
124-8	24764-24770	raised	_
124-9	24771-24774	the	_
124-10	24775-24786	possibility	_
124-11	24787-24791	that	_
124-12	24792-24800	salience	_
124-13	24801-24810	signaling	_
124-14	24811-24814	and	_
124-15	24815-24822	perhaps	_
124-16	24823-24827	also	_
124-17	24828-24835	emotion	_
124-18	24836-24846	regulation	_
124-19	24847-24853	linked	_
124-20	24854-24856	to	_
124-21	24857-24865	negative	_
124-22	24866-24873	emotion	_
124-23	24874-24884	processing	_
124-24	24885-24888	are	_
124-25	24889-24897	impaired	_
124-26	24898-24900	in	_
124-27	24901-24914	schizophrenia	_
124-28	24914-24915	,	_
124-29	24916-24921	which	_
124-30	24922-24924	is	_
124-31	24925-24927	in	_
124-32	24928-24932	line	_
124-33	24933-24937	with	_
124-34	24938-24946	previous	_
124-35	24947-24954	studies	_
124-36	24955-24964	examining	_
124-37	24965-24972	emotion	_
124-38	24973-24983	processing	_
124-39	24984-24986	in	_
124-40	24987-25000	schizophrenia	_
124-41	25001-25005	that	_
124-42	25006-25011	found	_
124-43	25012-25021	decreased	_
124-44	25022-25032	activation	_
124-45	25033-25035	in	_
124-46	25036-25039	the	_
124-47	25040-25045	VLPFC	_
124-48	25046-25054	relative	_
124-49	25055-25057	to	_
124-50	25058-25066	controls	_
124-51	25066-25067	.	_

#Text=Patients showed decreased activation relative to controls in the right middle occipital gyrus (RMOG/BA18) to facial conditions of mixed happy facial stimuli.
125-1	25068-25076	Patients	_
125-2	25077-25083	showed	_
125-3	25084-25093	decreased	_
125-4	25094-25104	activation	_
125-5	25105-25113	relative	_
125-6	25114-25116	to	_
125-7	25117-25125	controls	_
125-8	25126-25128	in	_
125-9	25129-25132	the	_
125-10	25133-25138	right	_
125-11	25139-25145	middle	_
125-12	25146-25155	occipital	_
125-13	25156-25161	gyrus	_
125-14	25162-25163	(	_
125-15	25163-25167	RMOG	_
125-16	25167-25168	/	_
125-17	25168-25172	BA18	_
125-18	25172-25173	)	_
125-19	25174-25176	to	_
125-20	25177-25183	facial	_
125-21	25184-25194	conditions	_
125-22	25195-25197	of	_
125-23	25198-25203	mixed	_
125-24	25204-25209	happy	_
125-25	25210-25216	facial	_
125-26	25217-25224	stimuli	_
125-27	25224-25225	.	_

#Text=The RMOG/BA18 is part of the ventral stream of visual processing for which preferential processing of affective stimuli has previously been demonstrated.
126-1	25226-25229	The	_
126-2	25230-25234	RMOG	_
126-3	25234-25235	/	_
126-4	25235-25239	BA18	_
126-5	25240-25242	is	_
126-6	25243-25247	part	_
126-7	25248-25250	of	_
126-8	25251-25254	the	_
126-9	25255-25262	ventral	_
126-10	25263-25269	stream	_
126-11	25270-25272	of	_
126-12	25273-25279	visual	_
126-13	25280-25290	processing	_
126-14	25291-25294	for	_
126-15	25295-25300	which	_
126-16	25301-25313	preferential	_
126-17	25314-25324	processing	_
126-18	25325-25327	of	_
126-19	25328-25337	affective	_
126-20	25338-25345	stimuli	_
126-21	25346-25349	has	_
126-22	25350-25360	previously	_
126-23	25361-25365	been	_
126-24	25366-25378	demonstrated	_
126-25	25378-25379	.	_

#Text=Previous studies found increased activation in the RMOG/BA18 to fearful faces compared to happy stimuli during facial emotion processing, furthermore a recent study found that this region is under control by the anterior cingulate cortex during facial emotion processing.
127-1	25380-25388	Previous	_
127-2	25389-25396	studies	_
127-3	25397-25402	found	_
127-4	25403-25412	increased	_
127-5	25413-25423	activation	_
127-6	25424-25426	in	_
127-7	25427-25430	the	_
127-8	25431-25435	RMOG	_
127-9	25435-25436	/	_
127-10	25436-25440	BA18	_
127-11	25441-25443	to	_
127-12	25444-25451	fearful	_
127-13	25452-25457	faces	_
127-14	25458-25466	compared	_
127-15	25467-25469	to	_
127-16	25470-25475	happy	_
127-17	25476-25483	stimuli	_
127-18	25484-25490	during	_
127-19	25491-25497	facial	_
127-20	25498-25505	emotion	_
127-21	25506-25516	processing	_
127-22	25516-25517	,	_
127-23	25518-25529	furthermore	_
127-24	25530-25531	a	_
127-25	25532-25538	recent	_
127-26	25539-25544	study	_
127-27	25545-25550	found	_
127-28	25551-25555	that	_
127-29	25556-25560	this	_
127-30	25561-25567	region	_
127-31	25568-25570	is	_
127-32	25571-25576	under	_
127-33	25577-25584	control	_
127-34	25585-25587	by	_
127-35	25588-25591	the	_
127-36	25592-25600	anterior	_
127-37	25601-25610	cingulate	_
127-38	25611-25617	cortex	_
127-39	25618-25624	during	_
127-40	25625-25631	facial	_
127-41	25632-25639	emotion	_
127-42	25640-25650	processing	_
127-43	25650-25651	.	_

#Text=Our finding is in line with previous results showing an early visual processing impairment in emotional facial processing in schizophrenia.
128-1	25652-25655	Our	_
128-2	25656-25663	finding	_
128-3	25664-25666	is	_
128-4	25667-25669	in	_
128-5	25670-25674	line	_
128-6	25675-25679	with	_
128-7	25680-25688	previous	_
128-8	25689-25696	results	_
128-9	25697-25704	showing	_
128-10	25705-25707	an	_
128-11	25708-25713	early	_
128-12	25714-25720	visual	_
128-13	25721-25731	processing	_
128-14	25732-25742	impairment	_
128-15	25743-25745	in	_
128-16	25746-25755	emotional	_
128-17	25756-25762	facial	_
128-18	25763-25773	processing	_
128-19	25774-25776	in	_
128-20	25777-25790	schizophrenia	_
128-21	25790-25791	.	_

#Text=Furthermore patients with schizophrenia showed decreased activations in the right middle frontal cortex (RMFG/BA10) and in the dorsomedial prefrontal cortex (DMPFC) to fearful facial stimuli.
129-1	25792-25803	Furthermore	_
129-2	25804-25812	patients	_
129-3	25813-25817	with	_
129-4	25818-25831	schizophrenia	_
129-5	25832-25838	showed	_
129-6	25839-25848	decreased	_
129-7	25849-25860	activations	_
129-8	25861-25863	in	_
129-9	25864-25867	the	_
129-10	25868-25873	right	_
129-11	25874-25880	middle	_
129-12	25881-25888	frontal	_
129-13	25889-25895	cortex	_
129-14	25896-25897	(	_
129-15	25897-25901	RMFG	_
129-16	25901-25902	/	_
129-17	25902-25906	BA10	_
129-18	25906-25907	)	_
129-19	25908-25911	and	_
129-20	25912-25914	in	_
129-21	25915-25918	the	_
129-22	25919-25930	dorsomedial	_
129-23	25931-25941	prefrontal	_
129-24	25942-25948	cortex	_
129-25	25949-25950	(	_
129-26	25950-25955	DMPFC	_
129-27	25955-25956	)	_
129-28	25957-25959	to	_
129-29	25960-25967	fearful	_
129-30	25968-25974	facial	_
129-31	25975-25982	stimuli	_
129-32	25982-25983	.	_

#Text=According to previous investigations decreased DMPFC activity in response to emotion facial cues may reflect less cognitive control involved in decoding and/or regulating negative emotions, which was also observed in chronically violent men, and in postpartum depression.
130-1	25984-25993	According	_
130-2	25994-25996	to	_
130-3	25997-26005	previous	_
130-4	26006-26020	investigations	_
130-5	26021-26030	decreased	_
130-6	26031-26036	DMPFC	_
130-7	26037-26045	activity	_
130-8	26046-26048	in	_
130-9	26049-26057	response	_
130-10	26058-26060	to	_
130-11	26061-26068	emotion	_
130-12	26069-26075	facial	_
130-13	26076-26080	cues	_
130-14	26081-26084	may	_
130-15	26085-26092	reflect	_
130-16	26093-26097	less	_
130-17	26098-26107	cognitive	_
130-18	26108-26115	control	_
130-19	26116-26124	involved	_
130-20	26125-26127	in	_
130-21	26128-26136	decoding	_
130-22	26137-26140	and	_
130-23	26140-26141	/	_
130-24	26141-26143	or	_
130-25	26144-26154	regulating	_
130-26	26155-26163	negative	_
130-27	26164-26172	emotions	_
130-28	26172-26173	,	_
130-29	26174-26179	which	_
130-30	26180-26183	was	_
130-31	26184-26188	also	_
130-32	26189-26197	observed	_
130-33	26198-26200	in	_
130-34	26201-26212	chronically	_
130-35	26213-26220	violent	_
130-36	26221-26224	men	_
130-37	26224-26225	,	_
130-38	26226-26229	and	_
130-39	26230-26232	in	_
130-40	26233-26243	postpartum	_
130-41	26244-26254	depression	_
130-42	26254-26255	.	_

#Text=A study examining the theory of mind impairments in subjects with autistic spectrum disorder found decreased activity in the DMPFC during inferring other person’s social emotions in a false belief task.
131-1	26256-26257	A	_
131-2	26258-26263	study	_
131-3	26264-26273	examining	_
131-4	26274-26277	the	_
131-5	26278-26284	theory	_
131-6	26285-26287	of	_
131-7	26288-26292	mind	_
131-8	26293-26304	impairments	_
131-9	26305-26307	in	_
131-10	26308-26316	subjects	_
131-11	26317-26321	with	_
131-12	26322-26330	autistic	_
131-13	26331-26339	spectrum	_
131-14	26340-26348	disorder	_
131-15	26349-26354	found	_
131-16	26355-26364	decreased	_
131-17	26365-26373	activity	_
131-18	26374-26376	in	_
131-19	26377-26380	the	_
131-20	26381-26386	DMPFC	_
131-21	26387-26393	during	_
131-22	26394-26403	inferring	_
131-23	26404-26409	other	_
131-24	26410-26416	person	_
131-25	26416-26417	’	_
131-26	26417-26418	s	_
131-27	26419-26425	social	_
131-28	26426-26434	emotions	_
131-29	26435-26437	in	_
131-30	26438-26439	a	_
131-31	26440-26445	false	_
131-32	26446-26452	belief	_
131-33	26453-26457	task	_
131-34	26457-26458	.	_

#Text=Patients on higher doses of APs showed decreased activation in the right amygdala to all emotional faces with the strongest correlation for mixed happy condition.
132-1	26459-26467	Patients	_
132-2	26468-26470	on	_
132-3	26471-26477	higher	_
132-4	26478-26483	doses	_
132-5	26484-26486	of	_
132-6	26487-26490	APs	_
132-7	26491-26497	showed	_
132-8	26498-26507	decreased	_
132-9	26508-26518	activation	_
132-10	26519-26521	in	_
132-11	26522-26525	the	_
132-12	26526-26531	right	_
132-13	26532-26540	amygdala	_
132-14	26541-26543	to	_
132-15	26544-26547	all	_
132-16	26548-26557	emotional	_
132-17	26558-26563	faces	_
132-18	26564-26568	with	_
132-19	26569-26572	the	_
132-20	26573-26582	strongest	_
132-21	26583-26594	correlation	_
132-22	26595-26598	for	_
132-23	26599-26604	mixed	_
132-24	26605-26610	happy	_
132-25	26611-26620	condition	_
132-26	26620-26621	.	_

#Text=Little is known so far on the effects of AP treatment on emotion processing in schizophrenia.
133-1	26622-26628	Little	_
133-2	26629-26631	is	_
133-3	26632-26637	known	_
133-4	26638-26640	so	_
133-5	26641-26644	far	_
133-6	26645-26647	on	_
133-7	26648-26651	the	_
133-8	26652-26659	effects	_
133-9	26660-26662	of	_
133-10	26663-26665	AP	_
133-11	26666-26675	treatment	_
133-12	26676-26678	on	_
133-13	26679-26686	emotion	_
133-14	26687-26697	processing	_
133-15	26698-26700	in	_
133-16	26701-26714	schizophrenia	_
133-17	26714-26715	.	_

#Text=In a previous study Sachs et al. reported no difference in amygdala activation between patients treated with atypical APs and healthy subjects.
134-1	26716-26718	In	_
134-2	26719-26720	a	_
134-3	26721-26729	previous	_
134-4	26730-26735	study	_
134-5	26736-26741	Sachs	_
134-6	26742-26744	et	_
134-7	26745-26747	al	_
134-8	26747-26748	.	_
134-9	26749-26757	reported	_
134-10	26758-26760	no	_
134-11	26761-26771	difference	_
134-12	26772-26774	in	_
134-13	26775-26783	amygdala	_
134-14	26784-26794	activation	_
134-15	26795-26802	between	_
134-16	26803-26811	patients	_
134-17	26812-26819	treated	_
134-18	26820-26824	with	_
134-19	26825-26833	atypical	_
134-20	26834-26837	APs	_
134-21	26838-26841	and	_
134-22	26842-26849	healthy	_
134-23	26850-26858	subjects	_
134-24	26858-26859	.	_

#Text=In another study 12 previously drug-free/naive patients with schizophrenia were treated with olanzapine for 8 weeks and underwent two fMRI scans after 4 and 8 weeks of treatment during implicit and explicit emotional processing.
135-1	26860-26862	In	_
135-2	26863-26870	another	_
135-3	26871-26876	study	_
135-4	26877-26879	12	_
135-5	26880-26890	previously	_
135-6	26891-26900	drug-free	_
135-7	26900-26901	/	_
135-8	26901-26906	naive	_
135-9	26907-26915	patients	_
135-10	26916-26920	with	_
135-11	26921-26934	schizophrenia	_
135-12	26935-26939	were	_
135-13	26940-26947	treated	_
135-14	26948-26952	with	_
135-15	26953-26963	olanzapine	_
135-16	26964-26967	for	_
135-17	26968-26969	8	_
135-18	26969-26970	 	_
135-19	26970-26975	weeks	_
135-20	26976-26979	and	_
135-21	26980-26989	underwent	_
135-22	26990-26993	two	_
135-23	26994-26998	fMRI	_
135-24	26999-27004	scans	_
135-25	27005-27010	after	_
135-26	27011-27012	4	_
135-27	27013-27016	and	_
135-28	27017-27018	8	_
135-29	27018-27019	 	_
135-30	27019-27024	weeks	_
135-31	27025-27027	of	_
135-32	27028-27037	treatment	_
135-33	27038-27044	during	_
135-34	27045-27053	implicit	_
135-35	27054-27057	and	_
135-36	27058-27066	explicit	_
135-37	27067-27076	emotional	_
135-38	27077-27087	processing	_
135-39	27087-27088	.	_

#Text=Activity in left amygdala was greater in patients than in controls at the first scan during both explicit and implicit processing, while it was lower in patients at the second relative to the first scan.
136-1	27089-27097	Activity	_
136-2	27098-27100	in	_
136-3	27101-27105	left	_
136-4	27106-27114	amygdala	_
136-5	27115-27118	was	_
136-6	27119-27126	greater	_
136-7	27127-27129	in	_
136-8	27130-27138	patients	_
136-9	27139-27143	than	_
136-10	27144-27146	in	_
136-11	27147-27155	controls	_
136-12	27156-27158	at	_
136-13	27159-27162	the	_
136-14	27163-27168	first	_
136-15	27169-27173	scan	_
136-16	27174-27180	during	_
136-17	27181-27185	both	_
136-18	27186-27194	explicit	_
136-19	27195-27198	and	_
136-20	27199-27207	implicit	_
136-21	27208-27218	processing	_
136-22	27218-27219	,	_
136-23	27220-27225	while	_
136-24	27226-27228	it	_
136-25	27229-27232	was	_
136-26	27233-27238	lower	_
136-27	27239-27241	in	_
136-28	27242-27250	patients	_
136-29	27251-27253	at	_
136-30	27254-27257	the	_
136-31	27258-27264	second	_
136-32	27265-27273	relative	_
136-33	27274-27276	to	_
136-34	27277-27280	the	_
136-35	27281-27286	first	_
136-36	27287-27291	scan	_
136-37	27291-27292	.	_

#Text=However none of the previous studies reported any dose related effect of APs on the activity of brain regions involved in emotion processing.
137-1	27293-27300	However	_
137-2	27301-27305	none	_
137-3	27306-27308	of	_
137-4	27309-27312	the	_
137-5	27313-27321	previous	_
137-6	27322-27329	studies	_
137-7	27330-27338	reported	_
137-8	27339-27342	any	_
137-9	27343-27347	dose	_
137-10	27348-27355	related	_
137-11	27356-27362	effect	_
137-12	27363-27365	of	_
137-13	27366-27369	APs	_
137-14	27370-27372	on	_
137-15	27373-27376	the	_
137-16	27377-27385	activity	_
137-17	27386-27388	of	_
137-18	27389-27394	brain	_
137-19	27395-27402	regions	_
137-20	27403-27411	involved	_
137-21	27412-27414	in	_
137-22	27415-27422	emotion	_
137-23	27423-27433	processing	_
137-24	27433-27434	.	_

#Text=Contrary to previous investigations no between group differences were found in the amygdala activation to fearful faces.
138-1	27435-27443	Contrary	_
138-2	27444-27446	to	_
138-3	27447-27455	previous	_
138-4	27456-27470	investigations	_
138-5	27471-27473	no	_
138-6	27474-27481	between	_
138-7	27482-27487	group	_
138-8	27488-27499	differences	_
138-9	27500-27504	were	_
138-10	27505-27510	found	_
138-11	27511-27513	in	_
138-12	27514-27517	the	_
138-13	27518-27526	amygdala	_
138-14	27527-27537	activation	_
138-15	27538-27540	to	_
138-16	27541-27548	fearful	_
138-17	27549-27554	faces	_
138-18	27554-27555	.	_

#Text=A possible explanation to that is that fearful faces in the present study were not as strong fear evoking stimuli as the scenarios depicted in the International Affective Picture Set (IAPS).
139-1	27556-27557	A	_
139-2	27558-27566	possible	_
139-3	27567-27578	explanation	_
139-4	27579-27581	to	_
139-5	27582-27586	that	_
139-6	27587-27589	is	_
139-7	27590-27594	that	_
139-8	27595-27602	fearful	_
139-9	27603-27608	faces	_
139-10	27609-27611	in	_
139-11	27612-27615	the	_
139-12	27616-27623	present	_
139-13	27624-27629	study	_
139-14	27630-27634	were	_
139-15	27635-27638	not	_
139-16	27639-27641	as	_
139-17	27642-27648	strong	_
139-18	27649-27653	fear	_
139-19	27654-27661	evoking	_
139-20	27662-27669	stimuli	_
139-21	27670-27672	as	_
139-22	27673-27676	the	_
139-23	27677-27686	scenarios	_
139-24	27687-27695	depicted	_
139-25	27696-27698	in	_
139-26	27699-27702	the	_
139-27	27703-27716	International	_
139-28	27717-27726	Affective	_
139-29	27727-27734	Picture	_
139-30	27735-27738	Set	_
139-31	27739-27740	(	_
139-32	27740-27744	IAPS	_
139-33	27744-27745	)	_
139-34	27745-27746	.	_

#Text=Previous studies found that the superior temporal gyrus and the insular cortex have been involved in the perception of emotions in facial stimuli, while the BA10 region is mainly activated during multi-tasking and theory of mind tasks.
140-1	27747-27755	Previous	_
140-2	27756-27763	studies	_
140-3	27764-27769	found	_
140-4	27770-27774	that	_
140-5	27775-27778	the	_
140-6	27779-27787	superior	_
140-7	27788-27796	temporal	_
140-8	27797-27802	gyrus	_
140-9	27803-27806	and	_
140-10	27807-27810	the	_
140-11	27811-27818	insular	_
140-12	27819-27825	cortex	_
140-13	27826-27830	have	_
140-14	27831-27835	been	_
140-15	27836-27844	involved	_
140-16	27845-27847	in	_
140-17	27848-27851	the	_
140-18	27852-27862	perception	_
140-19	27863-27865	of	_
140-20	27866-27874	emotions	_
140-21	27875-27877	in	_
140-22	27878-27884	facial	_
140-23	27885-27892	stimuli	_
140-24	27892-27893	,	_
140-25	27894-27899	while	_
140-26	27900-27903	the	_
140-27	27904-27908	BA10	_
140-28	27909-27915	region	_
140-29	27916-27918	is	_
140-30	27919-27925	mainly	_
140-31	27926-27935	activated	_
140-32	27936-27942	during	_
140-33	27943-27956	multi-tasking	_
140-34	27957-27960	and	_
140-35	27961-27967	theory	_
140-36	27968-27970	of	_
140-37	27971-27975	mind	_
140-38	27976-27981	tasks	_
140-39	27981-27982	.	_

#Text=In the present study an increased activation to fearful faces relative to happy faces were detected in the right superior temporal gyrus and in the right middle frontal gyrus (BA10) in healthy subjects, while the opposite difference (happy > fear) was found in patients.
141-1	27983-27985	In	_
141-2	27986-27989	the	_
141-3	27990-27997	present	_
141-4	27998-28003	study	_
141-5	28004-28006	an	_
141-6	28007-28016	increased	_
141-7	28017-28027	activation	_
141-8	28028-28030	to	_
141-9	28031-28038	fearful	_
141-10	28039-28044	faces	_
141-11	28045-28053	relative	_
141-12	28054-28056	to	_
141-13	28057-28062	happy	_
141-14	28063-28068	faces	_
141-15	28069-28073	were	_
141-16	28074-28082	detected	_
141-17	28083-28085	in	_
141-18	28086-28089	the	_
141-19	28090-28095	right	_
141-20	28096-28104	superior	_
141-21	28105-28113	temporal	_
141-22	28114-28119	gyrus	_
141-23	28120-28123	and	_
141-24	28124-28126	in	_
141-25	28127-28130	the	_
141-26	28131-28136	right	_
141-27	28137-28143	middle	_
141-28	28144-28151	frontal	_
141-29	28152-28157	gyrus	_
141-30	28158-28159	(	_
141-31	28159-28163	BA10	_
141-32	28163-28164	)	_
141-33	28165-28167	in	_
141-34	28168-28175	healthy	_
141-35	28176-28184	subjects	_
141-36	28184-28185	,	_
141-37	28186-28191	while	_
141-38	28192-28195	the	_
141-39	28196-28204	opposite	_
141-40	28205-28215	difference	_
141-41	28216-28217	(	_
141-42	28217-28222	happy	_
141-43	28223-28224	>	_
141-44	28225-28229	fear	_
141-45	28229-28230	)	_
141-46	28231-28234	was	_
141-47	28235-28240	found	_
141-48	28241-28243	in	_
141-49	28244-28252	patients	_
141-50	28252-28253	.	_

#Text=In a previous investigation, similarly to our results, an increased activation to fearful stimuli relative to safe stimuli was detected in the insular cortex in healthy subjects.
142-1	28254-28256	In	_
142-2	28257-28258	a	_
142-3	28259-28267	previous	_
142-4	28268-28281	investigation	_
142-5	28281-28282	,	_
142-6	28283-28292	similarly	_
142-7	28293-28295	to	_
142-8	28296-28299	our	_
142-9	28300-28307	results	_
142-10	28307-28308	,	_
142-11	28309-28311	an	_
142-12	28312-28321	increased	_
142-13	28322-28332	activation	_
142-14	28333-28335	to	_
142-15	28336-28343	fearful	_
142-16	28344-28351	stimuli	_
142-17	28352-28360	relative	_
142-18	28361-28363	to	_
142-19	28364-28368	safe	_
142-20	28369-28376	stimuli	_
142-21	28377-28380	was	_
142-22	28381-28389	detected	_
142-23	28390-28392	in	_
142-24	28393-28396	the	_
142-25	28397-28404	insular	_
142-26	28405-28411	cortex	_
142-27	28412-28414	in	_
142-28	28415-28422	healthy	_
142-29	28423-28431	subjects	_
142-30	28431-28432	.	_

#Text=The activation of the DLPFC is related to the regulation of cognitive processes linked to emotion processing such as attention.
143-1	28433-28436	The	_
143-2	28437-28447	activation	_
143-3	28448-28450	of	_
143-4	28451-28454	the	_
143-5	28455-28460	DLPFC	_
143-6	28461-28463	is	_
143-7	28464-28471	related	_
143-8	28472-28474	to	_
143-9	28475-28478	the	_
143-10	28479-28489	regulation	_
143-11	28490-28492	of	_
143-12	28493-28502	cognitive	_
143-13	28503-28512	processes	_
143-14	28513-28519	linked	_
143-15	28520-28522	to	_
143-16	28523-28530	emotion	_
143-17	28531-28541	processing	_
143-18	28542-28546	such	_
143-19	28547-28549	as	_
143-20	28550-28559	attention	_
143-21	28559-28560	.	_

#Text=A decreased activation difference between mixed happy faces and happy faces in patients relative to controls were found in the cerebellum (vermis) and in the right DLPFC.
144-1	28561-28562	A	_
144-2	28563-28572	decreased	_
144-3	28573-28583	activation	_
144-4	28584-28594	difference	_
144-5	28595-28602	between	_
144-6	28603-28608	mixed	_
144-7	28609-28614	happy	_
144-8	28615-28620	faces	_
144-9	28621-28624	and	_
144-10	28625-28630	happy	_
144-11	28631-28636	faces	_
144-12	28637-28639	in	_
144-13	28640-28648	patients	_
144-14	28649-28657	relative	_
144-15	28658-28660	to	_
144-16	28661-28669	controls	_
144-17	28670-28674	were	_
144-18	28675-28680	found	_
144-19	28681-28683	in	_
144-20	28684-28687	the	_
144-21	28688-28698	cerebellum	_
144-22	28699-28700	(	_
144-23	28700-28706	vermis	_
144-24	28706-28707	)	_
144-25	28708-28711	and	_
144-26	28712-28714	in	_
144-27	28715-28718	the	_
144-28	28719-28724	right	_
144-29	28725-28730	DLPFC	_
144-30	28730-28731	.	_

#Text=Controls showed an increased activation to mixed happy faces relative to happy faces in these regions, while similar between emotion differences were not found in patients.
145-1	28732-28740	Controls	_
145-2	28741-28747	showed	_
145-3	28748-28750	an	_
145-4	28751-28760	increased	_
145-5	28761-28771	activation	_
145-6	28772-28774	to	_
145-7	28775-28780	mixed	_
145-8	28781-28786	happy	_
145-9	28787-28792	faces	_
145-10	28793-28801	relative	_
145-11	28802-28804	to	_
145-12	28805-28810	happy	_
145-13	28811-28816	faces	_
145-14	28817-28819	in	_
145-15	28820-28825	these	_
145-16	28826-28833	regions	_
145-17	28833-28834	,	_
145-18	28835-28840	while	_
145-19	28841-28848	similar	_
145-20	28849-28856	between	_
145-21	28857-28864	emotion	_
145-22	28865-28876	differences	_
145-23	28877-28881	were	_
145-24	28882-28885	not	_
145-25	28886-28891	found	_
145-26	28892-28894	in	_
145-27	28895-28903	patients	_
145-28	28903-28904	.	_

#Text=These findings are in line with previous investigations showing that during emotion processing and social cognition tasks patients with schizophrenia showed decreased activations in the DLPFC and in the cerebellum during face processing.
146-1	28905-28910	These	_
146-2	28911-28919	findings	_
146-3	28920-28923	are	_
146-4	28924-28926	in	_
146-5	28927-28931	line	_
146-6	28932-28936	with	_
146-7	28937-28945	previous	_
146-8	28946-28960	investigations	_
146-9	28961-28968	showing	_
146-10	28969-28973	that	_
146-11	28974-28980	during	_
146-12	28981-28988	emotion	_
146-13	28989-28999	processing	_
146-14	29000-29003	and	_
146-15	29004-29010	social	_
146-16	29011-29020	cognition	_
146-17	29021-29026	tasks	_
146-18	29027-29035	patients	_
146-19	29036-29040	with	_
146-20	29041-29054	schizophrenia	_
146-21	29055-29061	showed	_
146-22	29062-29071	decreased	_
146-23	29072-29083	activations	_
146-24	29084-29086	in	_
146-25	29087-29090	the	_
146-26	29091-29096	DLPFC	_
146-27	29097-29100	and	_
146-28	29101-29103	in	_
146-29	29104-29107	the	_
146-30	29108-29118	cerebellum	_
146-31	29119-29125	during	_
146-32	29126-29130	face	_
146-33	29131-29141	processing	_
146-34	29141-29142	.	_

#Text=Structural impairments in patients may explain the functional differences, since some previous investigations found structural differences in patients with schizophrenia relative to healthy controls in temporal and frontal regions.
147-1	29143-29153	Structural	_
147-2	29154-29165	impairments	_
147-3	29166-29168	in	_
147-4	29169-29177	patients	_
147-5	29178-29181	may	_
147-6	29182-29189	explain	_
147-7	29190-29193	the	_
147-8	29194-29204	functional	_
147-9	29205-29216	differences	_
147-10	29216-29217	,	_
147-11	29218-29223	since	_
147-12	29224-29228	some	_
147-13	29229-29237	previous	_
147-14	29238-29252	investigations	_
147-15	29253-29258	found	_
147-16	29259-29269	structural	_
147-17	29270-29281	differences	_
147-18	29282-29284	in	_
147-19	29285-29293	patients	_
147-20	29294-29298	with	_
147-21	29299-29312	schizophrenia	_
147-22	29313-29321	relative	_
147-23	29322-29324	to	_
147-24	29325-29332	healthy	_
147-25	29333-29341	controls	_
147-26	29342-29344	in	_
147-27	29345-29353	temporal	_
147-28	29354-29357	and	_
147-29	29358-29365	frontal	_
147-30	29366-29373	regions	_
147-31	29373-29374	.	_

#Text=However no similar volumetric differences were found in the present study.
148-1	29375-29382	However	_
148-2	29383-29385	no	_
148-3	29386-29393	similar	_
148-4	29394-29404	volumetric	_
148-5	29405-29416	differences	_
148-6	29417-29421	were	_
148-7	29422-29427	found	_
148-8	29428-29430	in	_
148-9	29431-29434	the	_
148-10	29435-29442	present	_
148-11	29443-29448	study	_
148-12	29448-29449	.	_

#Text=A major limitation of the present study was that no neutral facial expressions were used.
149-1	29450-29451	A	_
149-2	29452-29457	major	_
149-3	29458-29468	limitation	_
149-4	29469-29471	of	_
149-5	29472-29475	the	_
149-6	29476-29483	present	_
149-7	29484-29489	study	_
149-8	29490-29493	was	_
149-9	29494-29498	that	_
149-10	29499-29501	no	_
149-11	29502-29509	neutral	_
149-12	29510-29516	facial	_
149-13	29517-29528	expressions	_
149-14	29529-29533	were	_
149-15	29534-29538	used	_
149-16	29538-29539	.	_

#Text=The reason was that we intended keep the paradigm as short as possible to avoid attention related confounds.
150-1	29540-29543	The	_
150-2	29544-29550	reason	_
150-3	29551-29554	was	_
150-4	29555-29559	that	_
150-5	29560-29562	we	_
150-6	29563-29571	intended	_
150-7	29572-29576	keep	_
150-8	29577-29580	the	_
150-9	29581-29589	paradigm	_
150-10	29590-29592	as	_
150-11	29593-29598	short	_
150-12	29599-29601	as	_
150-13	29602-29610	possible	_
150-14	29611-29613	to	_
150-15	29614-29619	avoid	_
150-16	29620-29629	attention	_
150-17	29630-29637	related	_
150-18	29638-29647	confounds	_
150-19	29647-29648	.	_

#Text=A further limitation was that patients were at antipsychotic medication, which may bias the activations, however there were no correlations between antipsychotic doses and BOLD activations in the regions where the between group differences were found.
151-1	29649-29650	A	_
151-2	29651-29658	further	_
151-3	29659-29669	limitation	_
151-4	29670-29673	was	_
151-5	29674-29678	that	_
151-6	29679-29687	patients	_
151-7	29688-29692	were	_
151-8	29693-29695	at	_
151-9	29696-29709	antipsychotic	_
151-10	29710-29720	medication	_
151-11	29720-29721	,	_
151-12	29722-29727	which	_
151-13	29728-29731	may	_
151-14	29732-29736	bias	_
151-15	29737-29740	the	_
151-16	29741-29752	activations	_
151-17	29752-29753	,	_
151-18	29754-29761	however	_
151-19	29762-29767	there	_
151-20	29768-29772	were	_
151-21	29773-29775	no	_
151-22	29776-29788	correlations	_
151-23	29789-29796	between	_
151-24	29797-29810	antipsychotic	_
151-25	29811-29816	doses	_
151-26	29817-29820	and	_
151-27	29821-29825	BOLD	_
151-28	29826-29837	activations	_
151-29	29838-29840	in	_
151-30	29841-29844	the	_
151-31	29845-29852	regions	_
151-32	29853-29858	where	_
151-33	29859-29862	the	_
151-34	29863-29870	between	_
151-35	29871-29876	group	_
151-36	29877-29888	differences	_
151-37	29889-29893	were	_
151-38	29894-29899	found	_
151-39	29899-29900	.	_

#Text=Study groups were matched by age, gender, and education, however this approach has the drawback that it does not take into consideration that patients with schizophrenia experience a significant reduction in educational attainment relative to what we be predicted had they not received such a diagnosis.
152-1	29901-29906	Study	_
152-2	29907-29913	groups	_
152-3	29914-29918	were	_
152-4	29919-29926	matched	_
152-5	29927-29929	by	_
152-6	29930-29933	age	_
152-7	29933-29934	,	_
152-8	29935-29941	gender	_
152-9	29941-29942	,	_
152-10	29943-29946	and	_
152-11	29947-29956	education	_
152-12	29956-29957	,	_
152-13	29958-29965	however	_
152-14	29966-29970	this	_
152-15	29971-29979	approach	_
152-16	29980-29983	has	_
152-17	29984-29987	the	_
152-18	29988-29996	drawback	_
152-19	29997-30001	that	_
152-20	30002-30004	it	_
152-21	30005-30009	does	_
152-22	30010-30013	not	_
152-23	30014-30018	take	_
152-24	30019-30023	into	_
152-25	30024-30037	consideration	_
152-26	30038-30042	that	_
152-27	30043-30051	patients	_
152-28	30052-30056	with	_
152-29	30057-30070	schizophrenia	_
152-30	30071-30081	experience	_
152-31	30082-30083	a	_
152-32	30084-30095	significant	_
152-33	30096-30105	reduction	_
152-34	30106-30108	in	_
152-35	30109-30120	educational	_
152-36	30121-30131	attainment	_
152-37	30132-30140	relative	_
152-38	30141-30143	to	_
152-39	30144-30148	what	_
152-40	30149-30151	we	_
152-41	30152-30154	be	_
152-42	30155-30164	predicted	_
152-43	30165-30168	had	_
152-44	30169-30173	they	_
152-45	30174-30177	not	_
152-46	30178-30186	received	_
152-47	30187-30191	such	_
152-48	30192-30193	a	_
152-49	30194-30203	diagnosis	_
152-50	30203-30204	.	_

#Text=Due to a technical malfunction of the input device several responses were lost, which made it impossible to include responses into the 1st level model.
153-1	30205-30208	Due	_
153-2	30209-30211	to	_
153-3	30212-30213	a	_
153-4	30214-30223	technical	_
153-5	30224-30235	malfunction	_
153-6	30236-30238	of	_
153-7	30239-30242	the	_
153-8	30243-30248	input	_
153-9	30249-30255	device	_
153-10	30256-30263	several	_
153-11	30264-30273	responses	_
153-12	30274-30278	were	_
153-13	30279-30283	lost	_
153-14	30283-30284	,	_
153-15	30285-30290	which	_
153-16	30291-30295	made	_
153-17	30296-30298	it	_
153-18	30299-30309	impossible	_
153-19	30310-30312	to	_
153-20	30313-30320	include	_
153-21	30321-30330	responses	_
153-22	30331-30335	into	_
153-23	30336-30339	the	_
153-24	30340-30343	1st	_
153-25	30344-30349	level	_
153-26	30350-30355	model	_
153-27	30355-30356	.	_

#Text=This may lead to confounds related to the motor activation needed to produce a button press, however no between study group differences were detected in motor areas or supplementary motor regions, which makes it unlikely that this was a major confound.
154-1	30357-30361	This	_
154-2	30362-30365	may	_
154-3	30366-30370	lead	_
154-4	30371-30373	to	_
154-5	30374-30383	confounds	_
154-6	30384-30391	related	_
154-7	30392-30394	to	_
154-8	30395-30398	the	_
154-9	30399-30404	motor	_
154-10	30405-30415	activation	_
154-11	30416-30422	needed	_
154-12	30423-30425	to	_
154-13	30426-30433	produce	_
154-14	30434-30435	a	_
154-15	30436-30442	button	_
154-16	30443-30448	press	_
154-17	30448-30449	,	_
154-18	30450-30457	however	_
154-19	30458-30460	no	_
154-20	30461-30468	between	_
154-21	30469-30474	study	_
154-22	30475-30480	group	_
154-23	30481-30492	differences	_
154-24	30493-30497	were	_
154-25	30498-30506	detected	_
154-26	30507-30509	in	_
154-27	30510-30515	motor	_
154-28	30516-30521	areas	_
154-29	30522-30524	or	_
154-30	30525-30538	supplementary	_
154-31	30539-30544	motor	_
154-32	30545-30552	regions	_
154-33	30552-30553	,	_
154-34	30554-30559	which	_
154-35	30560-30565	makes	_
154-36	30566-30568	it	_
154-37	30569-30577	unlikely	_
154-38	30578-30582	that	_
154-39	30583-30587	this	_
154-40	30588-30591	was	_
154-41	30592-30593	a	_
154-42	30594-30599	major	_
154-43	30600-30608	confound	_
154-44	30608-30609	.	_

#Text=Conclusions
#Text=Patients with schizophrenia showed decreased activation in the right anterior insula (RAI) and in the right VLPFC during facial emotion processing.
155-1	30610-30621	Conclusions	_
155-2	30622-30630	Patients	_
155-3	30631-30635	with	_
155-4	30636-30649	schizophrenia	_
155-5	30650-30656	showed	_
155-6	30657-30666	decreased	_
155-7	30667-30677	activation	_
155-8	30678-30680	in	_
155-9	30681-30684	the	_
155-10	30685-30690	right	_
155-11	30691-30699	anterior	_
155-12	30700-30706	insula	_
155-13	30707-30708	(	_
155-14	30708-30711	RAI	_
155-15	30711-30712	)	_
155-16	30713-30716	and	_
155-17	30717-30719	in	_
155-18	30720-30723	the	_
155-19	30724-30729	right	_
155-20	30730-30735	VLPFC	_
155-21	30736-30742	during	_
155-22	30743-30749	facial	_
155-23	30750-30757	emotion	_
155-24	30758-30768	processing	_
155-25	30768-30769	.	_

#Text=Whereas the former region is activated in emotional tasks with cognitive demand, the latter is responsible for salience signaling.
156-1	30770-30777	Whereas	_
156-2	30778-30781	the	_
156-3	30782-30788	former	_
156-4	30789-30795	region	_
156-5	30796-30798	is	_
156-6	30799-30808	activated	_
156-7	30809-30811	in	_
156-8	30812-30821	emotional	_
156-9	30822-30827	tasks	_
156-10	30828-30832	with	_
156-11	30833-30842	cognitive	_
156-12	30843-30849	demand	_
156-13	30849-30850	,	_
156-14	30851-30854	the	_
156-15	30855-30861	latter	_
156-16	30862-30864	is	_
156-17	30865-30876	responsible	_
156-18	30877-30880	for	_
156-19	30881-30889	salience	_
156-20	30890-30899	signaling	_
156-21	30899-30900	.	_

#Text=These impaired process were detected in response to facial expressions containing more or less fear with or without happiness, while no similar impairment was detected in the processing of happy facial expressions without fear.
157-1	30901-30906	These	_
157-2	30907-30915	impaired	_
157-3	30916-30923	process	_
157-4	30924-30928	were	_
157-5	30929-30937	detected	_
157-6	30938-30940	in	_
157-7	30941-30949	response	_
157-8	30950-30952	to	_
157-9	30953-30959	facial	_
157-10	30960-30971	expressions	_
157-11	30972-30982	containing	_
157-12	30983-30987	more	_
157-13	30988-30990	or	_
157-14	30991-30995	less	_
157-15	30996-31000	fear	_
157-16	31001-31005	with	_
157-17	31006-31008	or	_
157-18	31009-31016	without	_
157-19	31017-31026	happiness	_
157-20	31026-31027	,	_
157-21	31028-31033	while	_
157-22	31034-31036	no	_
157-23	31037-31044	similar	_
157-24	31045-31055	impairment	_
157-25	31056-31059	was	_
157-26	31060-31068	detected	_
157-27	31069-31071	in	_
157-28	31072-31075	the	_
157-29	31076-31086	processing	_
157-30	31087-31089	of	_
157-31	31090-31095	happy	_
157-32	31096-31102	facial	_
157-33	31103-31114	expressions	_
157-34	31115-31122	without	_
157-35	31123-31127	fear	_
157-36	31127-31128	.	_

#Text=Therefore we can conclude that fear and mixed happy/fear processing are impaired in schizophrenia, while happy facial expression processing is relatively intact.
158-1	31129-31138	Therefore	_
158-2	31139-31141	we	_
158-3	31142-31145	can	_
158-4	31146-31154	conclude	_
158-5	31155-31159	that	_
158-6	31160-31164	fear	_
158-7	31165-31168	and	_
158-8	31169-31174	mixed	_
158-9	31175-31180	happy	_
158-10	31180-31181	/	_
158-11	31181-31185	fear	_
158-12	31186-31196	processing	_
158-13	31197-31200	are	_
158-14	31201-31209	impaired	_
158-15	31210-31212	in	_
158-16	31213-31226	schizophrenia	_
158-17	31226-31227	,	_
158-18	31228-31233	while	_
158-19	31234-31239	happy	_
158-20	31240-31246	facial	_
158-21	31247-31257	expression	_
158-22	31258-31268	processing	_
158-23	31269-31271	is	_
158-24	31272-31282	relatively	_
158-25	31283-31289	intact	_
158-26	31289-31290	.	_

#Text=Furthermore patients with schizophrenia did not show a differential activation between mixed happy and happy facial expressions similar to controls in the right DLPFC, a region related to the regulation of cognitive processes linked to emotions such as attention, and valence evaluation.
159-1	31291-31302	Furthermore	_
159-2	31303-31311	patients	_
159-3	31312-31316	with	_
159-4	31317-31330	schizophrenia	_
159-5	31331-31334	did	_
159-6	31335-31338	not	_
159-7	31339-31343	show	_
159-8	31344-31345	a	_
159-9	31346-31358	differential	_
159-10	31359-31369	activation	_
159-11	31370-31377	between	_
159-12	31378-31383	mixed	_
159-13	31384-31389	happy	_
159-14	31390-31393	and	_
159-15	31394-31399	happy	_
159-16	31400-31406	facial	_
159-17	31407-31418	expressions	_
159-18	31419-31426	similar	_
159-19	31427-31429	to	_
159-20	31430-31438	controls	_
159-21	31439-31441	in	_
159-22	31442-31445	the	_
159-23	31446-31451	right	_
159-24	31452-31457	DLPFC	_
159-25	31457-31458	,	_
159-26	31459-31460	a	_
159-27	31461-31467	region	_
159-28	31468-31475	related	_
159-29	31476-31478	to	_
159-30	31479-31482	the	_
159-31	31483-31493	regulation	_
159-32	31494-31496	of	_
159-33	31497-31506	cognitive	_
159-34	31507-31516	processes	_
159-35	31517-31523	linked	_
159-36	31524-31526	to	_
159-37	31527-31535	emotions	_
159-38	31536-31540	such	_
159-39	31541-31543	as	_
159-40	31544-31553	attention	_
159-41	31553-31554	,	_
159-42	31555-31558	and	_
159-43	31559-31566	valence	_
159-44	31567-31577	evaluation	_
159-45	31577-31578	.	_

#Text=In sum patients with schizophrenia showed decreased functioning in right prefrontal regions responsible for salience signaling and valence evaluation during emotion recognition.
160-1	31579-31581	In	_
160-2	31582-31585	sum	_
160-3	31586-31594	patients	_
160-4	31595-31599	with	_
160-5	31600-31613	schizophrenia	_
160-6	31614-31620	showed	_
160-7	31621-31630	decreased	_
160-8	31631-31642	functioning	_
160-9	31643-31645	in	_
160-10	31646-31651	right	_
160-11	31652-31662	prefrontal	_
160-12	31663-31670	regions	_
160-13	31671-31682	responsible	_
160-14	31683-31686	for	_
160-15	31687-31695	salience	_
160-16	31696-31705	signaling	_
160-17	31706-31709	and	_
160-18	31710-31717	valence	_
160-19	31718-31728	evaluation	_
160-20	31729-31735	during	_
160-21	31736-31743	emotion	_
160-22	31744-31755	recognition	_
160-23	31755-31756	.	_

#Text=Abbreviations
#Text=AAL
#Text=Automated Anatomical Labeling
#Text=AP
#Text=Antipsychotic
#Text=BA
#Text=Brodmann Area
#Text=BOLD
#Text=Blood Oxygen Level Dependent
#Text=BZD
#Text=Benzodiazepine
#Text=CDT
#Text=cluster defining threshold
#Text=CNS
#Text=Central Nervous System
#Text=Cntrl
#Text=Control subjects
#Text=CPZ
#Text=Chlorpromazine Equivalent Dose
#Text=DLPFC
#Text=Dorsolateral Prefrontal Cortex
#Text=DLPFC
#Text=Dorsolateral Prefrontal Cortex
#Text=DMPFC
#Text=Dorsomedial Prefrontal Cortex
#Text=DODS
#Text=Different Offset, Different Slope
#Text=DSM-IV
#Text=Diagnostic and Statistical Manual of Mental Disorders, 4thEdition
#Text=EEG
#Text=Electroencephalogram
#Text=EPI
#Text=Echo-planar imaging
#Text=FEW
#Text=Familywise Error Correction
#Text=fMRI
#Text=Functional Magnetic Resonance Imaging
#Text=FOV
#Text=Field-of-view
#Text=FWHM
#Text=Full width at half maximum
#Text=GLM
#Text=General Linear Model
#Text=HRF
#Text=Hemodynamical Response Function
#Text=IAPS
#Text=International Affective Picture Set
#Text=MNI
#Text=Montreal Neurological Institute
#Text=MRI
#Text=Magnetic Resonance Imaging
#Text=PANSS
#Text=Positive and Negative Symptoms Scale
#Text=PSP
#Text=Personal and Social Performance Scale
#Text=QDEC
#Text=Query, Design, Estimate, Contrast
#Text=RAI
#Text=Right Anterior Insula
#Text=RMFG
#Text=Right Middle Frontal Cortex
#Text=RMOG
#Text=Right Middle Occipital Gyrus
#Text=ROI
#Text=Region of Interest
#Text=RPO
#Text=Right Parietal Operculum
#Text=RRO
#Text=Right Rolandic Operculum
#Text=RSTG
#Text=Right Superior Temporal Gyrus
#Text=Sch
#Text=Patients with Schizophrenia
#Text=SD
#Text=Standard Deviation
#Text=SNPM
#Text=Statistical non-Parametric Mapping
#Text=T1 W 3D TFE
#Text=T1 weighted 3 dimensional spoiled gradient echo
#Text=TE
#Text=Echo Time (fMRI)
#Text=TR
#Text=Temporal Resolution (fMRI sampling time)
#Text=VC
#Text=Vermis of the Cerebellum
#Text=VLPFC
#Text=Ventrolateral Prefrontal Cortex
#Text=VMPFC
#Text=Ventromedial Prefrontal Cortex
#Text=Authors’ contributions
#Text=GC designed the study, wrote the protocol, created the figures, and wrote the first draft of the “Introduction” and “Discussion” sections.
161-1	31757-31770	Abbreviations	_
161-2	31771-31774	AAL	_
161-3	31775-31784	Automated	_
161-4	31785-31795	Anatomical	_
161-5	31796-31804	Labeling	_
161-6	31805-31807	AP	_
161-7	31808-31821	Antipsychotic	_
161-8	31822-31824	BA	_
161-9	31825-31833	Brodmann	_
161-10	31834-31838	Area	_
161-11	31839-31843	BOLD	_
161-12	31844-31849	Blood	_
161-13	31850-31856	Oxygen	_
161-14	31857-31862	Level	_
161-15	31863-31872	Dependent	_
161-16	31873-31876	BZD	_
161-17	31877-31891	Benzodiazepine	_
161-18	31892-31895	CDT	_
161-19	31896-31903	cluster	_
161-20	31904-31912	defining	_
161-21	31913-31922	threshold	_
161-22	31923-31926	CNS	_
161-23	31927-31934	Central	_
161-24	31935-31942	Nervous	_
161-25	31943-31949	System	_
161-26	31950-31955	Cntrl	_
161-27	31956-31963	Control	_
161-28	31964-31972	subjects	_
161-29	31973-31976	CPZ	_
161-30	31977-31991	Chlorpromazine	_
161-31	31992-32002	Equivalent	_
161-32	32003-32007	Dose	_
161-33	32008-32013	DLPFC	_
161-34	32014-32026	Dorsolateral	_
161-35	32027-32037	Prefrontal	_
161-36	32038-32044	Cortex	_
161-37	32045-32050	DLPFC	_
161-38	32051-32063	Dorsolateral	_
161-39	32064-32074	Prefrontal	_
161-40	32075-32081	Cortex	_
161-41	32082-32087	DMPFC	_
161-42	32088-32099	Dorsomedial	_
161-43	32100-32110	Prefrontal	_
161-44	32111-32117	Cortex	_
161-45	32118-32122	DODS	_
161-46	32123-32132	Different	_
161-47	32133-32139	Offset	_
161-48	32139-32140	,	_
161-49	32141-32150	Different	_
161-50	32151-32156	Slope	_
161-51	32157-32163	DSM-IV	_
161-52	32164-32174	Diagnostic	_
161-53	32175-32178	and	_
161-54	32179-32190	Statistical	_
161-55	32191-32197	Manual	_
161-56	32198-32200	of	_
161-57	32201-32207	Mental	_
161-58	32208-32217	Disorders	_
161-59	32217-32218	,	_
161-60	32219-32229	4thEdition	_
161-61	32230-32233	EEG	_
161-62	32234-32254	Electroencephalogram	_
161-63	32255-32258	EPI	_
161-64	32259-32270	Echo-planar	_
161-65	32271-32278	imaging	_
161-66	32279-32282	FEW	_
161-67	32283-32293	Familywise	_
161-68	32294-32299	Error	_
161-69	32300-32310	Correction	_
161-70	32311-32315	fMRI	_
161-71	32316-32326	Functional	_
161-72	32327-32335	Magnetic	_
161-73	32336-32345	Resonance	_
161-74	32346-32353	Imaging	_
161-75	32354-32357	FOV	_
161-76	32358-32371	Field-of-view	_
161-77	32372-32376	FWHM	_
161-78	32377-32381	Full	_
161-79	32382-32387	width	_
161-80	32388-32390	at	_
161-81	32391-32395	half	_
161-82	32396-32403	maximum	_
161-83	32404-32407	GLM	_
161-84	32408-32415	General	_
161-85	32416-32422	Linear	_
161-86	32423-32428	Model	_
161-87	32429-32432	HRF	_
161-88	32433-32446	Hemodynamical	_
161-89	32447-32455	Response	_
161-90	32456-32464	Function	_
161-91	32465-32469	IAPS	_
161-92	32470-32483	International	_
161-93	32484-32493	Affective	_
161-94	32494-32501	Picture	_
161-95	32502-32505	Set	_
161-96	32506-32509	MNI	_
161-97	32510-32518	Montreal	_
161-98	32519-32531	Neurological	_
161-99	32532-32541	Institute	_
161-100	32542-32545	MRI	_
161-101	32546-32554	Magnetic	_
161-102	32555-32564	Resonance	_
161-103	32565-32572	Imaging	_
161-104	32573-32578	PANSS	_
161-105	32579-32587	Positive	_
161-106	32588-32591	and	_
161-107	32592-32600	Negative	_
161-108	32601-32609	Symptoms	_
161-109	32610-32615	Scale	_
161-110	32616-32619	PSP	_
161-111	32620-32628	Personal	_
161-112	32629-32632	and	_
161-113	32633-32639	Social	_
161-114	32640-32651	Performance	_
161-115	32652-32657	Scale	_
161-116	32658-32662	QDEC	_
161-117	32663-32668	Query	_
161-118	32668-32669	,	_
161-119	32670-32676	Design	_
161-120	32676-32677	,	_
161-121	32678-32686	Estimate	_
161-122	32686-32687	,	_
161-123	32688-32696	Contrast	_
161-124	32697-32700	RAI	_
161-125	32701-32706	Right	_
161-126	32707-32715	Anterior	_
161-127	32716-32722	Insula	_
161-128	32723-32727	RMFG	_
161-129	32728-32733	Right	_
161-130	32734-32740	Middle	_
161-131	32741-32748	Frontal	_
161-132	32749-32755	Cortex	_
161-133	32756-32760	RMOG	_
161-134	32761-32766	Right	_
161-135	32767-32773	Middle	_
161-136	32774-32783	Occipital	_
161-137	32784-32789	Gyrus	_
161-138	32790-32793	ROI	_
161-139	32794-32800	Region	_
161-140	32801-32803	of	_
161-141	32804-32812	Interest	_
161-142	32813-32816	RPO	_
161-143	32817-32822	Right	_
161-144	32823-32831	Parietal	_
161-145	32832-32841	Operculum	_
161-146	32842-32845	RRO	_
161-147	32846-32851	Right	_
161-148	32852-32860	Rolandic	_
161-149	32861-32870	Operculum	_
161-150	32871-32875	RSTG	_
161-151	32876-32881	Right	_
161-152	32882-32890	Superior	_
161-153	32891-32899	Temporal	_
161-154	32900-32905	Gyrus	_
161-155	32906-32909	Sch	_
161-156	32910-32918	Patients	_
161-157	32919-32923	with	_
161-158	32924-32937	Schizophrenia	_
161-159	32938-32940	SD	_
161-160	32941-32949	Standard	_
161-161	32950-32959	Deviation	_
161-162	32960-32964	SNPM	_
161-163	32965-32976	Statistical	_
161-164	32977-32991	non-Parametric	_
161-165	32992-32999	Mapping	_
161-166	33000-33002	T1	_
161-167	33002-33003	 	_
161-168	33003-33004	W	_
161-169	33005-33007	3D	_
161-170	33008-33011	TFE	_
161-171	33012-33014	T1	_
161-172	33015-33023	weighted	_
161-173	33024-33025	3	_
161-174	33026-33037	dimensional	_
161-175	33038-33045	spoiled	_
161-176	33046-33054	gradient	_
161-177	33055-33059	echo	_
161-178	33060-33062	TE	_
161-179	33063-33067	Echo	_
161-180	33068-33072	Time	_
161-181	33073-33074	(	_
161-182	33074-33078	fMRI	_
161-183	33078-33079	)	_
161-184	33080-33082	TR	_
161-185	33083-33091	Temporal	_
161-186	33092-33102	Resolution	_
161-187	33103-33104	(	_
161-188	33104-33108	fMRI	_
161-189	33109-33117	sampling	_
161-190	33118-33122	time	_
161-191	33122-33123	)	_
161-192	33124-33126	VC	_
161-193	33127-33133	Vermis	_
161-194	33134-33136	of	_
161-195	33137-33140	the	_
161-196	33141-33151	Cerebellum	_
161-197	33152-33157	VLPFC	_
161-198	33158-33171	Ventrolateral	_
161-199	33172-33182	Prefrontal	_
161-200	33183-33189	Cortex	_
161-201	33190-33195	VMPFC	_
161-202	33196-33208	Ventromedial	_
161-203	33209-33219	Prefrontal	_
161-204	33220-33226	Cortex	_
161-205	33227-33234	Authors	_
161-206	33234-33235	’	_
161-207	33236-33249	contributions	_
161-208	33250-33252	GC	_
161-209	33253-33261	designed	_
161-210	33262-33265	the	_
161-211	33266-33271	study	_
161-212	33271-33272	,	_
161-213	33273-33278	wrote	_
161-214	33279-33282	the	_
161-215	33283-33291	protocol	_
161-216	33291-33292	,	_
161-217	33293-33300	created	_
161-218	33301-33304	the	_
161-219	33305-33312	figures	_
161-220	33312-33313	,	_
161-221	33314-33317	and	_
161-222	33318-33323	wrote	_
161-223	33324-33327	the	_
161-224	33328-33333	first	_
161-225	33334-33339	draft	_
161-226	33340-33342	of	_
161-227	33343-33346	the	_
161-228	33347-33348	“	_
161-229	33348-33360	Introduction	_
161-230	33360-33361	”	_
161-231	33362-33365	and	_
161-232	33366-33367	“	_
161-233	33367-33377	Discussion	_
161-234	33377-33378	”	_
161-235	33379-33387	sections	_
161-236	33387-33388	.	_

#Text=ÁS participated in the execution of measurements, managed the literature searches and analyses, undertook the statistical analysis, and wrote the first draft of the “Results” and “Methods” sections.
162-1	33389-33391	ÁS	_
162-2	33392-33404	participated	_
162-3	33405-33407	in	_
162-4	33408-33411	the	_
162-5	33412-33421	execution	_
162-6	33422-33424	of	_
162-7	33425-33437	measurements	_
162-8	33437-33438	,	_
162-9	33439-33446	managed	_
162-10	33447-33450	the	_
162-11	33451-33461	literature	_
162-12	33462-33470	searches	_
162-13	33471-33474	and	_
162-14	33475-33483	analyses	_
162-15	33483-33484	,	_
162-16	33485-33494	undertook	_
162-17	33495-33498	the	_
162-18	33499-33510	statistical	_
162-19	33511-33519	analysis	_
162-20	33519-33520	,	_
162-21	33521-33524	and	_
162-22	33525-33530	wrote	_
162-23	33531-33534	the	_
162-24	33535-33540	first	_
162-25	33541-33546	draft	_
162-26	33547-33549	of	_
162-27	33550-33553	the	_
162-28	33554-33555	“	_
162-29	33555-33562	Results	_
162-30	33562-33563	”	_
162-31	33564-33567	and	_
162-32	33568-33569	“	_
162-33	33569-33576	Methods	_
162-34	33576-33577	”	_
162-35	33578-33586	sections	_
162-36	33586-33587	.	_

#Text=KF contributed substantially to the design of the study and to the finalization of all sections of the manuscript.
163-1	33588-33590	KF	_
163-2	33591-33602	contributed	_
163-3	33603-33616	substantially	_
163-4	33617-33619	to	_
163-5	33620-33623	the	_
163-6	33624-33630	design	_
163-7	33631-33633	of	_
163-8	33634-33637	the	_
163-9	33638-33643	study	_
163-10	33644-33647	and	_
163-11	33648-33650	to	_
163-12	33651-33654	the	_
163-13	33655-33667	finalization	_
163-14	33668-33670	of	_
163-15	33671-33674	all	_
163-16	33675-33683	sections	_
163-17	33684-33686	of	_
163-18	33687-33690	the	_
163-19	33691-33701	manuscript	_
163-20	33701-33702	.	_

#Text=CM participated in the execution of measurements, and contributed to the writing of the methods section.
164-1	33703-33705	CM	_
164-2	33706-33718	participated	_
164-3	33719-33721	in	_
164-4	33722-33725	the	_
164-5	33726-33735	execution	_
164-6	33736-33738	of	_
164-7	33739-33751	measurements	_
164-8	33751-33752	,	_
164-9	33753-33756	and	_
164-10	33757-33768	contributed	_
164-11	33769-33771	to	_
164-12	33772-33775	the	_
164-13	33776-33783	writing	_
164-14	33784-33786	of	_
164-15	33787-33790	the	_
164-16	33791-33798	methods	_
164-17	33799-33806	section	_
164-18	33806-33807	.	_

#Text=JR, LRK and GR were involved in the interpretation of the data and gave supervision for the experiments during the study including the writing and revising of the manuscript.
165-1	33808-33810	JR	_
165-2	33810-33811	,	_
165-3	33812-33815	LRK	_
165-4	33816-33819	and	_
165-5	33820-33822	GR	_
165-6	33823-33827	were	_
165-7	33828-33836	involved	_
165-8	33837-33839	in	_
165-9	33840-33843	the	_
165-10	33844-33858	interpretation	_
165-11	33859-33861	of	_
165-12	33862-33865	the	_
165-13	33866-33870	data	_
165-14	33871-33874	and	_
165-15	33875-33879	gave	_
165-16	33880-33891	supervision	_
165-17	33892-33895	for	_
165-18	33896-33899	the	_
165-19	33900-33911	experiments	_
165-20	33912-33918	during	_
165-21	33919-33922	the	_
165-22	33923-33928	study	_
165-23	33929-33938	including	_
165-24	33939-33942	the	_
165-25	33943-33950	writing	_
165-26	33951-33954	and	_
165-27	33955-33963	revising	_
165-28	33964-33966	of	_
165-29	33967-33970	the	_
165-30	33971-33981	manuscript	_
165-31	33981-33982	.	_

#Text=All authors contributed to and have approved the final manuscript.
166-1	33983-33986	All	_
166-2	33987-33994	authors	_
166-3	33995-34006	contributed	_
166-4	34007-34009	to	_
166-5	34010-34013	and	_
166-6	34014-34018	have	_
166-7	34019-34027	approved	_
166-8	34028-34031	the	_
166-9	34032-34037	final	_
166-10	34038-34048	manuscript	_
166-11	34048-34049	.	_

#Text=Ethics approval and consent to participate
#Text=All procedures were carried out only after written informed consent was obtained from the participants.
167-1	34050-34056	Ethics	_
167-2	34057-34065	approval	_
167-3	34066-34069	and	_
167-4	34070-34077	consent	_
167-5	34078-34080	to	_
167-6	34081-34092	participate	_
167-7	34093-34096	All	_
167-8	34097-34107	procedures	_
167-9	34108-34112	were	_
167-10	34113-34120	carried	_
167-11	34121-34124	out	_
167-12	34125-34129	only	_
167-13	34130-34135	after	_
167-14	34136-34143	written	_
167-15	34144-34152	informed	_
167-16	34153-34160	consent	_
167-17	34161-34164	was	_
167-18	34165-34173	obtained	_
167-19	34174-34178	from	_
167-20	34179-34182	the	_
167-21	34183-34195	participants	_
167-22	34195-34196	.	_

#Text=All potential participants who declined to participate or otherwise did not participate were not disadvantaged in any way by not participating in the study.
168-1	34197-34200	All	_
168-2	34201-34210	potential	_
168-3	34211-34223	participants	_
168-4	34224-34227	who	_
168-5	34228-34236	declined	_
168-6	34237-34239	to	_
168-7	34240-34251	participate	_
168-8	34252-34254	or	_
168-9	34255-34264	otherwise	_
168-10	34265-34268	did	_
168-11	34269-34272	not	_
168-12	34273-34284	participate	_
168-13	34285-34289	were	_
168-14	34290-34293	not	_
168-15	34294-34307	disadvantaged	_
168-16	34308-34310	in	_
168-17	34311-34314	any	_
168-18	34315-34318	way	_
168-19	34319-34321	by	_
168-20	34322-34325	not	_
168-21	34326-34339	participating	_
168-22	34340-34342	in	_
168-23	34343-34346	the	_
168-24	34347-34352	study	_
168-25	34352-34353	.	_

#Text=The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
169-1	34354-34357	The	_
169-2	34358-34365	authors	_
169-3	34366-34372	assert	_
169-4	34373-34377	that	_
169-5	34378-34381	all	_
169-6	34382-34392	procedures	_
169-7	34393-34405	contributing	_
169-8	34406-34408	to	_
169-9	34409-34413	this	_
169-10	34414-34418	work	_
169-11	34419-34425	comply	_
169-12	34426-34430	with	_
169-13	34431-34434	the	_
169-14	34435-34442	ethical	_
169-15	34443-34452	standards	_
169-16	34453-34455	of	_
169-17	34456-34459	the	_
169-18	34460-34468	relevant	_
169-19	34469-34477	national	_
169-20	34478-34481	and	_
169-21	34482-34495	institutional	_
169-22	34496-34506	committees	_
169-23	34507-34509	on	_
169-24	34510-34515	human	_
169-25	34516-34531	experimentation	_
169-26	34532-34535	and	_
169-27	34536-34540	with	_
169-28	34541-34544	the	_
169-29	34545-34553	Helsinki	_
169-30	34554-34565	Declaration	_
169-31	34566-34568	of	_
169-32	34569-34573	1975	_
169-33	34573-34574	,	_
169-34	34575-34577	as	_
169-35	34578-34585	revised	_
169-36	34586-34588	in	_
169-37	34589-34593	2008	_
169-38	34593-34594	.	_

#Text=The research was approved by the “Scientific and Research Committee, Medical Research Council, Hungary”.
170-1	34595-34598	The	_
170-2	34599-34607	research	_
170-3	34608-34611	was	_
170-4	34612-34620	approved	_
170-5	34621-34623	by	_
170-6	34624-34627	the	_
170-7	34628-34629	“	_
170-8	34629-34639	Scientific	_
170-9	34640-34643	and	_
170-10	34644-34652	Research	_
170-11	34653-34662	Committee	_
170-12	34662-34663	,	_
170-13	34664-34671	Medical	_
170-14	34672-34680	Research	_
170-15	34681-34688	Council	_
170-16	34688-34689	,	_
170-17	34690-34697	Hungary	_
170-18	34697-34698	”	_
170-19	34698-34699	.	_

#Text=Consent for publication
#Text=Not applicable.
171-1	34700-34707	Consent	_
171-2	34708-34711	for	_
171-3	34712-34723	publication	_
171-4	34724-34727	Not	_
171-5	34728-34738	applicable	_
171-6	34738-34739	.	_

#Text=Competing interests
#Text=The authors declare that they have no competing interests.
172-1	34740-34749	Competing	_
172-2	34750-34759	interests	_
172-3	34760-34763	The	_
172-4	34764-34771	authors	_
172-5	34772-34779	declare	_
172-6	34780-34784	that	_
172-7	34785-34789	they	_
172-8	34790-34794	have	_
172-9	34795-34797	no	_
172-10	34798-34807	competing	_
172-11	34808-34817	interests	_
172-12	34817-34818	.	_

#Text=Publisher’s Note
#Text=Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
173-1	34819-34828	Publisher	_
173-2	34828-34829	’	_
173-3	34829-34830	s	_
173-4	34831-34835	Note	_
173-5	34836-34844	Springer	_
173-6	34845-34851	Nature	_
173-7	34852-34859	remains	_
173-8	34860-34867	neutral	_
173-9	34868-34872	with	_
173-10	34873-34879	regard	_
173-11	34880-34882	to	_
173-12	34883-34897	jurisdictional	_
173-13	34898-34904	claims	_
173-14	34905-34907	in	_
173-15	34908-34917	published	_
173-16	34918-34922	maps	_
173-17	34923-34926	and	_
173-18	34927-34940	institutional	_
173-19	34941-34953	affiliations	_
173-20	34953-34954	.	_

#Text=References
#Text=Influence of social perception and social knowledge on cognitive and social functioning in early psychosis
#Text=Social cognition in schizophrenia
#Text=Social cognitive neuroscience: a review of core processes
#Text=Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI
#Text=Activation of the left amygdala to a cognitive representation of fear
#Text=Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies
#Text=Segregated neural representation of distinct emotion dimensions in the prefrontal cortex-an fMRI study
#Text=Neural network of cognitive emotion regulation--an ALE meta-analysis and MACM analysis
#Text=Emotional discrimination during viewing unpleasant pictures: timing in human anterior ventrolateral prefrontal cortex and amygdala
#Text=Cognitive control and right ventrolateral prefrontal cortex: reflexive reorienting, motor inhibition, and action updating
#Text=Neural correlates of emotion recognition in schizophrenia
#Text=Ventrolateral prefrontal cortex and the effects of task demand context on facial affect appraisal in schizophrenia
#Text=Disordered corticolimbic interactions during affective processing in children and adolescents at risk for schizophrenia revealed by functional magnetic resonance imaging and dynamic causal modeling
#Text=Social cognition in schizophrenia: a review of face processing
#Text=Neural correlates of emotion regulation in patients with schizophrenia and non-affected siblings
#Text=The brief symptom inventory: an introductory report
#Text=Validity and reliability of the SCL-90 in a Hungarian population sample
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Social functioning as an outcome measure in schizophrenia studies
#Text=
#Text=Facial expressions of emotions and schizophrenia: a review
#Text=Actively paranoid patients with schizophrenia over attribute anger to neutral faces
#Text=Overactivation of fear systems to neutral faces in schizophrenia
#Text=A reversal of the normal pattern of parahippocampal response to neutral and fearful faces is associated with reality distortion in schizophrenia
#Text=Nonparametric permutation tests for functional neuroimaging: a primer with examples
#Text=Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
#Text=Brett M, Anton JL, Valabregue R, Poline JB.
174-1	34955-34965	References	_
174-2	34966-34975	Influence	_
174-3	34976-34978	of	_
174-4	34979-34985	social	_
174-5	34986-34996	perception	_
174-6	34997-35000	and	_
174-7	35001-35007	social	_
174-8	35008-35017	knowledge	_
174-9	35018-35020	on	_
174-10	35021-35030	cognitive	_
174-11	35031-35034	and	_
174-12	35035-35041	social	_
174-13	35042-35053	functioning	_
174-14	35054-35056	in	_
174-15	35057-35062	early	_
174-16	35063-35072	psychosis	_
174-17	35073-35079	Social	_
174-18	35080-35089	cognition	_
174-19	35090-35092	in	_
174-20	35093-35106	schizophrenia	_
174-21	35107-35113	Social	_
174-22	35114-35123	cognitive	_
174-23	35124-35136	neuroscience	_
174-24	35136-35137	:	_
174-25	35138-35139	a	_
174-26	35140-35146	review	_
174-27	35147-35149	of	_
174-28	35150-35154	core	_
174-29	35155-35164	processes	_
174-30	35165-35175	Functional	_
174-31	35176-35188	neuroanatomy	_
174-32	35189-35191	of	_
174-33	35192-35199	emotion	_
174-34	35199-35200	:	_
174-35	35201-35202	a	_
174-36	35203-35216	meta-analysis	_
174-37	35217-35219	of	_
174-38	35220-35227	emotion	_
174-39	35228-35238	activation	_
174-40	35239-35246	studies	_
174-41	35247-35249	in	_
174-42	35250-35253	PET	_
174-43	35254-35257	and	_
174-44	35258-35262	fMRI	_
174-45	35263-35273	Activation	_
174-46	35274-35276	of	_
174-47	35277-35280	the	_
174-48	35281-35285	left	_
174-49	35286-35294	amygdala	_
174-50	35295-35297	to	_
174-51	35298-35299	a	_
174-52	35300-35309	cognitive	_
174-53	35310-35324	representation	_
174-54	35325-35327	of	_
174-55	35328-35332	fear	_
174-56	35333-35343	Functional	_
174-57	35344-35349	atlas	_
174-58	35350-35352	of	_
174-59	35353-35362	emotional	_
174-60	35363-35368	faces	_
174-61	35369-35379	processing	_
174-62	35379-35380	:	_
174-63	35381-35382	a	_
174-64	35383-35394	voxel-based	_
174-65	35395-35408	meta-analysis	_
174-66	35409-35411	of	_
174-67	35412-35415	105	_
174-68	35416-35426	functional	_
174-69	35427-35435	magnetic	_
174-70	35436-35445	resonance	_
174-71	35446-35453	imaging	_
174-72	35454-35461	studies	_
174-73	35462-35472	Segregated	_
174-74	35473-35479	neural	_
174-75	35480-35494	representation	_
174-76	35495-35497	of	_
174-77	35498-35506	distinct	_
174-78	35507-35514	emotion	_
174-79	35515-35525	dimensions	_
174-80	35526-35528	in	_
174-81	35529-35532	the	_
174-82	35533-35543	prefrontal	_
174-83	35544-35553	cortex-an	_
174-84	35554-35558	fMRI	_
174-85	35559-35564	study	_
174-86	35565-35571	Neural	_
174-87	35572-35579	network	_
174-88	35580-35582	of	_
174-89	35583-35592	cognitive	_
174-90	35593-35600	emotion	_
174-91	35601-35611	regulation	_
174-92	35611-35612	-	_
174-93	35612-35613	-	_
174-94	35613-35615	an	_
174-95	35616-35619	ALE	_
174-96	35620-35633	meta-analysis	_
174-97	35634-35637	and	_
174-98	35638-35642	MACM	_
174-99	35643-35651	analysis	_
174-100	35652-35661	Emotional	_
174-101	35662-35676	discrimination	_
174-102	35677-35683	during	_
174-103	35684-35691	viewing	_
174-104	35692-35702	unpleasant	_
174-105	35703-35711	pictures	_
174-106	35711-35712	:	_
174-107	35713-35719	timing	_
174-108	35720-35722	in	_
174-109	35723-35728	human	_
174-110	35729-35737	anterior	_
174-111	35738-35751	ventrolateral	_
174-112	35752-35762	prefrontal	_
174-113	35763-35769	cortex	_
174-114	35770-35773	and	_
174-115	35774-35782	amygdala	_
174-116	35783-35792	Cognitive	_
174-117	35793-35800	control	_
174-118	35801-35804	and	_
174-119	35805-35810	right	_
174-120	35811-35824	ventrolateral	_
174-121	35825-35835	prefrontal	_
174-122	35836-35842	cortex	_
174-123	35842-35843	:	_
174-124	35844-35853	reflexive	_
174-125	35854-35865	reorienting	_
174-126	35865-35866	,	_
174-127	35867-35872	motor	_
174-128	35873-35883	inhibition	_
174-129	35883-35884	,	_
174-130	35885-35888	and	_
174-131	35889-35895	action	_
174-132	35896-35904	updating	_
174-133	35905-35911	Neural	_
174-134	35912-35922	correlates	_
174-135	35923-35925	of	_
174-136	35926-35933	emotion	_
174-137	35934-35945	recognition	_
174-138	35946-35948	in	_
174-139	35949-35962	schizophrenia	_
174-140	35963-35976	Ventrolateral	_
174-141	35977-35987	prefrontal	_
174-142	35988-35994	cortex	_
174-143	35995-35998	and	_
174-144	35999-36002	the	_
174-145	36003-36010	effects	_
174-146	36011-36013	of	_
174-147	36014-36018	task	_
174-148	36019-36025	demand	_
174-149	36026-36033	context	_
174-150	36034-36036	on	_
174-151	36037-36043	facial	_
174-152	36044-36050	affect	_
174-153	36051-36060	appraisal	_
174-154	36061-36063	in	_
174-155	36064-36077	schizophrenia	_
174-156	36078-36088	Disordered	_
174-157	36089-36102	corticolimbic	_
174-158	36103-36115	interactions	_
174-159	36116-36122	during	_
174-160	36123-36132	affective	_
174-161	36133-36143	processing	_
174-162	36144-36146	in	_
174-163	36147-36155	children	_
174-164	36156-36159	and	_
174-165	36160-36171	adolescents	_
174-166	36172-36174	at	_
174-167	36175-36179	risk	_
174-168	36180-36183	for	_
174-169	36184-36197	schizophrenia	_
174-170	36198-36206	revealed	_
174-171	36207-36209	by	_
174-172	36210-36220	functional	_
174-173	36221-36229	magnetic	_
174-174	36230-36239	resonance	_
174-175	36240-36247	imaging	_
174-176	36248-36251	and	_
174-177	36252-36259	dynamic	_
174-178	36260-36266	causal	_
174-179	36267-36275	modeling	_
174-180	36276-36282	Social	_
174-181	36283-36292	cognition	_
174-182	36293-36295	in	_
174-183	36296-36309	schizophrenia	_
174-184	36309-36310	:	_
174-185	36311-36312	a	_
174-186	36313-36319	review	_
174-187	36320-36322	of	_
174-188	36323-36327	face	_
174-189	36328-36338	processing	_
174-190	36339-36345	Neural	_
174-191	36346-36356	correlates	_
174-192	36357-36359	of	_
174-193	36360-36367	emotion	_
174-194	36368-36378	regulation	_
174-195	36379-36381	in	_
174-196	36382-36390	patients	_
174-197	36391-36395	with	_
174-198	36396-36409	schizophrenia	_
174-199	36410-36413	and	_
174-200	36414-36426	non-affected	_
174-201	36427-36435	siblings	_
174-202	36436-36439	The	_
174-203	36440-36445	brief	_
174-204	36446-36453	symptom	_
174-205	36454-36463	inventory	_
174-206	36463-36464	:	_
174-207	36465-36467	an	_
174-208	36468-36480	introductory	_
174-209	36481-36487	report	_
174-210	36488-36496	Validity	_
174-211	36497-36500	and	_
174-212	36501-36512	reliability	_
174-213	36513-36515	of	_
174-214	36516-36519	the	_
174-215	36520-36523	SCL	_
174-216	36523-36524	-	_
174-217	36524-36526	90	_
174-218	36527-36529	in	_
174-219	36530-36531	a	_
174-220	36532-36541	Hungarian	_
174-221	36542-36552	population	_
174-222	36553-36559	sample	_
174-223	36560-36563	The	_
174-224	36564-36572	positive	_
174-225	36573-36576	and	_
174-226	36577-36585	negative	_
174-227	36586-36594	syndrome	_
174-228	36595-36600	scale	_
174-229	36601-36602	(	_
174-230	36602-36607	PANSS	_
174-231	36607-36608	)	_
174-232	36609-36612	for	_
174-233	36613-36626	schizophrenia	_
174-234	36627-36633	Social	_
174-235	36634-36645	functioning	_
174-236	36646-36648	as	_
174-237	36649-36651	an	_
174-238	36652-36659	outcome	_
174-239	36660-36667	measure	_
174-240	36668-36670	in	_
174-241	36671-36684	schizophrenia	_
174-242	36685-36692	studies	_
174-243	36694-36700	Facial	_
174-244	36701-36712	expressions	_
174-245	36713-36715	of	_
174-246	36716-36724	emotions	_
174-247	36725-36728	and	_
174-248	36729-36742	schizophrenia	_
174-249	36742-36743	:	_
174-250	36744-36745	a	_
174-251	36746-36752	review	_
174-252	36753-36761	Actively	_
174-253	36762-36770	paranoid	_
174-254	36771-36779	patients	_
174-255	36780-36784	with	_
174-256	36785-36798	schizophrenia	_
174-257	36799-36803	over	_
174-258	36804-36813	attribute	_
174-259	36814-36819	anger	_
174-260	36820-36822	to	_
174-261	36823-36830	neutral	_
174-262	36831-36836	faces	_
174-263	36837-36851	Overactivation	_
174-264	36852-36854	of	_
174-265	36855-36859	fear	_
174-266	36860-36867	systems	_
174-267	36868-36870	to	_
174-268	36871-36878	neutral	_
174-269	36879-36884	faces	_
174-270	36885-36887	in	_
174-271	36888-36901	schizophrenia	_
174-272	36902-36903	A	_
174-273	36904-36912	reversal	_
174-274	36913-36915	of	_
174-275	36916-36919	the	_
174-276	36920-36926	normal	_
174-277	36927-36934	pattern	_
174-278	36935-36937	of	_
174-279	36938-36953	parahippocampal	_
174-280	36954-36962	response	_
174-281	36963-36965	to	_
174-282	36966-36973	neutral	_
174-283	36974-36977	and	_
174-284	36978-36985	fearful	_
174-285	36986-36991	faces	_
174-286	36992-36994	is	_
174-287	36995-37005	associated	_
174-288	37006-37010	with	_
174-289	37011-37018	reality	_
174-290	37019-37029	distortion	_
174-291	37030-37032	in	_
174-292	37033-37046	schizophrenia	_
174-293	37047-37060	Nonparametric	_
174-294	37061-37072	permutation	_
174-295	37073-37078	tests	_
174-296	37079-37082	for	_
174-297	37083-37093	functional	_
174-298	37094-37106	neuroimaging	_
174-299	37106-37107	:	_
174-300	37108-37109	a	_
174-301	37110-37116	primer	_
174-302	37117-37121	with	_
174-303	37122-37130	examples	_
174-304	37131-37140	Automated	_
174-305	37141-37151	anatomical	_
174-306	37152-37160	labeling	_
174-307	37161-37163	of	_
174-308	37164-37175	activations	_
174-309	37176-37178	in	_
174-310	37179-37182	SPM	_
174-311	37183-37188	using	_
174-312	37189-37190	a	_
174-313	37191-37202	macroscopic	_
174-314	37203-37213	anatomical	_
174-315	37214-37226	parcellation	_
174-316	37227-37229	of	_
174-317	37230-37233	the	_
174-318	37234-37237	MNI	_
174-319	37238-37241	MRI	_
174-320	37242-37256	single-subject	_
174-321	37257-37262	brain	_
174-322	37263-37268	Brett	_
174-323	37269-37270	M	_
174-324	37270-37271	,	_
174-325	37272-37277	Anton	_
174-326	37278-37280	JL	_
174-327	37280-37281	,	_
174-328	37282-37292	Valabregue	_
174-329	37293-37294	R	_
174-330	37294-37295	,	_
174-331	37296-37302	Poline	_
174-332	37303-37305	JB	_
174-333	37305-37306	.	_

#Text=Region of interest analysis using an SPM toolbox.
175-1	37307-37313	Region	_
175-2	37314-37316	of	_
175-3	37317-37325	interest	_
175-4	37326-37334	analysis	_
175-5	37335-37340	using	_
175-6	37341-37343	an	_
175-7	37344-37347	SPM	_
175-8	37348-37355	toolbox	_
175-9	37355-37356	.	_

#Text=In: 8th International Conference on Functional Mapping of the Human Brain: 2002; Sendai.
176-1	37357-37359	In	_
176-2	37359-37360	:	_
176-3	37361-37364	8th	_
176-4	37365-37378	International	_
176-5	37379-37389	Conference	_
176-6	37390-37392	on	_
176-7	37393-37403	Functional	_
176-8	37404-37411	Mapping	_
176-9	37412-37414	of	_
176-10	37415-37418	the	_
176-11	37419-37424	Human	_
176-12	37425-37430	Brain	_
176-13	37430-37431	:	_
176-14	37432-37436	2002	_
176-15	37436-37437	;	_
176-16	37438-37444	Sendai	_
176-17	37444-37445	.	_

#Text=NeuroImage. 2002;13(2):210–17.
177-1	37446-37456	NeuroImage	_
177-2	37456-37457	.	_
177-3	37458-37462	2002	_
177-4	37462-37463	;	_
177-5	37463-37465	13	_
177-6	37465-37466	(	_
177-7	37466-37467	2	_
177-8	37467-37468	)	_
177-9	37468-37469	:	_
177-10	37469-37472	210	_
177-11	37472-37473	–	_
177-12	37473-37475	17	_
177-13	37475-37476	.	_

#Text=Bad and worse: neural systems underlying reappraisal of high- and low-intensity negative emotions
#Text=Advancing understanding of affect labeling with dynamic causal modeling
#Text=Prefrontal-subcortical pathways mediating successful emotion regulation
#Text=Lack of cortico-limbic coupling in bipolar disorder and schizophrenia during emotion regulation
#Text=Neural processing of emotional faces requires attention
#Text=Cognitive control modulates preferential sensory processing of affective stimuli
#Text=Emotion-related visual mismatch responses in schizophrenia: impairments and correlations with emotion recognition
#Text=De SP, Foxe JJ, Czobor P, Wylie GR, Kamiel SM, Huening J, Nair-Collins M, Krakowski MI.
178-1	37477-37480	Bad	_
178-2	37481-37484	and	_
178-3	37485-37490	worse	_
178-4	37490-37491	:	_
178-5	37492-37498	neural	_
178-6	37499-37506	systems	_
178-7	37507-37517	underlying	_
178-8	37518-37529	reappraisal	_
178-9	37530-37532	of	_
178-10	37533-37537	high	_
178-11	37537-37538	-	_
178-12	37539-37542	and	_
178-13	37543-37556	low-intensity	_
178-14	37557-37565	negative	_
178-15	37566-37574	emotions	_
178-16	37575-37584	Advancing	_
178-17	37585-37598	understanding	_
178-18	37599-37601	of	_
178-19	37602-37608	affect	_
178-20	37609-37617	labeling	_
178-21	37618-37622	with	_
178-22	37623-37630	dynamic	_
178-23	37631-37637	causal	_
178-24	37638-37646	modeling	_
178-25	37647-37669	Prefrontal-subcortical	_
178-26	37670-37678	pathways	_
178-27	37679-37688	mediating	_
178-28	37689-37699	successful	_
178-29	37700-37707	emotion	_
178-30	37708-37718	regulation	_
178-31	37719-37723	Lack	_
178-32	37724-37726	of	_
178-33	37727-37741	cortico-limbic	_
178-34	37742-37750	coupling	_
178-35	37751-37753	in	_
178-36	37754-37761	bipolar	_
178-37	37762-37770	disorder	_
178-38	37771-37774	and	_
178-39	37775-37788	schizophrenia	_
178-40	37789-37795	during	_
178-41	37796-37803	emotion	_
178-42	37804-37814	regulation	_
178-43	37815-37821	Neural	_
178-44	37822-37832	processing	_
178-45	37833-37835	of	_
178-46	37836-37845	emotional	_
178-47	37846-37851	faces	_
178-48	37852-37860	requires	_
178-49	37861-37870	attention	_
178-50	37871-37880	Cognitive	_
178-51	37881-37888	control	_
178-52	37889-37898	modulates	_
178-53	37899-37911	preferential	_
178-54	37912-37919	sensory	_
178-55	37920-37930	processing	_
178-56	37931-37933	of	_
178-57	37934-37943	affective	_
178-58	37944-37951	stimuli	_
178-59	37952-37967	Emotion-related	_
178-60	37968-37974	visual	_
178-61	37975-37983	mismatch	_
178-62	37984-37993	responses	_
178-63	37994-37996	in	_
178-64	37997-38010	schizophrenia	_
178-65	38010-38011	:	_
178-66	38012-38023	impairments	_
178-67	38024-38027	and	_
178-68	38028-38040	correlations	_
178-69	38041-38045	with	_
178-70	38046-38053	emotion	_
178-71	38054-38065	recognition	_
178-72	38066-38068	De	_
178-73	38069-38071	SP	_
178-74	38071-38072	,	_
178-75	38073-38077	Foxe	_
178-76	38078-38080	JJ	_
178-77	38080-38081	,	_
178-78	38082-38088	Czobor	_
178-79	38089-38090	P	_
178-80	38090-38091	,	_
178-81	38092-38097	Wylie	_
178-82	38098-38100	GR	_
178-83	38100-38101	,	_
178-84	38102-38108	Kamiel	_
178-85	38109-38111	SM	_
178-86	38111-38112	,	_
178-87	38113-38120	Huening	_
178-88	38121-38122	J	_
178-89	38122-38123	,	_
178-90	38124-38136	Nair-Collins	_
178-91	38137-38138	M	_
178-92	38138-38139	,	_
178-93	38140-38149	Krakowski	_
178-94	38150-38152	MI	_
178-95	38152-38153	.	_

#Text=Early sensory-perceptual processing deficits for affectively valenced inputs are more pronounced in schizophrenia patients with a history of violence than in their non-violent peers.
179-1	38154-38159	Early	_
179-2	38160-38178	sensory-perceptual	_
179-3	38179-38189	processing	_
179-4	38190-38198	deficits	_
179-5	38199-38202	for	_
179-6	38203-38214	affectively	_
179-7	38215-38223	valenced	_
179-8	38224-38230	inputs	_
179-9	38231-38234	are	_
179-10	38235-38239	more	_
179-11	38240-38250	pronounced	_
179-12	38251-38253	in	_
179-13	38254-38267	schizophrenia	_
179-14	38268-38276	patients	_
179-15	38277-38281	with	_
179-16	38282-38283	a	_
179-17	38284-38291	history	_
179-18	38292-38294	of	_
179-19	38295-38303	violence	_
179-20	38304-38308	than	_
179-21	38309-38311	in	_
179-22	38312-38317	their	_
179-23	38318-38329	non-violent	_
179-24	38330-38335	peers	_
179-25	38335-38336	.	_

#Text=Soc Cogn Affect Neurosci. 2013;8(6):678–87.
180-1	38337-38340	Soc	_
180-2	38341-38345	Cogn	_
180-3	38346-38352	Affect	_
180-4	38353-38361	Neurosci	_
180-5	38361-38362	.	_
180-6	38363-38367	2013	_
180-7	38367-38368	;	_
180-8	38368-38369	8	_
180-9	38369-38370	(	_
180-10	38370-38371	6	_
180-11	38371-38372	)	_
180-12	38372-38373	:	_
180-13	38373-38376	678	_
180-14	38376-38377	–	_
180-15	38377-38379	87	_
180-16	38379-38380	.	_

#Text=When doors of perception close: bottom-up models of disrupted cognition in schizophrenia
#Text=Neural mechanisms of reading facial emotions in young and older adults
#Text=Neural responses to emotional and neutral facial expressions in chronically violent men
#Text=Abnormally reduced dorsomedial prefrontal cortical activity and effective connectivity with amygdala in response to negative emotional faces in postpartum depression
#Text=Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism
#Text=No amygdala attenuation in schizophrenic patients treated with atypical antipsychotics
#Text=Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia
#Text=
#Text=Neural response to specific components of fearful faces in healthy and schizophrenic adults
#Text=Functional specialization within rostral prefrontal cortex (area 10): a meta-analysis
#Text=Prefrontal cortical deficits and impaired cognition-emotion interactions in schizophrenia
#Text=Involvement of the dorsolateral prefrontal cortex and superior temporal sulcus in impaired social perception in schizophrenia
#Text=Altered medial prefrontal activity during dynamic face processing in schizophrenia spectrum patients
#Text=Temporal lobe structures and facial emotion recognition in schizophrenia patients and nonpsychotic relatives
181-1	38381-38385	When	_
181-2	38386-38391	doors	_
181-3	38392-38394	of	_
181-4	38395-38405	perception	_
181-5	38406-38411	close	_
181-6	38411-38412	:	_
181-7	38413-38422	bottom-up	_
181-8	38423-38429	models	_
181-9	38430-38432	of	_
181-10	38433-38442	disrupted	_
181-11	38443-38452	cognition	_
181-12	38453-38455	in	_
181-13	38456-38469	schizophrenia	_
181-14	38470-38476	Neural	_
181-15	38477-38487	mechanisms	_
181-16	38488-38490	of	_
181-17	38491-38498	reading	_
181-18	38499-38505	facial	_
181-19	38506-38514	emotions	_
181-20	38515-38517	in	_
181-21	38518-38523	young	_
181-22	38524-38527	and	_
181-23	38528-38533	older	_
181-24	38534-38540	adults	_
181-25	38541-38547	Neural	_
181-26	38548-38557	responses	_
181-27	38558-38560	to	_
181-28	38561-38570	emotional	_
181-29	38571-38574	and	_
181-30	38575-38582	neutral	_
181-31	38583-38589	facial	_
181-32	38590-38601	expressions	_
181-33	38602-38604	in	_
181-34	38605-38616	chronically	_
181-35	38617-38624	violent	_
181-36	38625-38628	men	_
181-37	38629-38639	Abnormally	_
181-38	38640-38647	reduced	_
181-39	38648-38659	dorsomedial	_
181-40	38660-38670	prefrontal	_
181-41	38671-38679	cortical	_
181-42	38680-38688	activity	_
181-43	38689-38692	and	_
181-44	38693-38702	effective	_
181-45	38703-38715	connectivity	_
181-46	38716-38720	with	_
181-47	38721-38729	amygdala	_
181-48	38730-38732	in	_
181-49	38733-38741	response	_
181-50	38742-38744	to	_
181-51	38745-38753	negative	_
181-52	38754-38763	emotional	_
181-53	38764-38769	faces	_
181-54	38770-38772	in	_
181-55	38773-38783	postpartum	_
181-56	38784-38794	depression	_
181-57	38795-38803	Oxytocin	_
181-58	38804-38812	improves	_
181-59	38813-38824	behavioural	_
181-60	38825-38828	and	_
181-61	38829-38835	neural	_
181-62	38836-38844	deficits	_
181-63	38845-38847	in	_
181-64	38848-38857	inferring	_
181-65	38858-38864	others	_
181-66	38864-38865	'	_
181-67	38866-38872	social	_
181-68	38873-38881	emotions	_
181-69	38882-38884	in	_
181-70	38885-38891	autism	_
181-71	38892-38894	No	_
181-72	38895-38903	amygdala	_
181-73	38904-38915	attenuation	_
181-74	38916-38918	in	_
181-75	38919-38932	schizophrenic	_
181-76	38933-38941	patients	_
181-77	38942-38949	treated	_
181-78	38950-38954	with	_
181-79	38955-38963	atypical	_
181-80	38964-38978	antipsychotics	_
181-81	38979-38986	Changes	_
181-82	38987-38989	in	_
181-83	38990-39000	prefrontal	_
181-84	39001-39004	and	_
181-85	39005-39013	amygdala	_
181-86	39014-39022	activity	_
181-87	39023-39029	during	_
181-88	39030-39040	olanzapine	_
181-89	39041-39050	treatment	_
181-90	39051-39053	in	_
181-91	39054-39067	schizophrenia	_
181-92	39069-39075	Neural	_
181-93	39076-39084	response	_
181-94	39085-39087	to	_
181-95	39088-39096	specific	_
181-96	39097-39107	components	_
181-97	39108-39110	of	_
181-98	39111-39118	fearful	_
181-99	39119-39124	faces	_
181-100	39125-39127	in	_
181-101	39128-39135	healthy	_
181-102	39136-39139	and	_
181-103	39140-39153	schizophrenic	_
181-104	39154-39160	adults	_
181-105	39161-39171	Functional	_
181-106	39172-39186	specialization	_
181-107	39187-39193	within	_
181-108	39194-39201	rostral	_
181-109	39202-39212	prefrontal	_
181-110	39213-39219	cortex	_
181-111	39220-39221	(	_
181-112	39221-39225	area	_
181-113	39226-39228	10	_
181-114	39228-39229	)	_
181-115	39229-39230	:	_
181-116	39231-39232	a	_
181-117	39233-39246	meta-analysis	_
181-118	39247-39257	Prefrontal	_
181-119	39258-39266	cortical	_
181-120	39267-39275	deficits	_
181-121	39276-39279	and	_
181-122	39280-39288	impaired	_
181-123	39289-39306	cognition-emotion	_
181-124	39307-39319	interactions	_
181-125	39320-39322	in	_
181-126	39323-39336	schizophrenia	_
181-127	39337-39348	Involvement	_
181-128	39349-39351	of	_
181-129	39352-39355	the	_
181-130	39356-39368	dorsolateral	_
181-131	39369-39379	prefrontal	_
181-132	39380-39386	cortex	_
181-133	39387-39390	and	_
181-134	39391-39399	superior	_
181-135	39400-39408	temporal	_
181-136	39409-39415	sulcus	_
181-137	39416-39418	in	_
181-138	39419-39427	impaired	_
181-139	39428-39434	social	_
181-140	39435-39445	perception	_
181-141	39446-39448	in	_
181-142	39449-39462	schizophrenia	_
181-143	39463-39470	Altered	_
181-144	39471-39477	medial	_
181-145	39478-39488	prefrontal	_
181-146	39489-39497	activity	_
181-147	39498-39504	during	_
181-148	39505-39512	dynamic	_
181-149	39513-39517	face	_
181-150	39518-39528	processing	_
181-151	39529-39531	in	_
181-152	39532-39545	schizophrenia	_
181-153	39546-39554	spectrum	_
181-154	39555-39563	patients	_
181-155	39564-39572	Temporal	_
181-156	39573-39577	lobe	_
181-157	39578-39588	structures	_
181-158	39589-39592	and	_
181-159	39593-39599	facial	_
181-160	39600-39607	emotion	_
181-161	39608-39619	recognition	_
181-162	39620-39622	in	_
181-163	39623-39636	schizophrenia	_
181-164	39637-39645	patients	_
181-165	39646-39649	and	_
181-166	39650-39662	nonpsychotic	_
181-167	39663-39672	relatives	_
